

DAVITA HEALTHCARE PARTNERS INC.
Form 10-Q
November 05, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

For the Quarterly Period Ended September 30, 2015

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-14106

DAVITA HEALTHCARE PARTNERS INC.

2000 16th Street

Denver, CO 80202

Telephone number (303) 405-2100

Delaware
(State of incorporation) 51-0354549
(I.R.S. Employer
Identification No.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 30, 2015, the number of shares of the Registrant's common stock outstanding was approximately 211.0 million shares and the aggregate market value of the common stock outstanding held by non-affiliates based upon the closing price of these shares on the New York Stock Exchange was approximately \$16.4 billion.

DAVITA HEALTHCARE PARTNERS INC.

INDEX

| | Page No. |
|--|----------|
| PART I. FINANCIAL INFORMATION | |
| Item 1. Condensed Consolidated Financial Statements: | |
| <u>Consolidated Statements of Income for the three and nine months ended September 30, 2015 and September 30, 2014</u> | 1 |
| <u>Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2015 and September 30, 2014</u> | 2 |
| <u>Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014</u> | 3 |
| <u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and September 30, 2014</u> | 4 |
| <u>Consolidated Statements of Equity for the nine months ended September 30, 2015 and for the year ended December 31, 2014</u> | 5 |
| <u>Notes to Condensed Consolidated Financial Statements</u> | 6 |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | 31 |
| Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u> | 49 |
| Item 4. <u>Controls and Procedures</u> | 50 |
| PART II. OTHER INFORMATION | |
| Item 1. <u>Legal Proceedings</u> | 51 |
| Item 1A. <u>Risk Factors</u> | 52 |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 77 |
| Item 6. <u>Exhibits</u> | 78 |
| <u>Signature</u> | 79 |

Note: Items 3, 4 and 5 of Part II are omitted because they are not applicable.

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(dollars in thousands, except per share data)

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|-------------------------------------|-------------|------------------------------------|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Patient service revenues | \$2,414,034 | \$2,242,533 | \$7,049,428 | \$6,543,880 |
| Less: Provision for uncollectible accounts | (109,452) | (98,971) | (314,581) | (270,220) |
| Net patient service revenues | 2,304,582 | 2,143,562 | 6,734,847 | 6,273,660 |
| Capitated revenues | 926,847 | 848,546 | 2,643,552 | 2,435,480 |
| Other revenues | 294,236 | 259,716 | 869,849 | 757,949 |
| Total net revenues | 3,525,665 | 3,251,824 | 10,248,248 | 9,467,089 |
| Operating expenses and charges: | | | | |
| Patient care costs and other costs | 2,501,015 | 2,326,534 | 7,309,703 | 6,752,844 |
| General and administrative | 353,492 | 322,822 | 1,047,318 | 905,519 |
| Depreciation and amortization | 162,062 | 149,196 | 474,694 | 437,682 |
| Provision for uncollectible accounts | 2,511 | 3,961 | 6,497 | 9,680 |
| Equity investment income | (2,783) | (5,225) | (10,724) | (18,692) |
| Loss contingency accrual and settlement charge | | 17,000 | 495,000 | 17,000 |
| Total operating expenses and charges | 3,016,297 | 2,814,288 | 9,322,488 | 8,104,033 |
| Operating income | 509,368 | 437,536 | 925,760 | 1,363,056 |
| Debt expense | (103,481) | (99,878) | (305,121) | (312,345) |
| Debt redemption and refinancing charges | | | (48,072) | (97,548) |
| Other income (loss), net | 2,484 | (1,246) | 4,262 | 2,145 |
| Income before income taxes | 408,371 | 336,412 | 576,829 | 955,308 |
| Income tax expense | 147,064 | 116,628 | 183,893 | 342,366 |
| Net income | 261,307 | 219,784 | 392,936 | 612,942 |
| Less: Net income attributable to noncontrolling interests | (45,435) | (35,662) | (117,204) | (97,848) |
| Net income attributable to DaVita HealthCare Partners Inc. | \$215,872 | \$184,122 | \$275,732 | \$515,094 |
| Earnings per share: | | | | |
| Basic net income per share attributable to DaVita HealthCare | | | | |
| Partners Inc. | \$1.02 | \$0.87 | \$1.30 | \$2.43 |
| Diluted net income per share attributable to DaVita HealthCare | | | | |
| Partners Inc. | \$1.00 | \$0.85 | \$1.27 | \$2.38 |
| Weighted average shares for earnings per share: | | | | |
| Basic | 212,374,897 | 212,617,238 | 212,914,126 | 212,086,735 |
| Diluted | 216,691,461 | 217,236,493 | 217,421,213 | 216,695,033 |

See notes to condensed consolidated financial statements.

1

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(unaudited)

(dollars in thousands)

| | Three months ended | | Nine months ended | |
|---|--------------------|-----------|-------------------|-----------|
| | September 30, | | September 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| Net income | \$261,307 | \$219,784 | \$392,936 | \$612,942 |
| Other comprehensive (loss) income, net of tax: | | | | |
| Unrealized (losses) gains on interest rate swap and | | | | |
| cap agreements: | | | | |
| Unrealized (losses) gains on interest rate swap and | | | | |
| cap agreements | (1,851) | 537 | (10,064) | (7,177) |
| Reclassifications of net swap and cap agreements realized | | | | |
| losses into net income | 771 | 1,403 | 2,372 | 9,759 |
| Unrealized (losses) gains on investments: | | | | |
| Unrealized (losses) gains on investments | (1,651) | (392) | (1,368) | 517 |
| Reclassification of net investment realized gains into | | | | |
| net income | (203) | — | (376) | (207) |
| Foreign currency translation adjustments | (7,023) | (13,838) | (19,883) | (11,871) |
| Other comprehensive loss | (9,957) | (12,290) | (29,319) | (8,979) |
| Total comprehensive income | 251,350 | 207,494 | 363,617 | 603,963 |
| Less: Comprehensive income attributable to noncontrolling | | | | |
| interests | (45,435) | (35,662) | (117,204) | (97,848) |
| Comprehensive income attributable to DaVita HealthCare | | | | |
| Partners Inc. | \$205,915 | \$171,832 | \$246,413 | \$506,115 |

See notes to condensed consolidated financial statements.

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(dollars in thousands, except per share data)

| | September 30, 2015 | December 31, 2014 |
|---|--------------------------|----------------------|
| ASSETS | | |
| Cash and cash equivalents | \$ 1,047,419 | \$ 965,241 |
| Short-term investments | 922,848 | 337,399 |
| Accounts receivable, less allowance of \$261,850 and \$242,674 | 1,699,892 | 1,525,849 |
| Inventories | 173,050 | 136,085 |
| Other receivables | 416,932 | 400,916 |
| Other current assets | 175,715 | 186,842 |
| Income tax receivable | 48,963 | 83,839 |
| Deferred income taxes | 253,067 | 240,626 |
| Total current assets | 4,737,886 | 3,876,797 |
| Property and equipment, net of accumulated depreciation of \$2,305,141 and \$2,029,506 | 2,621,918 | 2,469,099 |
| Intangibles, net of accumulated amortization of \$751,806 and \$621,891 | 1,826,782 | 1,949,498 |
| Equity investments | 67,883 | 65,637 |
| Long-term investments | 90,393 | 89,389 |
| Other long-term assets | 62,387 | 77,000 |
| Goodwill | 9,487,579 | 9,415,295 |
| | \$ 18,894,828 | \$ 17,942,715 |
| LIABILITIES AND EQUITY | | |
| Accounts payable | \$ 487,945 | \$ 445,453 |
| Other liabilities | 632,331 | 510,223 |
| Accrued compensation and benefits | 835,518 | 698,475 |
| Medical payables | 340,143 | 314,347 |
| Current portion of long-term debt | 114,617 | 120,154 |
| Total current liabilities | 2,410,554 | 2,088,652 |
| Long-term debt | 9,082,096 | 8,383,280 |
| Other long-term liabilities | 406,035 | 389,806 |
| Deferred income taxes | 906,807 | 890,701 |
| Total liabilities | 12,805,492 | 11,752,439 |
| Commitments and contingencies: | | |
| Noncontrolling interests subject to put provisions | 897,139 | 829,965 |
| Equity: | | |
| Preferred stock (\$0.001 par value, 5,000,000 shares authorized; none issued) | | |
| Common stock (\$0.001 par value, 450,000,000 shares authorized; 216,632,600 and 215,640,968 shares issued and 211,009,593 and 215,640,968 shares outstanding, respectively) | 217 | 216 |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | |
|--|---------------|---------------|
| Additional paid-in capital | 1,106,342 | 1,108,211 |
| Retained earnings | 4,362,835 | 4,087,103 |
| Treasury stock (5,623,007 shares) | (424,705) | |
| Accumulated other comprehensive loss | (54,336) | (25,017) |
| Total DaVita HealthCare Partners Inc. shareholders' equity | 4,990,353 | 5,170,513 |
| Noncontrolling interests not subject to put provisions | 201,844 | 189,798 |
| Total equity | 5,192,197 | 5,360,311 |
| | \$ 18,894,828 | \$ 17,942,715 |

See notes to condensed consolidated financial statements.

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(dollars in thousands)

| | Nine months ended September 30, | |
|--|------------------------------------|------------|
| | 2015 | 2014 |
| Cash flows from operating activities: | | |
| Net income | \$ 392,936 | \$ 612,942 |
| Adjustments to reconcile net income to cash provided by operating activities: | | |
| Settlement charge and loss contingency accrual | 495,000 | 17,000 |
| Settlement payments | (493,775) | |
| Depreciation and amortization | 474,694 | 437,335 |
| Debt redemption and refinancing charges | 48,072 | 97,548 |
| Stock-based compensation expense | 42,794 | 44,323 |
| Tax benefits from stock award exercises | 31,069 | 45,527 |
| Excess tax benefits from stock award exercises | (19,555) | (32,665) |
| Deferred income taxes | (1,994) | (2,167) |
| Equity investment income, net | 10,563 | 6,007 |
| Other non-cash charges and loss on disposal of assets | 26,583 | 30,604 |
| Changes in operating assets and liabilities, other than from acquisitions and divestitures: | | |
| Accounts receivable | (178,148) | 16,610 |
| Inventories | (35,856) | (25,198) |
| Other receivables and other current assets | 54,924 | 7,563 |
| Other long-term assets | 1,940 | 2,622 |
| Accounts payable | 11,473 | 2,332 |
| Accrued compensation and benefits | 123,081 | 147,570 |
| Other current liabilities | 96,671 | 72,932 |
| Income taxes | 35,282 | 72,283 |
| Other long-term liabilities | 4,773 | (23,770) |
| Net cash provided by operating activities | 1,120,527 | 1,529,398 |
| Cash flows from investing activities: | | |
| Additions of property and equipment | (462,213) | (443,507) |
| Acquisitions | (90,709) | (218,117) |
| Proceeds from asset and business sales | 6,865 | 3,620 |
| Purchase of investments available for sale | (6,667) | (7,138) |
| Purchase of investments held-to-maturity | (1,555,604) | (163,046) |
| Proceeds from sale of investments available for sale | 1,961 | 1,321 |
| Proceeds from investments held-to-maturity | 969,549 | 27,781 |
| Purchase of intangible assets | — | (50) |
| Purchase of equity investments | (13,623) | (32,483) |
| Distributions received on equity investments | 57 | 434 |
| Net cash used in investing activities | (1,150,384) | (831,185) |
| Cash flows from financing activities: | | |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | |
|--|--------------|--------------|
| Borrowings | 41,371,392 | 46,619,292 |
| Payments on long-term debt and other financing costs | (40,732,075) | (46,587,984) |
| Deferred financing costs and debt redemption and refinancing costs | (59,354) | (122,154) |
| Purchase of treasury stock | (384,110) | |
| Distributions to noncontrolling interests | (125,938) | (105,143) |
| Stock award exercises and other share issuances, net | 19,802 | 14,524 |
| Excess tax benefits from stock award exercises | 19,555 | 32,665 |
| Contributions from noncontrolling interests | 28,212 | 38,083 |
| Proceeds from sales of additional noncontrolling interests | | 3,777 |
| Purchase of noncontrolling interests | (23,605) | (12,069) |
| Net cash provided by (used in) financing activities | 113,879 | (119,009) |
| Effect of exchange rate changes on cash and cash equivalents | (1,844) | 1,582 |
| Net increase in cash and cash equivalents | 82,178 | 580,786 |
| Cash and cash equivalents at beginning of the year | 965,241 | 946,249 |
| Cash and cash equivalents at end of the period | \$1,047,419 | \$1,527,035 |

See notes to condensed consolidated financial statements.

DAVITA HEALTHCARE PARTNERS INC.

CONSOLIDATED STATEMENTS OF EQUITY

(unaudited)

(dollars and shares in thousands)

| | DaVita HealthCare Partners Inc. Shareholders' Equity | | | | | | | Accumulated other comprehensive loss | Total | Non- controlling interests not subject to put provisions |
|---|---|-----------------|----------------------------------|----------------------|----------------|---|-----|---|-------------|--|
| | Non- controlling interests subject to put provisions | Common stock | Additional paid-in capital | Retained earnings | Treasury stock | | | | | |
| Balance at December 31, 2013 | \$697,300 | 213,163 | \$213 | \$1,070,922 | \$3,363,989 | — | \$— | \$(2,645) | \$4,432,479 | \$173,062 |
| Comprehensive income: | | | | | | | | | | |
| Net income | 88,425 | | | | 723,114 | | | | 723,114 | 51,791 |
| Other comprehensive loss | — | | | | | | | (22,372) | (22,372) | |
| Stock purchase shares issued | | 298 | | | 19,010 | | | | 19,010 | |
| Stock unit shares issued | | 304 | 1 | (28) | | | | | (27) | |
| Stock-settled SAR shares issued | | 1,876 | 2 | (2) | | | | | — | |
| Stock-settled stock-based compensation expense | | | | | 54,969 | | | | 54,969 | |
| Excess tax benefits from stock awards exercised | | | | | 45,271 | | | | 45,271 | |
| Distributions to noncontrolling interests | (93,884) | | | | | | | | | (55,455) |
| Contributions from | 41,876 | | | | | | | | | 22,779 |

| | | | | | | | | | | |
|--|-----------|---------|-------|-------------|-------------|---|-----|------------|-------------|-----------|
| noncontrolling interests | | | | | | | | | | |
| Sales and assumptions of additional noncontrolling interests | 25,220 | | | 355 | | | | 355 | | 4,165 |
| Purchases from noncontrolling interests | (6,111) | | | (5,357) | | | | (5,357) | | (6,544) |
| Other reclassification | | | | 210 | | | | 210 | | |
| Changes in fair value of noncontrolling interests | 77,139 | | | (77,139) | | | | (77,139) | | |
| Balance at December 31, 2014 | \$829,965 | 215,641 | \$216 | \$1,108,211 | \$4,087,103 | — | \$— | \$(25,017) | \$5,170,513 | \$189,798 |
| Comprehensive income: | | | | | | | | | | |
| Net income | 74,221 | | | | 275,732 | | | 275,732 | | 42,983 |
| Other comprehensive loss | | | | | | | | (29,319) | (29,319) | |
| Stock unit shares issued | | 343 | — | 5 | | | | | 5 | |
| Stock-settled SAR shares issued | | 649 | 1 | (1) | | | | | — | |
| Stock-settled stock-based compensation expense | | | | 43,022 | | | | 43,022 | | |
| Excess tax benefits from stock awards exercised | | | | 19,555 | | | | 19,555 | | |
| Distributions to noncontrolling interests | (74,874) | | | | | | | | | (51,064) |

| | | | | | | | | | | |
|--|-----------|---------|-----------|-------------|-------------|------------|--------------|------------|-------------|-----------|
| interests | | | | | | | | | | |
| Contributions from | | | | | | | | | | |
| noncontrolling interests | 14,951 | | | | | | | | | 13,261 |
| Assumptions of additional noncontrolling interests | 12,031 | | | | | | | | | 6,866 |
| Purchase of noncontrolling interests | (3,090) | | (20,515) | | | | | (20,515) | | |
| Changes in fair value of noncontrolling interests | 43,935 | | (43,935) | | | | | (43,935) | | |
| Purchase of treasury stock | | | | | (5,623) | (424,705) | | (424,705) | | |
| Balance at September 30, 2015 | \$897,139 | 216,633 | \$217 | \$1,106,342 | \$4,362,835 | (5,623) | \$(424,705) | \$(54,336) | \$4,990,353 | \$201,844 |

See notes to condensed consolidated financial statements

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

(dollars and shares in thousands, except per share data)

Unless otherwise indicated in this Quarterly Report on Form 10-Q “the Company”, “we”, “us”, “our” and similar terms refer to DaVita HealthCare Partners Inc. and its consolidated subsidiaries.

1. Condensed consolidated interim financial statements

The condensed consolidated interim financial statements included in this report are prepared by the Company without audit. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve revenue recognition and accounts receivable, contingencies, impairments of long-lived assets and goodwill, fair value estimates, accounting for income taxes, variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, long-term incentive program compensation and medical liability claims. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the operating results for the full year. The condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Prior year balances and amounts have been reclassified to conform to the current year presentation. The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued and has included all necessary adjustments and disclosures.

2. Earnings per share

Basic net income per share is calculated by dividing net income attributable to the Company, adjusted for any change in noncontrolling interests redemption rights in excess of fair value, by the weighted average number of common shares and vested stock units outstanding, net of shares held in escrow that under certain circumstances may be returned to the Company.

Diluted net income per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units (under the treasury stock method) as well as contingently returnable shares held in escrow.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share are as follows:

| | Three months ended September 30, | | Nine months ended September 30, | |
|---|-------------------------------------|-----------|------------------------------------|-----------|
| | 2015 | 2014 | 2015 | 2014 |
| Basic: | | | | |
| Net income attributable to DaVita HealthCare | | | | |
| Partners Inc. | \$215,872 | \$184,122 | \$275,732 | \$515,094 |
| Weighted average shares outstanding during | | | | |
| the period | 214,569 | 214,810 | 215,108 | 214,280 |
| Vested stock units | — | 1 | — | 1 |
| Contingently returnable shares held in escrow | | | | |
| for the DaVita HealthCare Partners merger | (2,194) | (2,194) | (2,194) | (2,194) |
| Weighted average shares for basic earnings | | | | |
| per share calculation | 212,375 | 212,617 | 212,914 | 212,087 |
| Basic net income per share attributable to | | | | |
| DaVita HealthCare Partners Inc. | \$1.02 | \$0.87 | \$1.30 | \$2.43 |
| Diluted: | | | | |
| Net income attributable to DaVita HealthCare | | | | |
| Partners Inc. | \$215,872 | \$184,122 | \$275,732 | \$515,094 |
| Weighted average shares outstanding during | | | | |
| the period | 214,569 | 214,810 | 215,108 | 214,280 |
| Vested stock units | — | 1 | — | 1 |
| Assumed incremental shares from stock plans | 2,122 | 2,425 | 2,313 | 2,414 |
| Weighted average shares for diluted earnings | | | | |
| per share calculation | 216,691 | 217,236 | 217,421 | 216,695 |
| Diluted net income per share attributable | | | | |
| to DaVita HealthCare Partners Inc. | \$1.00 | \$0.85 | \$1.27 | \$2.38 |
| Anti-dilutive potential common shares | 1,184 | 1,422 | 1,092 | 1,804 |

excluded from calculation ⁽¹⁾

⁽¹⁾ Shares associated with stock-settled stock appreciation rights that are excluded from the diluted denominator calculation because they are anti-dilutive under the treasury stock method.

3. Accounts receivable

Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the ultimate collectability of the Company's accounts receivable, the Company analyzes its historical cash collection experience and trends for each of its government payors and commercial payors to estimate the adequacy of the allowance for doubtful accounts and the amount of the provision for uncollectible accounts. Management regularly updates its analysis based upon the most recent information available to determine its current provision for uncollectible accounts and the adequacy of its allowance for doubtful accounts. For receivables associated with dialysis patient services covered by government payors, like Medicare, the Company receives 80% of the payment directly from Medicare as established under the government's bundled payment system and determines an appropriate allowance for doubtful accounts and provision for uncollectible accounts on the remaining balance due depending upon the Company's estimate of the amounts ultimately collectible from other secondary coverage sources or from the patients. For receivables associated with services to patients covered by commercial payors that are either based upon contractual terms or for non-contracted health plan coverage, the Company provides an allowance for doubtful accounts by recording a provision for uncollectible accounts based upon its historical collection experience, potential inefficiencies in its billing processes and for which collectability is determined to be unlikely. Approximately 1% of the Company's net accounts receivable are associated with patient pay and it is the Company's policy to reserve 100% of the outstanding accounts receivable balances for dialysis services when those amounts due are outstanding for more than three months.

During the nine months ended September 30, 2015, the Company's allowance for doubtful accounts increased by \$19,176. This was primarily due to an increase in U.S. dialysis and lab provision for uncollectible accounts as a result of an increase in write-offs of certain balances. There were no unusual transactions impacting the allowance for doubtful accounts.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

4. Investments in debt and equity securities and other investments

Based on the Company's intentions and strategy concerning investments in debt securities, the Company classifies certain debt securities as held-to-maturity and records them at amortized cost. Equity securities that have readily determinable fair values, including those of mutual funds, common stock and other debt securities, are classified as available-for-sale and recorded at fair value.

The Company's investments in securities consist of the following:

| | September 30, 2015 | | | December 31, 2014 | | |
|--|---------------------|-----------------------|-----------|---------------------|-----------------------|-----------|
| | Held to maturity | Available for sale | Total | Held to maturity | Available for sale | Total |
| Certificates of deposit and money market funds | | | | | | |
| due within one year | \$921,648 | \$— | \$921,648 | \$335,975 | \$— | \$335,975 |
| Investments in mutual funds and common stock | — | 31,343 | 31,343 | — | 28,123 | 28,123 |
| | \$921,648 | \$31,343 | \$952,991 | \$335,975 | \$28,123 | \$364,098 |
| Short-term investments | \$921,648 | \$1,200 | \$922,848 | \$335,975 | \$1,424 | \$337,399 |
| Long-term investments | — | 30,143 | 30,143 | — | 26,699 | 26,699 |
| | \$921,648 | \$31,343 | \$952,991 | \$335,975 | \$28,123 | \$364,098 |

The cost of the certificates of deposit and money market funds at September 30, 2015 and December 31, 2014 approximates their fair value. As of September 30, 2015 and December 31, 2014, the available-for-sale investments included \$2,700 and \$4,976 of gross pre-tax unrealized gains, respectively. During the nine months ended September 30, 2015, the Company recorded gross pre-tax unrealized losses of \$1,992, or \$1,446 after tax, in other comprehensive income associated with changes in the fair value of these investments. During the nine months ended September 30, 2015, the Company sold investments in mutual funds for net proceeds of \$1,611 and recognized a pre-tax gain of \$284, or \$173 after-tax, which was previously recorded in other comprehensive income. During the nine months ended September 30, 2014, the Company sold investments in mutual funds for net proceeds of \$1,321 and recognized a pre-tax gain of \$340, or \$207 after-tax, which was previously recorded in other comprehensive income.

The investments in mutual funds classified as available-for-sale are held within a trust to fund existing obligations associated with several of the Company's non-qualified deferred compensation plans.

As of September 30, 2015, the Company held \$5,000 of preferred stock in a privately held company that is accounted for under the cost method as this investment does not have a readily determinable fair value.

Certain HCP entities are required to maintain minimum cash balances in order to comply with regulatory requirements in conjunction with medical claim reserves. As of September 30, 2015, this minimum cash balance was approximately

\$54,900.

5. Goodwill

Changes in goodwill by reportable segments were as follows:

| | U.S. dialysis and related lab services | HCP | Other-ancillary services and strategic initiatives | Consolidated total |
|--|---|-------------|--|--------------------|
| Balance at January 1, 2014 | \$ 5,469,473 | \$3,516,162 | \$ 227,339 | \$ 9,212,974 |
| Acquisitions | 143,021 | 48,649 | 29,844 | 221,514 |
| Divestitures | (1,851) | — | — | (1,851) |
| Foreign currency and other adjustments | — | (2,277) | (15,065) | (17,342) |
| Balance at December 31, 2014 | \$ 5,610,643 | \$3,562,534 | \$ 242,118 | \$ 9,415,295 |
| Acquisitions | 21,910 | 27,665 | 39,558 | 89,133 |
| Divestitures | — | (446) | — | (446) |
| Foreign currency and other adjustments | — | — | (16,403) | (16,403) |
| Balance at September 30, 2015 | \$ 5,632,553 | \$3,589,753 | \$ 265,273 | \$ 9,487,579 |

8

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Each of the Company's operating segments described in Note 17 to these condensed consolidated financial statements represents an individual reporting unit for goodwill impairment testing purposes, except that each sovereign jurisdiction within the Company's international operating segments is considered a separate reporting unit.

Within the U.S. dialysis and related lab services operating segment, the Company considers each of its dialysis centers to constitute an individual business for which discrete financial information is available. However, since these dialysis centers have similar operating and economic characteristics, and the allocation of resources and significant investment decisions concerning these businesses are highly centralized and the benefits broadly distributed, the Company has aggregated these centers and deemed them to constitute a single reporting unit.

The Company has applied a similar aggregation to the HCP operations in each region, to the vascular access service centers in its vascular access services reporting unit, to the physician practices in its physician services reporting unit, and to the dialysis centers within each sovereign international jurisdiction. For the Company's additional operating segments, no component below the operating segment level is considered a discrete business and therefore these operating segments directly constitute individual reporting units.

HCP's current and expected future operating results have eroded, primarily as a result of recent reductions in its Medicare Advantage reimbursement rates, including the Medicare Advantage final benchmark rates for 2016 announced on April 6, 2015.

As a result, the Company has determined that three of its HCP reporting units, HCP California, HCP Nevada and HCP New Mexico, remain at risk of goodwill impairment. As of September 30, 2015, HCP California, HCP Nevada and HCP New Mexico have goodwill of \$2,518,569, \$520,968, and \$71,684, respectively.

The Company prepared valuation updates, informed by third-party assistance, for these three businesses as of September 30, 2015, which indicate that the estimated fair values of HCP California, HCP Nevada and HCP New Mexico exceed their total carrying values by approximately 15.2%, 8.8% and 16.2%, respectively.

Further reductions in HCP's reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future. For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 1.8%, 1.9% and 2.1%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 4.6%, 3.4% and 3.9%, respectively.

During the first nine months of 2015, the Company recorded an immaterial goodwill impairment charge related to its international operations. Except as described above, no significant goodwill associated with the Company's various other reporting units was considered at risk of impairment as of September 30, 2015. Since the dates of the Company's last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected the Company's businesses. However, these have not caused management to believe it is more likely than not that the fair value of any of its reporting units would

be less than its carrying amount.

6. Health care costs payable

The following table includes estimates for the cost of professional medical services provided by non-employed physicians and other providers, as well as inpatient and other ancillary costs for all markets other than California. The Company does not include inpatient and other ancillary costs for contracts held by its California licensed health plan and for contracts held by its California medical group entities; only professional medical services are included as state regulation does not allow those medical group entities to assume risk for inpatient services. Health care costs payable are included in medical payables in the condensed consolidated balance sheet.

9

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

The following table shows the components of changes in health care costs payable for the nine months ended September 30, 2015:

| | Nine months ended September 30, 2015 |
|--|--|
| Health care costs payable, beginning of the period | \$214,405 |
| Add: Components of incurred health care costs | |
| Current year | 1,193,444 |
| Prior years | (1,327) |
| Total incurred health care costs | 1,192,117 |
| Less: Claims paid | |
| Current year | 1,008,193 |
| Prior years | 195,460 |
| Total claims paid | 1,203,653 |
| Health care costs payable, end of the period | \$202,869 |

The Company's prior year estimates of health care costs payable decreased by \$1,327 resulting from certain medical claims being settled for amounts less than originally estimated. When significant increases (decreases) in prior-year health care cost estimates occur that the Company believes significantly impacts its current year operating results, the Company discloses that amount as unfavorable (favorable) development of prior-year's health care cost estimates. Actual claim payments for prior year services have not been materially different from the Company's year-end estimates.

7. Income taxes

As of September 30, 2015, the Company's total liability for unrecognized tax benefits relating to tax positions that do not meet the more-likely-than-not threshold is \$36,004, all of which would impact the Company's effective tax rate if recognized. This balance represents an increase of \$4,127 from the December 31, 2014 balance of \$31,877.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits in its income tax expense. At September 30, 2015 and December 31, 2014, the Company had approximately \$10,174 and \$10,123, respectively, accrued for interest and penalties related to unrecognized tax benefits, net of federal tax benefits.

8. Long-term debt

Long-term debt was comprised of the following:

| | September 30, 2015 | December 31, 2014 |
|---|--------------------------|----------------------|
| Senior Secured Credit Facilities: | | |
| Term Loan A | \$937,500 | \$ 975,000 |
| Term Loan B | 3,456,250 | 3,482,500 |
| Senior notes | 4,500,000 | 3,775,000 |
| Acquisition obligations and other notes payable | 61,348 | 69,045 |
| Capital lease obligations | 255,897 | 218,097 |
| Total debt principal outstanding | 9,210,995 | 8,519,642 |
| Discount on long-term debt | (14,282) | (16,208) |
| | 9,196,713 | 8,503,434 |
| Less current portion | (114,617) | (120,154) |
| | \$9,082,096 | \$ 8,383,280 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Scheduled maturities of long-term debt at September 30, 2015 were as follows:

| | |
|------------------------------|-----------|
| 2015 (remainder of the year) | 29,880 |
| 2016 | 119,395 |
| 2017 | 149,372 |
| 2018 | 160,391 |
| 2019 | 734,892 |
| 2020 | 58,790 |
| Thereafter | 7,958,275 |

During the first nine months of 2015, the Company made mandatory principal payments under its Senior Secured Credit Facilities totaling \$37,500 on the Term Loan A and \$26,250 on the Term Loan B.

In April 2015, the Company issued \$1,500,000 5.0% Senior Notes due 2025 (the 5.0% Senior Notes). The 5.0% Senior Notes pay interest on May 1 and November 1 of each year beginning November 1, 2015. The 5.0% Senior Notes are unsecured senior obligations and rank equally in right of payment with the Company's existing and future unsecured senior indebtedness. The 5.0% Senior Notes are guaranteed by certain of the Company's domestic subsidiaries. The Company may redeem up to 35% of the 5.0% Senior Notes at any time prior to May 1, 2018 at a certain specified price from the proceeds of one or more equity offerings. In addition, the Company may redeem some or all of the 5.0% Senior Notes at any time prior to May 1, 2020 at make whole redemption prices and on or after such date at certain specified redemption rates. The proceeds from the 5.0% Senior Notes were used to repurchase all of the outstanding principal balances of the \$775,000 6 % Senior Notes due 2020 (the 6 % Notes) through a combination of a tender offer and a redemption process and to pay fees and expenses. The remaining proceeds may be used for general corporate purposes, future acquisitions and share repurchases. As a result of these transactions, the Company incurred \$48,072 in debt redemption charges consisting of tender and redemption fees as well as the write-off of deferred financing fees associated with the repurchase of the 6 % Senior Notes.

The Company has entered into several interest rate swap agreements as a means of hedging its exposure to and volatility from variable-based interest rate changes as part of its overall interest rate risk management strategy. These agreements are not held for trading or speculative purposes and have the economic effect of converting the LIBOR variable component of the Company's interest rate to a fixed rate. These swap agreements are designated as cash flow hedges, and as a result, hedge-effective gains or losses resulting from changes in the fair values of these swaps are reported in other comprehensive income until such time as the hedged forecasted cash flows occur, at which time the amounts are reclassified into net income. Net amounts paid or received for each specific swap tranche that have settled have been reflected as adjustments to debt expense. In addition, the Company has entered into several active and forward interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's floating rate debt, as described below. The cap agreements are also designated as cash flow hedges and, as a result, changes in the fair values of these cap

agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the term of the cap agreements. The swap and cap agreements do not contain credit-risk contingent features.

As of September 30, 2015, the Company maintains several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts totaling \$783,750. These agreements have the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the Term Loan A margin of 2.00%. The overall weighted average effective interest rate also includes the effects of \$153,750 of unhedged Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 2.00%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the nine months ended September 30, 2015, the Company recognized debt expense of \$2,061 from these swaps. As of September 30, 2015, the total fair value of these swap agreements was a net liability of approximately \$914. During the nine months ended September 30, 2015, the Company recorded a loss of \$4,798 in other comprehensive income due to a decrease in the unrealized fair value of these swap agreements. The Company estimates that approximately \$914 of existing unrealized pre-tax losses in other comprehensive income at September 30, 2015 will be reclassified into income over the next twelve months.

As of September 30, 2015, the Company maintains several forward interest rate cap agreements that were entered into in November 2014 with notional amounts totaling \$3,500,000. These forward cap agreements will be effective September 30, 2016 and will have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 3.50% on an equivalent amount of the Company's debt. The cap agreements expire on June 30, 2018. As of September 30, 2015, the total fair value of these cap agreements was an asset of approximately \$2,176. During the nine months ended September 30, 2015, the Company recorded a loss of \$10,164 in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

As of September 30, 2015, the Company maintains several active interest rate cap agreements that were entered into in March 2013 with notional amounts totaling \$2,735,000 on the Company's Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 2.50% on an equivalent amount of the Company's Term Loan B. During the nine months ended September 30, 2015, the Company recognized debt expense of \$1,829 from these caps. The cap agreements expire on September 30, 2016. As of September 30, 2015, the total fair value of these cap agreements was an asset of approximately \$43. During the nine months ended September 30, 2015, the Company recorded a loss of \$1,551 in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

In October 2015, the Company entered into several forward interest rate cap agreements with notional amounts totaling \$3,500,000. These forward cap agreements will be effective June 29, 2018 and will have the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 3.50% on an equivalent amount of its debt. These cap agreements expire on June 30, 2020.

The following table summarizes the Company's derivative instruments as of September 30, 2015 and December 31, 2014:

| Derivatives designated as hedging instruments | September 30, 2015 | | December 31, 2014 | |
|---|------------------------------|------------|------------------------------|------------|
| | Balance sheet location | Fair value | Balance sheet location | Fair value |
| Interest rate swap agreements | Other short-term liabilities | \$ 914 | Other short-term liabilities | \$ 1,457 |
| Interest rate swap agreements | Other long-term assets | \$ — | Other long-term assets | \$ 3,281 |
| Interest rate cap agreements | Other long-term assets | \$ 2,219 | Other long-term assets | \$ 13,934 |

The following table summarizes the effects of the Company's interest rate swap and cap agreements for the three and nine months ended September 30, 2015 and 2014:

| Derivatives designated as cash flow hedges | Amount of (losses) gains recognized in OCI on interest rate swap and cap agreements | | | | Location of losses reclassified from accumulated OCI into income | Amount of losses reclassified from accumulated OCI into income | | | |
|--|---|--------------------|--------------------|--------------------|--|--|--------------------|--------------------|--------------------|
| | Three months ended | | Nine months ended | | | Three months ended | | Nine months ended | |
| | September 30, 2015 | September 30, 2014 | September 30, 2015 | September 30, 2014 | Debt expense | September 30, 2015 | September 30, 2014 | September 30, 2015 | September 30, 2014 |
| Interest rate swap agreements | \$(1,128) | \$1,058 | \$(4,798) | \$(6,728) | | \$(655) | \$(795) | \$(2,061) | \$(11,495) |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| Interest rate cap agreements | Debt expense | | | | | | | |
|------------------------------|--------------|--------|------------|-----------|---------|-----------|-----------|------------|
| | (1,909) | (178) | (11,715) | (5,052) | (609) | (1,507) | (1,829) | (4,521) |
| Tax benefit (expense) | 1,186 | (343) | 6,449 | 4,603 | 493 | 899 | 1,518 | 6,257 |
| Total | \$(1,851) | \$537 | \$(10,064) | \$(7,177) | \$(771) | \$(1,403) | \$(2,372) | \$(9,759) |

As of September 30, 2015, the interest rate on the Company's Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date. The Term Loan B is also subject to interest rate caps if LIBOR should rise above 2.50%. See above for further details. Interest rates on the Company's senior notes are fixed by their terms. The LIBOR variable component of the Company's interest rate on a majority of the Company's Term Loan A is economically fixed as a result of interest rate swaps.

As a result of embedded LIBOR floors on the Term Loan B debt agreement and the swap and cap agreements, the Company's overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.50%, based on the current margins in effect of 2.00% for the Term Loan A and 2.75% for the Term Loan B, as of September 30, 2015.

The Company's overall weighted average effective interest rate during the third quarter of 2015 was 4.40% and as of September 30, 2015 was 4.40%.

As of September 30, 2015, the Company had undrawn revolving credit facilities totaling \$1,000,000 of which approximately \$40,000 was committed for outstanding letters of credit. In addition, the Company has outstanding letters of credit of approximately \$56,000, of which \$1,000 is secured by a certificate of deposit. The remaining amount is unencumbered.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

9. Contingencies

The majority of the Company's revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient's medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company's revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.

Inquiries by the Federal Government and Certain Related Civil Proceedings

Vainer Private Civil Suit: As previously disclosed, the Company received a subpoena for documents from the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and erythropoietin (EPO), as well as other related matters, covering the period from January 2003 to December 2008. The Company subsequently learned that the allegations underlying this inquiry were made as part of a civil complaint filed by relators, Daniel Barbir and Dr. Alon Vainer, pursuant to the qui tam provisions of the federal False Claims Act. The relators also alleged that the Company's drug administration practices for the Company's dialysis operations for Vitamin D and iron agents from 2003 through 2010 fraudulently created unnecessary waste, which was billed to and paid for by the government. In June 2015, the Company finalized the terms of the settlement with plaintiffs, including a settlement amount of \$450,000 and attorney fees and other costs of \$45,000.

2011 U.S. Attorney Medicaid Investigation: In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the OIG. Subsequent to the Company's announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney's Office for the Eastern District of New York. The request related to payments for infusion drugs covered by Medicaid composite payments for dialysis. It is the Company's understanding that this inquiry is civil in nature. The Company understands further that certain other providers that operate dialysis clinics in New York may have received a similar request for documents. The Company has cooperated with the government and produced the requested documents. In April 2014, the Company reached an agreement in principle with the government to resolve this matter, and is currently in the process of working with the government to finalize the specific terms of the settlement, and has accrued an amount that is immaterial.

Swoben Private Civil Suit: In April 2013, the Company's HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the qui tam provisions of the federal False Claims Act (FCA) and the California False Claims Act, James M. Swoben, as relator, filed a qui tam action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a Settlement Agreement with the United States of America and the State of California. The United States and the State

of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal FCA and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP's motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services (CMS). In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court's disposition of the appeal is pending.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

2015 U.S. Attorney Transportation Investigation: In February 2015, the Company announced that it received six subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of the respective dialysis center. The Company has been advised by an attorney with the Civil Division of the United States Attorney's Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation. The Company does not provide transportation or bill for the transport of its dialysis patients. The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.

2015 U.S. OIG Medicare Advantage Civil Investigation: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of HCP, received a subpoena from the OIG. The Company has been advised by an attorney with the Civil Division of the United States Department of Justice in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers' risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA's communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government's investigation.

In addition to the subpoena described above, in June 2015, the Company received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company's and its subsidiaries' (including HealthCare Partners and its subsidiary JSA HealthCare Corporation) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. Some of the information requested relates to what the Company disclosed in the risk factors of the Company's quarterly report on Form 10-Q for the first quarter of 2015 as a potentially improper historical HCP coding practice related to a particular condition. The practice in question was discontinued following the Company's November 1, 2012 acquisition of HCP and, as the Company previously disclosed, the Company notified CMS of the coding practice and potential overpayments. In connection with the HCP merger, the Company has certain indemnification rights against the sellers and an escrow was established as security for the indemnification. The Company would pursue an indemnification claim against the sellers secured by the escrow for any and all liabilities incurred. The Company can make no assurances that the indemnification and escrow would cover the full amount of the Company's potential losses related to this matter. The Company is cooperating with the government and will gather and produce the requested information.

Except for the private civil complaints filed by the relators as described above, to the Company's knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time

through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management's attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and if criminal proceedings were initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators' claims (except as described above), or the potential range of damages, if any.

Shareholder Derivative Claims

DaVita HealthCare Partners Inc. Derivative Litigation: On January 7, 2014, the U.S. District Court for the District of Colorado consolidated the two previously disclosed shareholder derivative lawsuits: the Haverhill Retirement System action filed on May 17, 2013 and the Clark Shareholder action filed on August 7, 2012. The court appointed Haverhill lead plaintiff. The complaints filed against the directors of the Company and against the Company, as nominal defendant allege, among other things, that the Company's directors breached fiduciary duties to the Company relating to the 2010 and 2011 U.S. Attorney physician relationship investigations described above, the Vainer qui tam private civil suit described above and the Woodard qui tam private civil suit for which the Company previously announced a settlement in July 2012. The Company entered into a settlement with the lead plaintiff, which as previously disclosed, were described in a court-ordered notice sent to shareholders in late January 2015, and included enhancements to the Company's corporate governance practices and provides that the Company will not oppose the derivative plaintiff's application for an award of fees and expenses, the dollar amount of which is not material to the Company. The Court approved the settlement and entered an order granting final approval of the settlement on June 5, 2015 and final judgment in the case was entered on June 9, 2015.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Other

The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.

A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs' motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court's decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company's condensed consolidated financial statements. In June 2015, the Company reached an agreement in principle to resolve the remainder of the claims in this litigation. The settlement must be approved by the court, and the parties are in the process of seeking that approval. The amount of the settlement is not material to the Company's condensed consolidated financial statements.

In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

10. Noncontrolling interests subject to put provisions and other commitments

The Company has potential obligations to purchase the noncontrolling interests held by third parties in several of its majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or

cash flow attributable to the noncontrolling interests put to the Company, which is intended to approximate fair value. The methodology the Company uses to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from the Company's current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled could vary significantly depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial.

The Company has certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment as well as to physician-owned vascular access clinics or medical practices that the Company operates under management and administrative services agreements of approximately \$1,000.

Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years. Accordingly, the noncontrolling interests in these joint ventures are considered mandatorily redeemable instruments, for which the classification and measurement requirements have been indefinitely deferred. Future distributions upon dissolution of these entities would be valued below the related noncontrolling interest carrying balances in the consolidated balance sheet.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

11. Long-term incentive compensation

Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to the dialysis and related lab services business, the HCP business, corporate support costs, and the ancillary services and strategic initiatives.

The Company's stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.

During the nine months ended September 30, 2015, the Company granted 920 stock-settled stock appreciation rights with an aggregate grant-date fair value of \$16,763 and a weighted-average expected life of approximately 4.1 years, and also granted 272 stock units with an aggregate grant-date fair value of \$21,933 and a weighted-average expected life of approximately 3.1 years.

For the nine months ended September 30, 2015 and 2014, the Company recognized \$100,171 and \$88,323, respectively, in total LTIP expense, of which \$42,794 and \$44,323, respectively, represented stock-based compensation expense for stock appreciation rights, stock units and discounted employee stock plan purchases, which are primarily included in general and administrative expenses. The estimated tax benefits recorded for stock-based compensation for the nine months ended September 30, 2015 and 2014 was \$14,870 and \$16,075, respectively. As of September 30, 2015, the Company had \$145,914 of total estimated unrecognized compensation cost for outstanding LTIP awards, including \$75,635 related to stock-based compensation arrangements under the Company's equity compensation and stock purchase plans. The Company expects to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.1 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.3 years.

For the nine months ended September 30, 2015 and 2014, the Company received \$31,069 and \$45,527, respectively, in actual tax benefits upon the exercise of stock awards.

12. Share repurchases

During the three months ended September 30, 2015, the Company repurchased a total of 4,556 shares of its common stock for \$340,592, or an average price of \$74.76 per share. During the nine months ended September 30, 2015, the Company repurchased a total of 5,623 shares of its common stock for \$424,705, or an average price of \$75.53 per share. The Company also repurchased a total of 2 shares of its common stock subsequent to September 30, 2015 for \$156, or an average price of \$71.01 per share.

On April 14, 2015, the Company's Board of Directors approved additional share repurchases in the amount of \$725,944. These share repurchases are in addition to the \$274,056 remaining under the Company's Board of Directors' prior share repurchase approval announced on November 4, 2010. As a result of these transactions, the Company now has a total of \$659,252 in outstanding authorizations available for share repurchases as of October 30, 2015. These share repurchase authorizations have no expiration dates. However, the Company is subject to share repurchase limitations under the terms of its Senior Secured Credit Facilities and the indentures governing its Senior Notes.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

13. Comprehensive income

| | For the three months ended September 30, 2015 | | | | For the nine months ended September 30, 2015 | | | |
|---|---|--------------------------|---|---|---|--------------------------|---|---|
| | Interest rate swap and cap agreements | Investment securities | Foreign currency translation adjustments | Accumulated other comprehensive income (loss) | Interest rate swap and cap agreements | Investment securities | Foreign currency translation adjustments | Accumulated other comprehensive income (loss) |
| Beginning balance | \$(8,407) | \$ 3,261 | \$(39,233) | \$(44,379) | \$(1,795) | \$ 3,151 | \$(26,373) | \$(25,017) |
| Unrealized losses | (3,037) | (2,325) | (7,023) | (12,385) | (16,513) | (1,864) | (19,883) | (38,260) |
| Related income tax benefit | 1,186 | 674 | — | 1,860 | 6,449 | 496 | — | 6,945 |
| | (1,851) | (1,651) | (7,023) | (10,525) | (10,064) | (1,368) | (19,883) | (31,315) |
| Reclassification from accumulated other comprehensive income into net income | 1,264 | (333) | — | 931 | 3,890 | (617) | — | 3,273 |
| Related income tax (expense) benefit | (493) | 130 | — | (363) | (1,518) | 241 | — | (1,277) |
| | 771 | (203) | — | 568 | 2,372 | (376) | — | 1,996 |
| Ending balance | \$(9,487) | \$ 1,407 | \$(46,256) | \$(54,336) | \$(9,487) | \$ 1,407 | \$(46,256) | \$(54,336) |

| | For the three months ended September 30, 2014 | | | | For the nine months ended September 30, 2014 | | | |
|------------------------------|---|--------------------------|---|---|---|--------------------------|---|---|
| | Interest rate swap and cap agreements | Investment securities | Foreign currency translation adjustments | Accumulated other comprehensive income (loss) | Interest rate swap and cap agreements | Investment securities | Foreign currency translation adjustments | Accumulated other comprehensive income (loss) |
| Beginning balance | \$(1,702) | \$ 3,822 | \$(1,454) | \$ 666 | \$(2,344) | \$ 3,120 | \$(3,421) | \$(2,645) |
| Unrealized gains (losses) | 880 | (567) | (13,838) | (13,525) | (11,780) | 838 | (11,871) | (22,813) |

| | | | | | | | | |
|--------------------------------------|--------|---------|-------------|-------------|----------|---------|-------------|-------------|
| Related income tax (expense) benefit | (343) | 175 | — | (168) | 4,603 | (321) | — | 4,282 |
| | 537 | (392) | (13,838) | (13,693) | (7,177) | 517 | (11,871) | (18,531) |
| Reclassification from accumulated | | | | | | | | |
| other comprehensive | | | | | | | | |
| income into net | | | | | | | | |
| income | 2,302 | — | — | 2,302 | 16,016 | (340) | — | 15,676 |
| Related income tax (expense) benefit | (899) | — | — | (899) | (6,257) | 133 | — | (6,124) |
| | 1,403 | — | — | 1,403 | 9,759 | (207) | — | 9,552 |
| Ending balance | \$238 | \$3,430 | \$(15,292) | \$(11,624) | \$238 | \$3,430 | \$(15,292) | \$(11,624) |

The reclassification of net swap and cap realized losses into income are recorded as debt expense in the corresponding condensed consolidated statements of income. See Note 8 to the condensed consolidated financial statements for further details.

The reclassification of net investment realized gains into income are recorded in other income in the corresponding condensed consolidated statements of income. See Note 4 to the condensed consolidated financial statements for further details.

14. Acquisitions

On August 17, 2015, the Company entered into a definitive agreement to acquire Colorado-based Renal Ventures Limited, LLC (Renal Ventures), including a 100 percent interest in all dialysis centers owned by Renal Ventures, for approximately \$415,000 in cash, subject to, among other things, adjustments for certain items such as working capital. Renal Ventures currently operates 36 dialysis clinics in six states serving approximately 2,400 patients, and also operates other ancillary businesses. The transaction is subject to approval by the Federal Trade Commission (FTC) including Hart-Scott-Rodino antitrust clearance. The Company anticipates that it will be required by the FTC to divest a certain number of outpatient dialysis centers as a condition of the transaction. The Company currently expects the transaction to close in early 2016.

During the nine months ended September 30, 2015, the Company acquired dialysis businesses and other businesses consisting of six dialysis centers located in the U.S., seven dialysis centers located outside the U.S., three vascular access centers, and other medical businesses for a total of \$90,709 in net cash and deferred purchase price obligations totaling \$830. The assets and liabilities

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

for all acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company's condensed consolidated financial statements, as are their operating results from the designated effective dates of the acquisitions. Certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of medical claims liabilities and certain other working capital items relating to several of these acquisitions are pending final quantification.

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values:

| | Nine months ended September 30, 2015 |
|---|---|
| Current assets | \$ 3,324 |
| Property and equipment | 12,040 |
| Amortizable intangible and other long-term assets | 8,478 |
| Goodwill | 89,133 |
| Long-term deferred income taxes | (750) |
| Noncontrolling interests assumed | (18,898) |
| Liabilities assumed | (1,788) |
| Aggregate purchase price | \$ 91,539 |

Amortizable intangible assets acquired during the first nine months of 2015 had weighted-average estimated useful lives of nine years. The majority of the intangible assets acquired relate to non-compete agreements and trade names. The weighted-average amortization period for non-compete agreements was ten years. The weighted-average amortization period for trade names was three years. The total amount of goodwill deductible for tax purposes associated with these acquisitions was approximately \$71,566.

Contingent earn-out obligations

The Company has several contingent earn-out obligations associated with acquisitions that could result in the Company paying the former shareholders of acquired companies a total of up to \$133,791 if certain EBITDA, operating income performance targets or quality margins are met over the next one to three years.

Contingent earn-out obligations are remeasured to fair value at each reporting date until the contingencies are resolved with changes in the liability due to the re-measurement recorded in earnings. See Note 16 to these condensed consolidated financial statements for further details. As of September 30, 2015, the Company has estimated the fair value of these contingent earn-out obligations to be \$30,309, of which a total of \$21,915 is included in other liabilities

and the remaining \$8,394 is included in other long-term liabilities in the Company's condensed consolidated balance sheet.

The following is a reconciliation of changes in the contingent earn-out obligations for the nine months ended September 30, 2015:

| | |
|---|----------|
| Beginning balance, January 1, 2015 | \$39,129 |
| Remeasurement of fair value for contingent earn-out obligations | (2,818) |
| Payments on contingent earn-out obligations | (6,002) |
| | \$30,309 |

15. Variable interest entities

The Company relies on the operating activities of certain entities that it does not directly own or control, but over which it has indirect influence and of which it is considered the primary beneficiary. These entities are subject to the consolidation guidance applicable to variable interest entities (VIEs).

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Under U.S. generally accepted accounting principles (GAAP), VIEs typically include (i) entities for which the entity's equity is not sufficient to finance its activities without additional subordinated financial support; (ii) entities for which the equity holders as a group lack the power to direct the activities that most significantly influence the entity's economic performance, the obligation to absorb the entity's expected losses, or the right to receive the entity's expected returns; or (iii) entities for which the voting rights of some investors are not proportional to their obligations to absorb the entity's losses.

Under U.S. GAAP, the Company has determined that substantially all of the entities it is associated with that qualify as VIEs must be included in its consolidated financial statements. The Company manages these entities and provides operating and capital funding as necessary for these entities to accomplish their operational and strategic objectives. A number of these entities are subject to nominee share ownership or share transfer restriction agreements that effectively transfer the majority of the economic risks and rewards of their ownership to the Company. In other cases the Company's management agreements with these entities include both financial terms and protective and participating rights to the entities' operating, strategic and non-clinical governance decisions which transfer substantial powers over and economic responsibility for the entities to the Company. In some cases such entities are subject to broad exclusivity or noncompetition restrictions that benefit the Company. Further, in some cases the Company has contractual arrangements with its related party nominee owners that effectively indemnify these parties from the economic losses from, or entitle the Company to the economic benefits of, these entities.

The analyses upon which these consolidation determinations rest are complex, involve uncertainties, and require significant judgment on various matters, some of which could be subject to different interpretations. At September 30, 2015, these condensed consolidated financial statements include total assets of VIEs of \$652,690 and total liabilities and noncontrolling interests of VIEs to third parties of \$337,476.

The Company also sponsors certain deferred compensation plans whose trusts qualify as VIEs and the Company consolidates each of these plans as their primary beneficiary. The assets of these plans are recorded in short-term or long-term investments with matching offsetting liabilities recorded in accrued compensation and benefits and other long-term liabilities. See Note 4 for disclosures on the assets of these consolidated non-qualified deferred compensation plans.

16. Fair value of financial instruments

The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets, liabilities, temporary equity and commitments. The Company also has classified certain assets, liabilities and temporary equity that are measured at fair value into the appropriate fair value hierarchy levels as defined by the FASB.

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

The following table summarizes the Company's assets, liabilities and temporary equity measured at fair value on a recurring basis as of September 30, 2015:

| | Total | Quoted prices in active markets for identical assets (Level 1) | Significant other observable inputs (Level 2) | Significant unobservable inputs (Level 3) |
|--|-----------|---|---|--|
| Assets | | | | |
| Available-for-sale securities | \$31,343 | \$ 31,343 | \$ — | \$ — |
| Interest rate cap agreements | \$2,219 | \$ — | \$ 2,219 | \$ — |
| Interest rate swap agreements | \$— | \$ — | \$ — | \$ — |
| Funds on deposit with third parties | \$87,710 | \$ 87,710 | \$ — | \$ — |
| Liabilities | | | | |
| Contingent earn-out obligations | \$30,309 | \$ — | \$ — | \$ 30,309 |
| Interest rate swap agreements | \$914 | \$ — | \$ 914 | — |
| Temporary equity | | | | |
| Noncontrolling interests subject to put provisions | \$897,139 | \$ — | \$ — | \$ 897,139 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

The available-for-sale securities represent investments in various open-ended registered investment companies, or mutual funds, and are recorded at estimated fair value based upon quoted prices reported by each mutual fund. See Note 4 to these condensed consolidated financial statements for further discussion.

The interest rate swap and cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate swap and cap agreements would be materially different from the fair value estimates currently reported. See Note 8 to the condensed consolidated financial statements for further discussion.

The funds on deposit with third parties represent funds held with various third parties as required by regulation or contract and invested by those parties in various investments, which are measured at estimated fair value based primarily on quoted market prices.

The estimated fair value measurements of contingent earn-out obligations are primarily based on unobservable inputs including projected EBITDA, estimated probability of achieving gross margins or quality margins of certain medical procedures and the estimated probability of earn-out payments being made using an option pricing technique and a simulation model for expected EBITDA and operating income. In addition, a probability adjusted model was used to estimate the fair value amounts of the quality margins. The estimated fair value of these contingent earn-out obligations are remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company credit risk adjusted rate that is used to discount obligations to present value.

See Note 10 to these condensed consolidated financial statements for a discussion of the Company's methodology for estimating the fair value of noncontrolling interests subject to put obligations.

Other financial instruments consist primarily of cash, accounts receivable, life insurance contracts, accounts payable, other accrued liabilities and debt. The balances of the non-debt financial instruments are presented in the consolidated financial statements at September 30, 2015 at their approximate fair values due to the short-term nature of their settlements. The carrying balance of the Company's Senior Secured Credit Facilities totaled \$4,393,750 as of September 30, 2015, and the fair value was approximately \$4,382,766 based upon quoted market prices. The fair value of the Company's senior notes was approximately \$4,459,375 at September 30, 2015 based upon quoted market prices, as compared to their carrying amount of \$4,500,000.

17. Segment reporting

The Company operates two major divisions, Kidney Care and HCP. The Kidney Care division is comprised of the Company's U.S. dialysis and related lab services business, various other ancillary services and strategic initiatives, including its international dialysis operations, and the Company's corporate support costs. The Company's U.S. dialysis and related lab services business is the Company's largest line of business, and is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as ESRD. The Company's HCP division is a patient- and physician-focused integrated health care delivery and management company with nearly three decades of providing coordinated outcomes-based medical care in a cost-effective manner.

The Company's ancillary services and strategic initiatives consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care and the Company's international dialysis operations.

The Company's operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company's chief operating decision maker in making decisions about allocating resources to and assessing the financial results of the Company's various operating lines of business. The chief operating decision maker for the Company is its Chief Executive Officer.

The Company's separate operating segments include its U.S. dialysis and related lab services business, its HCP operations in each region, each of its ancillary services and strategic initiatives, and its international operations in the European, Middle Eastern, Asia Pacific, and Latin American regions. The U.S. dialysis and related lab services business and the HCP business each qualify as separately reportable segments, and all of the other ancillary services and strategic initiatives operating segments, including the international operating segments, have been combined and disclosed in the other segments category.

The Company's operating segment financial information included in this report is prepared on the internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the financial results of the operating

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

segments. For internal management reporting, segment operations include direct segment operating expenses but exclude corporate support costs, which consist primarily of indirect labor, benefits and long-term incentive based compensation of certain departments which provide support to all of the Company's various operating lines of business. Corporate support costs are reduced by internal management fees received from the Company's ancillary lines of businesses.

The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|-------------------------------------|-------------|------------------------------------|-------------|
| | 2015 | 2014 | 2015 | 2014 |
| Segment net revenues: | | | | |
| U.S. dialysis and related lab services | | | | |
| Patient service revenues: | | | | |
| External sources | \$2,287,329 | \$2,153,914 | \$6,679,251 | \$6,279,263 |
| Intersegment revenues | 13,630 | 10,701 | 39,078 | 27,617 |
| Total dialysis and related lab services | | | | |
| revenues | 2,300,959 | 2,164,615 | 6,718,329 | 6,306,880 |
| Less: Provision for uncollectible accounts | (103,543) | (91,996) | (302,324) | (257,687) |
| Net dialysis and related lab services | | | | |
| patient service revenues | 2,197,416 | 2,072,619 | 6,416,005 | 6,049,193 |
| Other revenues ⁽¹⁾ | 3,490 | 3,427 | 10,214 | 10,159 |
| Total net dialysis and related lab services | | | | |
| revenues | 2,200,906 | 2,076,046 | 6,426,219 | 6,059,352 |
| HCP | | | | |
| HCP revenues: | | | | |
| Capitated revenues | 906,478 | 827,933 | 2,587,545 | 2,382,656 |
| Net patient service revenues | 78,938 | 49,783 | 241,385 | 164,081 |
| Other revenues ⁽²⁾ | 15,536 | 14,013 | 66,124 | 72,566 |
| Intersegment capitated and other revenues | 84 | 251 | 96 | 608 |
| Total revenues | 1,001,036 | 891,980 | 2,895,150 | 2,619,911 |
| Other—Ancillary services and strategic initiatives | | | | |
| Net patient service revenues | 41,858 | 31,860 | 116,535 | 88,003 |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | |
|--|-------------|-------------|--------------|-------------|
| Capitated revenues | 20,369 | 20,613 | 56,007 | 52,824 |
| Other external sources | 275,210 | 242,277 | 793,511 | 675,224 |
| Intersegment revenues | 7,385 | 4,995 | 18,079 | 14,287 |
| Total ancillary services and strategic initiatives revenues | | | | |
| initiatives revenues | 344,822 | 299,745 | 984,132 | 830,338 |
| Total net segment revenues | 3,546,764 | 3,267,771 | 10,305,501 | 9,509,601 |
| Elimination of intersegment revenues | (21,099) | (15,947) | (57,253) | (42,512) |
| Consolidated net revenues | \$3,525,665 | \$3,251,824 | \$10,248,248 | \$9,467,089 |
| Segment operating margin (loss): | | | | |
| U.S. dialysis and related lab services | \$461,899 | \$400,226 | \$795,255 | \$1,194,874 |
| HCP | 82,562 | 46,339 | 215,192 | 182,341 |
| Other—Ancillary services and strategic initiatives | (30,118) | (5,502) | (70,153) | (5,744) |
| Total segment operating margin | 514,343 | 441,063 | 940,294 | 1,371,471 |
| Reconciliation of segment operating margin to consolidated income before income taxes: | | | | |
| Corporate support costs | (4,975) | (3,527) | (14,534) | (8,415) |
| Consolidated operating income | 509,368 | 437,536 | 925,760 | 1,363,056 |
| Debt expense | (103,481) | (99,878) | (305,121) | (312,345) |
| Debt redemption and refinancing charges | | | (48,072) | (97,548) |
| Other income (loss), net | 2,484 | (1,246) | 4,262 | 2,145 |
| Consolidated income before income taxes | \$408,371 | \$336,412 | \$576,829 | \$955,308 |

⁽¹⁾Includes management fees for providing management and administrative services to dialysis centers that are wholly-owned by third parties or centers in which the Company owns a minority equity investment.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

⁽²⁾Includes payments received for medical consulting services and management fees for providing management and administrative services to an unconsolidated joint venture that provides medical services in which the Company owns a 50% interest, as well as revenue related to the maintenance of existing physician networks.

Depreciation and amortization expense by reportable segment is as follows:

| | Three months ended September 30, | | Nine months ended September 30, | |
|--|-------------------------------------|------------|------------------------------------|------------|
| | 2015 | 2014 | 2015 | 2014 |
| U.S. dialysis and related lab services | \$ 111,828 | \$ 101,870 | \$ 326,281 | \$ 297,477 |
| HCP | 43,523 | 42,558 | 129,890 | 126,555 |
| Ancillary services and strategic initiatives | 6,711 | 4,768 | 18,523 | 13,650 |
| | \$ 162,062 | \$ 149,196 | \$ 474,694 | \$ 437,682 |

Summary of assets by reportable segment is as follows:

| | September 30, 2015 | December 31, 2014 |
|--|--------------------------|-------------------------|
| Segment assets | | |
| U.S. dialysis and related lab services (including equity investments of \$29,784 and \$28,138, respectively) | \$ 11,752,159 | \$ 10,959,096 |
| HCP (including equity investments of \$16,618 and \$15,393, respectively) | 6,403,622 | 6,285,984 |
| Other—Ancillary services and strategic initiatives (including equity investments of \$21,481 and \$22,106, respectively) | 739,047 | 697,635 |
| Consolidated assets | \$ 18,894,828 | \$ 17,942,715 |

Expenditures for property and equipment by reportable segment is as follows:

Three months ended Nine months ended

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | September 30, | | September 30, | |
|--|---------------|-----------|---------------|-----------|
| | 2015 | 2014 | 2015 | 2014 |
| U.S. dialysis and related lab services. | \$138,683 | \$149,247 | \$385,734 | \$399,114 |
| HCP | 18,885 | 6,121 | 36,870 | 16,401 |
| Ancillary services and strategic initiatives | 13,772 | 9,546 | 39,609 | 27,992 |
| | \$171,340 | \$164,914 | \$462,213 | \$443,507 |

18. Changes in DaVita HealthCare Partners Inc.'s ownership interest in consolidated subsidiaries

The effects of changes in DaVita HealthCare Partners Inc.'s ownership interest on the Company's equity are as follows:

| | Three months ended | | Nine months ended | |
|--|--------------------|-----------|-------------------|-----------|
| | September 30, | | September 30, | |
| | 2015 | 2014 | 2015 | 2014 |
| Net income attributable to DaVita HealthCare Partners Inc. | \$215,872 | \$184,122 | \$275,732 | \$515,094 |
| (Decrease) increase in paid-in capital for sales of noncontrolling interests | — | (316) | — | 355 |
| Decrease in paid-in capital for the purchase of noncontrolling interests and adjustments to ownership interest | (12,094) | (1,962) | (20,515) | (506) |
| Net transfers to noncontrolling interests | (12,094) | (2,278) | (20,515) | (151) |
| Net income attributable to DaVita HealthCare Partners Inc., net of transfers to noncontrolling interests | \$203,778 | \$181,844 | \$255,217 | \$514,943 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

19. New accounting standards

In September 2015, the FASB issued Accounting Standards Update (ASU) No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. The amendments in this ASU allow an acquirer to recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This will be inclusive of the effect on earnings of changes in depreciation, amortization, or other income effects as a result of the change to provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments in this ASU are effective for the Company beginning on January 1, 2016, to be applied prospectively. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company's condensed consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The amendments in this ASU apply to all inventory with the exception of inventory measured using last-in, first-out or the retail inventory method. This ASU simplifies the measurement of inventory. Under this new standard, inventory should be measured using the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonable predictable costs of completion, disposal and transportation. The amendments in this ASU are effective for the Company beginning January 1, 2017 and should be applied prospectively. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company's condensed consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued ASU 2015-15, Interest - Imputation of Interest (Subtopic 835-30) - Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements, which clarifies that the treatment of debt issuance costs related to a line-of-credit may continue to be deferred in an asset position and subsequently amortized over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The amendments in these ASUs are effective for the Company beginning January 1, 2016. Early adoption is permitted. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The adoption of this standard will not have a material impact on the Company's condensed consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-05, Customer's Accounting for Fees Paid in a Cloud Computing Arrangement, which amends ASC 350-40, Intangibles-Goodwill and Other-Internal-Use Software. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license. If an arrangement includes a software license, the accounting for the license will be consistent with licenses of other intangible assets. If the arrangement does not include a license, the arrangement will be accounted for as a service contract. The effective date will be the first quarter of fiscal year 2017 and can be adopted prospectively or retrospectively. The adoption of this standard will not have a material impact on the Company's condensed consolidated financial statements.

In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. The amendments in the ASU clarify consolidation of VIEs regarding which reporting entity consolidates the legal entity. The amendments in the ASU are effective for the Company January 1, 2016. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company's condensed consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard as issued is effective for the Company on January 1, 2017. In July 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date. This guidance approves a one-year deferral of the effective date of ASU 2014-09. The final ASU now permits the Company to adopt this standard on January 1, 2018. Early application is permitted as of the initial effective date of January 1, 2017, but not prior to that date. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

20. Condensed consolidating financial statements

The following information is presented in accordance with Rule 3-10 of Regulation S-X. The operating and investing activities of the separate legal entities included in the Company's consolidated financial statements are fully interdependent and integrated. Revenues and operating expenses of the separate legal entities include intercompany charges for management and other administrative services. The Company's senior notes are guaranteed by substantially all of its domestic wholly-owned subsidiaries. Each of the guarantor subsidiaries has guaranteed the notes on a joint and several basis. However, the guarantor subsidiaries can be released from their obligations in the event of a sale or other disposition of all or substantially all of the assets of such subsidiary, including by merger or consolidation or the sale of all equity interests in such subsidiary owned by the Company, if such subsidiary guarantor is designated as an unrestricted subsidiary or otherwise ceases to be a restricted subsidiary, and if such subsidiary guarantor no longer guaranties any other indebtedness of the Company. Non-wholly-owned subsidiaries, certain wholly-owned subsidiaries, foreign subsidiaries, joint ventures, partnerships, non-owned entities and third parties are not guarantors of these obligations.

Condensed Consolidating Statements of Income

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|--|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the three months ended September 30, 2015 | | | | | |
| Patient service revenues | \$ — | \$ 1,656,648 | \$ 795,325 | \$ (37,939) | \$ 2,414,034 |
| Less: Provision for uncollectible accounts | — | (78,494) | (30,958) | — | (109,452) |
| Net patient service revenues | — | 1,578,154 | 764,367 | (37,939) | 2,304,582 |
| Capitated revenues | — | 453,766 | 473,196 | (115) | 926,847 |
| Other revenues | 184,561 | 480,412 | 7,869 | (378,606) | 294,236 |
| Total net revenues | 184,561 | 2,512,332 | 1,245,432 | (416,660) | 3,525,665 |
| Operating expenses | 110,935 | 2,244,237 | 1,077,785 | (416,660) | 3,016,297 |
| Operating income | 73,626 | 268,095 | 167,647 | — | 509,368 |
| Debt expense, including debt refinancing charges | (102,136) | (83,037) | (9,766) | 91,458 | (103,481) |
| Other income | 89,824 | 2,379 | 1,739 | (91,458) | 2,484 |
| Income tax expense | 25,368 | 112,310 | 9,386 | — | 147,064 |
| Equity earnings in subsidiaries | 179,926 | 104,799 | — | (284,725) | — |
| Net income | 215,872 | 179,926 | 150,234 | (284,725) | 261,307 |
| Less: Net income attributable to noncontrolling interests | — | — | — | (45,435) | (45,435) |
| Net income attributable to DaVita HealthCare | \$ 215,872 | \$ 179,926 | \$ 150,234 | \$ (330,160) | \$ 215,872 |

Partners Inc.

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|--|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the three months ended September 30, 2014 | | | | | |
| Patient service revenues | \$ — | \$ 1,592,398 | \$ 683,171 | \$ (33,036) | \$ 2,242,533 |
| Less: Provision for uncollectible accounts | — | (61,973) | (36,998) | — | (98,971) |
| Net patient service revenues | — | 1,530,425 | 646,173 | (33,036) | 2,143,562 |
| Capitated revenues | — | 442,472 | 406,926 | (852) | 848,546 |
| Other revenues | 174,226 | 422,733 | 5,821 | (343,064) | 259,716 |
| Total net revenues | 174,226 | 2,395,630 | 1,058,920 | (376,952) | 3,251,824 |
| Operating expenses | 123,856 | 2,126,918 | 940,466 | (376,952) | 2,814,288 |
| Operating income | 50,370 | 268,712 | 118,454 | — | 437,536 |
| Debt expense | (98,496) | (89,048) | (8,730) | 96,396 | (99,878) |
| Other income | 94,258 | 388 | 504 | (96,396) | (1,246) |
| Income tax expense | 18,395 | 99,927 | (1,694) | — | 116,628 |
| Equity earnings in subsidiaries | 156,385 | 76,260 | — | (232,645) | — |
| Net income | 184,122 | 156,385 | 111,922 | (232,645) | 219,784 |
| Less: Net income attributable to noncontrolling interests | — | — | — | (35,662) | (35,662) |
| Net income attributable to DaVita HealthCare | | | | | |
| Partners Inc. | \$ 184,122 | \$ 156,385 | \$ 111,922 | \$ (268,307) | \$ 184,122 |

24

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

| For the nine months ended September 30, 2015 | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|---|--|---------------------------|-----------------------------------|------------------------------|-----------------------|
| Patient service revenues | \$— | \$4,901,959 | \$2,254,624 | \$(107,155) | \$7,049,428 |
| Less: Provision for uncollectible accounts | — | (212,816) | (101,765) | — | (314,581) |
| Net patient service revenues | — | 4,689,143 | 2,152,859 | (107,155) | 6,734,847 |
| Capitated revenues | — | 1,340,838 | 1,302,862 | (148) | 2,643,552 |
| Other revenues | 542,412 | 1,360,261 | 21,547 | (1,054,371) | 869,849 |
| Total net revenues | 542,412 | 7,390,242 | 3,477,268 | (1,161,674) | 10,248,248 |
| Operating expenses | 363,347 | 7,042,896 | 3,077,919 | (1,161,674) | 9,322,488 |
| Operating income | 179,065 | 347,346 | 399,349 | — | 925,760 |
| Debt expense, including debt refinancing charges | (347,719) | (253,939) | (30,532) | 278,997 | (353,193) |
| Other income | 271,847 | 6,780 | 4,632 | (278,997) | 4,262 |
| Income tax expense | 41,215 | 116,934 | 25,744 | — | 183,893 |
| Equity earnings in subsidiaries | 213,754 | 230,501 | — | (444,255) | — |
| Net income | 275,732 | 213,754 | 347,705 | (444,255) | 392,936 |
| Less: Net income attributable to noncontrolling interests | — | — | — | (117,204) | (117,204) |
| Net income attributable to DaVita HealthCare Partners Inc. | \$275,732 | \$213,754 | \$347,705 | \$(561,459) | \$275,732 |

| For the nine months ended September 30, 2014 | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|---|--|---------------------------|-----------------------------------|------------------------------|-----------------------|
| Patient service revenues | \$— | \$4,622,943 | \$2,007,435 | \$(86,498) | \$6,543,880 |
| Less: Provision for uncollectible accounts | — | (169,133) | (101,087) | — | (270,220) |
| Net patient service revenues | — | 4,453,810 | 1,906,348 | (86,498) | 6,273,660 |
| Capitated revenues | — | 1,261,385 | 1,175,354 | (1,259) | 2,435,480 |
| Other revenues | 518,468 | 1,241,043 | 17,229 | (1,018,791) | 757,949 |
| Total net revenues | 518,468 | 6,956,238 | 3,098,931 | (1,106,548) | 9,467,089 |
| Operating expenses | 358,968 | 6,141,200 | 2,710,413 | (1,106,548) | 8,104,033 |
| Operating income | 159,500 | 815,038 | 388,518 | — | 1,363,056 |
| Debt expense | (406,037) | (277,854) | (28,662) | 302,660 | (409,893) |
| Other income | 293,733 | 9,323 | 1,749 | (302,660) | 2,145 |
| Income tax expense | 18,826 | 315,473 | 8,067 | — | 342,366 |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | | |
|--|------------|------------|------------|---------------|------------|
| Equity earnings in subsidiaries | 486,724 | 255,690 | — | (742,414) | — |
| Net income | 515,094 | 486,724 | 353,538 | (742,414) | 612,942 |
| Less: Net income attributable to noncontrolling interests | — | — | — | (97,848) | (97,848) |
| Net income attributable to DaVita HealthCare Partners Inc. | \$ 515,094 | \$ 486,724 | \$ 353,538 | \$ (840,262) | \$ 515,094 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Condensed Consolidating Statements of Comprehensive Income

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|---|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the three months ended September 30, 2015 | | | | | |
| Net income | \$ 215,872 | \$ 179,926 | \$ 150,234 | \$ (284,725) | \$ 261,307 |
| Other comprehensive loss | (2,934) | — | (7,023) | — | (9,957) |
| Total comprehensive income | 212,938 | 179,926 | 143,211 | (284,725) | 251,350 |
| Less: comprehensive income attributable to the | | | | | |
| noncontrolling interests | — | — | — | (45,435) | (45,435) |
| Comprehensive income attributable to DaVita | | | | | |
| HealthCare Partners Inc. | \$ 212,938 | \$ 179,926 | \$ 143,211 | \$ (330,160) | \$ 205,915 |

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|---|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the three months ended September 30, 2014 | | | | | |
| Net income | \$ 184,122 | \$ 156,385 | \$ 111,922 | \$ (232,645) | \$ 219,784 |
| Other comprehensive income (loss) | 1,548 | — | (13,838) | — | (12,290) |
| Total comprehensive income | 185,670 | 156,385 | 98,084 | (232,645) | 207,494 |
| Less: comprehensive income attributable to the | | | | | |
| noncontrolling interests | — | — | — | (35,662) | (35,662) |
| Comprehensive income attributable to DaVita | | | | | |
| HealthCare Partners Inc. | \$ 185,670 | \$ 156,385 | \$ 98,084 | \$ (268,307) | \$ 171,832 |

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|--|--|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the nine months ended September 30, 2015 | | | | | |
| Net income | \$ 275,732 | \$ 213,754 | \$ 347,705 | \$ (444,255) | \$ 392,936 |
| Other comprehensive loss | (9,436) | — | (19,883) | — | (29,319) |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | | |
|--|------------|------------|------------|---------------|------------|
| Total comprehensive income | 266,296 | 213,754 | 327,822 | (444,255) | 363,617 |
| Less: comprehensive income attributable to the | | | | | |
| noncontrolling interests | — | — | — | (117,204) | (117,204) |
| Comprehensive income attributable to DaVita HealthCare | | | | | |
| Partners Inc. | \$ 266,296 | \$ 213,754 | \$ 327,822 | \$ (561,459) | \$ 246,413 |

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|--|--|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the nine months ended September 30, 2014 | | | | | |
| Net income | \$ 515,094 | \$ 486,724 | \$ 353,538 | \$ (742,414) | \$ 612,942 |
| Other comprehensive income (loss) | 2,892 | — | (11,871) | — | (8,979) |
| Total comprehensive income | 517,986 | 486,724 | 341,667 | (742,414) | 603,963 |
| Less: comprehensive income attributable to the | | | | | |
| noncontrolling interests | — | — | — | (97,848) | (97,848) |
| Comprehensive income attributable to DaVita HealthCare | | | | | |
| Partners Inc. | \$ 517,986 | \$ 486,724 | \$ 341,667 | \$ (840,262) | \$ 506,115 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Condensed Consolidating Balance Sheets

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|--|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| As of September 30, 2015 | | | | | |
| Cash and cash equivalents | \$721,477 | \$88,969 | \$236,973 | \$— | \$1,047,419 |
| Accounts receivable, net | — | 940,399 | 759,493 | — | 1,699,892 |
| Other current assets | 941,660 | 956,238 | 92,677 | — | 1,990,575 |
| Total current assets | 1,663,137 | 1,985,606 | 1,089,143 | — | 4,737,886 |
| Property and equipment, net | 204,437 | 1,510,820 | 906,661 | — | 2,621,918 |
| Amortizable intangibles, net | 86,336 | 1,690,110 | 50,336 | — | 1,826,782 |
| Investments in subsidiaries | 8,995,822 | 1,580,113 | — | (10,575,935) | — |
| Intercompany receivables | 3,508,016 | — | 644,469 | (4,152,485) | — |
| Other long-term assets and investments | 59,900 | 54,381 | 106,382 | — | 220,663 |
| Goodwill | — | 8,028,591 | 1,458,988 | — | 9,487,579 |
| Total assets | \$14,517,648 | \$14,849,621 | \$4,255,979 | \$(14,728,420) | \$18,894,828 |
| Current liabilities | \$167,134 | \$1,764,955 | \$478,465 | \$— | \$2,410,554 |
| Intercompany payables | — | 2,725,877 | 1,426,608 | (4,152,485) | — |
| Long-term debt and other long-term liabilities | 8,787,905 | 1,362,967 | 244,066 | — | 10,394,938 |
| Noncontrolling interests subject to put provisions | 572,256 | — | — | 324,883 | 897,139 |
| Total DaVita HealthCare Partners Inc. shareholders' equity | 4,990,353 | 8,995,822 | 1,580,113 | (10,575,935) | 4,990,353 |
| Noncontrolling interests not subject to put provisions | — | — | 526,727 | (324,883) | 201,844 |
| Total equity | 4,990,353 | 8,995,822 | 2,106,840 | (10,900,818) | 5,192,197 |
| Total liabilities and equity | \$14,517,648 | \$14,849,621 | \$4,255,979 | \$(14,728,420) | \$18,894,828 |

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|------------------------------|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| As of December 31, 2014 | | | | | |
| Cash and cash equivalents | \$698,876 | \$77,921 | \$188,444 | \$— | \$965,241 |
| Accounts receivable, net | — | 915,851 | 609,998 | — | 1,525,849 |
| Other current assets | 362,672 | 930,093 | 92,942 | — | 1,385,707 |
| Total current assets | 1,061,548 | 1,923,865 | 891,384 | — | 3,876,797 |
| Property and equipment, net | 195,690 | 1,473,188 | 800,221 | — | 2,469,099 |
| Amortizable intangibles, net | 85,338 | 1,811,218 | 52,942 | — | 1,949,498 |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | | |
|--|---------------|---------------|--------------|------------------|---------------|
| Investments in subsidiaries | 8,868,335 | 1,561,195 | — | (10,429,530) | — |
| Intercompany receivables | 3,723,454 | — | 564,241 | (4,287,695) | — |
| Other long-term assets and investments | 70,309 | 60,385 | 101,332 | — | 232,026 |
| Goodwill | — | 7,958,221 | 1,457,074 | — | 9,415,295 |
| Total assets | \$ 14,004,674 | \$ 14,788,072 | \$ 3,867,194 | \$ (14,717,225) | \$ 17,942,715 |
| Current liabilities | \$ 180,977 | \$ 1,493,243 | \$ 414,432 | \$ — | \$ 2,088,652 |
| Intercompany payables | — | 3,105,173 | 1,182,522 | (4,287,695) | — |
| Long-term debt and other long-term liabilities | 8,124,863 | 1,321,321 | 217,603 | — | 9,663,787 |
| Noncontrolling interests subject to put provisions | 528,321 | — | — | 301,644 | 829,965 |
| Total DaVita HealthCare Partners Inc. shareholders' equity | 5,170,513 | 8,868,335 | 1,561,195 | (10,429,530) | 5,170,513 |
| Noncontrolling interests not subject to put provisions | — | — | 491,442 | (301,644) | 189,798 |
| Total equity | 5,170,513 | 8,868,335 | 2,052,637 | (10,731,174) | 5,360,311 |
| Total liabilities and equity | \$ 14,004,674 | \$ 14,788,072 | \$ 3,867,194 | \$ (14,717,225) | \$ 17,942,715 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Condensed Consolidating Statements of Cash Flows

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|---|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the nine months ended September 30, 2015 | | | | | |
| Cash flows from operating activities: | | | | | |
| Net income | \$ 275,732 | \$ 213,754 | \$ 347,705 | \$ (444,255) | \$ 392,936 |
| Changes in operating assets and liabilities and non-cash | | | | | |
| items included in net income | (187,876) | 441,752 | 29,460 | 444,255 | 727,591 |
| Net cash provided by operating activities | 87,856 | 655,506 | 377,165 | — | 1,120,527 |
| Cash flows from investing activities: | | | | | |
| Additions of property and equipment, net | (39,448) | (222,447) | (200,318) | | (462,213) |
| Acquisitions | — | (73,339) | (17,370) | | (90,709) |
| Proceeds from asset and business sales | — | 6,865 | — | | 6,865 |
| (Purchases) proceeds from investment sales and other items | (587,583) | 1,513 | (18,257) | | (604,327) |
| Net cash used in investing activities | (627,031) | (287,408) | (235,945) | — | (1,150,384) |
| Cash flows from financing activities: | | | | | |
| Long-term debt and related financing costs, net | 661,260 | (13,183) | (8,760) | | 639,317 |
| Intercompany borrowing | 304,623 | (320,262) | 15,639 | | — |
| Other items | (404,107) | (23,605) | (97,726) | | (525,438) |
| Net cash provided by (used in) financing activities | 561,776 | (357,050) | (90,847) | — | 113,879 |
| Effect of exchange rate changes on cash | — | — | (1,844) | — | (1,844) |
| Net increase in cash and cash equivalents | 22,601 | 11,048 | 48,529 | | 82,178 |
| Cash and cash equivalents at beginning of period | 698,876 | 77,921 | 188,444 | | 965,241 |
| Cash and cash equivalents at end of period | \$ 721,477 | \$ 88,969 | \$ 236,973 | \$ — | \$ 1,047,419 |

| | DaVita HealthCare Partners Inc. | Guarantor subsidiaries | Non- Guarantor subsidiaries | Consolidating adjustments | Consolidated total |
|---|---------------------------------------|---------------------------|-----------------------------------|------------------------------|-----------------------|
| For the nine months ended September 30, 2014 | | | | | |
| Cash flows from operating activities: | | | | | |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | | |
|---|--------------|------------|------------|---------------|--------------|
| Net income | \$ 515,094 | \$ 486,724 | \$ 353,538 | \$ (742,414) | \$ 612,942 |
| Changes in operating assets and liabilities and non-cash items included in net income | (479,441) | 578,778 | 74,705 | 742,414 | 916,456 |
| Net cash provided by operating activities | 35,653 | 1,065,502 | 428,243 | — | 1,529,398 |
| Cash flows from investing activities: | | | | | |
| Additions of property and equipment, net | (37,752) | (215,072) | (190,683) | | (443,507) |
| Acquisitions | — | (204,670) | (13,447) | | (218,117) |
| Proceeds from asset sales | — | 3,620 | — | | 3,620 |
| Purchases of investments and other items | (137,313) | (33,111) | (2,757) | | (173,181) |
| Net cash used in investing activities | (175,065) | (449,233) | (206,887) | — | (831,185) |
| Cash flows from financing activities: | | | | | |
| Long-term debt and related financing costs, net | 40,250 | (9,247) | 295 | | 31,298 |
| Intercompany borrowing | 759,648 | (622,853) | (136,795) | | — |
| Other items | (74,955) | (8,292) | (67,060) | | (150,307) |
| Net cash provided by (used in) financing activities | 724,943 | (640,392) | (203,560) | — | (119,009) |
| Effect of exchange rate changes on cash | | | 1,582 | | 1,582 |
| Net increase (decrease) in cash and cash equivalents | 585,531 | (24,123) | 19,378 | | 580,786 |
| Cash and cash equivalents at beginning of period | 602,188 | 151,454 | 192,607 | | 946,249 |
| Cash and cash equivalents at end of period | \$ 1,187,719 | \$ 127,331 | \$ 211,985 | \$ — | \$ 1,527,035 |

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

21. Supplemental data

The following information is presented as supplemental data as required by the indentures governing the Company's senior notes.

Condensed Consolidating Statements of Income

| | Consolidated | Physician | Unrestricted | Company and |
|--|--------------|-----------|--------------|--|
| For the nine months ended September 30, 2015 | Total | Groups | Subsidiaries | Restricted Subsidiaries ⁽¹⁾ |
| Patient service operating revenues | \$7,049,428 | \$98,305 | \$ — | \$ 6,951,123 |
| Less: Provision for uncollectible accounts | (314,581) | (5,335) | — | (309,246) |
| Net patient service operating revenues | 6,734,847 | 92,970 | — | 6,641,877 |
| Capitated revenues | 2,643,552 | 1,242,486 | — | 1,401,066 |
| Other revenues | 869,849 | 4,132 | — | 865,717 |
| Total net operating revenues | 10,248,248 | 1,339,588 | — | 8,908,660 |
| Operating expenses | 9,322,488 | 1,287,321 | (78) | 8,035,245 |
| Operating income | 925,760 | 52,267 | 78 | 873,415 |
| Debt expense, including refinancing charges | (353,193) | (6,518) | — | (346,675) |
| Other income | 4,262 | 195 | — | 4,067 |
| Income tax expense | 183,893 | 8,314 | 31 | 175,548 |
| Net income | 392,936 | 37,630 | 47 | 355,259 |
| Less: Net income attributable to noncontrolling interests | (117,204) | — | — | (117,204) |
| Net income attributable to DaVita HealthCare Partners Inc. | \$275,732 | \$37,630 | \$ 47 | \$ 238,055 |

⁽¹⁾After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Comprehensive Income

| | Consolidated | Physician | Unrestricted | Company and |
|--|--------------|-----------|--------------|--|
| For the nine months ended September 30, 2015 | Total | Groups | Subsidiaries | Restricted Subsidiaries ⁽¹⁾ |
| Net income | \$ 392,936 | \$ 37,630 | \$ 47 | \$ 355,259 |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | |
|---|------------|-----------|-------|------------|
| Other comprehensive loss | (29,319) | — | — | (29,319) |
| Total comprehensive income | 363,617 | 37,630 | 47 | 325,940 |
| Less: comprehensive income attributable to the noncontrolling interests | (117,204) | — | — | (117,204) |
| Comprehensive income attributable to DaVita HealthCare Partners Inc. | \$ 246,413 | \$ 37,630 | \$ 47 | \$ 208,736 |

(1) After elimination of the unrestricted subsidiaries and the physician groups.

29

DAVITA HEALTHCARE PARTNERS INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)

(unaudited)

(dollars and shares in thousands, except per share data)

Condensed Consolidating Balance Sheets

| As of September 30, 2015 | Consolidated Total | Physician Groups | Unrestricted Subsidiaries | Company and Restricted Subsidiaries ⁽¹⁾ |
|--|-----------------------|---------------------|------------------------------|--|
| Cash and cash equivalents | \$ 1,047,419 | \$ 81,730 | \$ — | \$ 965,689 |
| Accounts receivable, net | 1,699,892 | 336,176 | — | 1,363,716 |
| Other current assets | 1,990,575 | 17,033 | — | 1,973,542 |
| Total current assets | 4,737,886 | 434,939 | — | 4,302,947 |
| Property and equipment, net | 2,621,918 | 1,902 | — | 2,620,016 |
| Amortizable intangibles, net | 1,826,782 | 6,218 | — | 1,820,564 |
| Other long-term assets | 220,663 | 69,010 | 2,889 | 148,764 |
| Goodwill | 9,487,579 | 15,967 | — | 9,471,612 |
| Total assets | \$ 18,894,828 | \$ 528,036 | \$ 2,889 | \$ 18,363,903 |
| Current liabilities | \$ 2,410,554 | \$ 249,122 | \$ — | \$ 2,161,432 |
| Payables to parent | — | 172,149 | 2,889 | (175,038) |
| Long-term debt and other long-term liabilities | 10,394,938 | 52,611 | — | 10,342,327 |
| Noncontrolling interests subject to put provisions | 897,139 | — | — | 897,139 |
| Total DaVita HealthCare Partners Inc. shareholders' equity | 4,990,353 | 54,154 | — | 4,936,199 |
| Noncontrolling interests not subject to put provisions | 201,844 | — | — | 201,844 |
| Shareholders' equity | 5,192,197 | 54,154 | — | 5,138,043 |
| Total liabilities and shareholder's equity | \$ 18,894,828 | \$ 528,036 | \$ 2,889 | \$ 18,363,903 |

⁽¹⁾After elimination of the unrestricted subsidiaries and the physician groups.

Condensed Consolidating Statements of Cash Flows

| For the nine months ended September 30, 2015 | Consolidated Total | Physician Groups | Unrestricted Subsidiaries | Company and Restricted Subsidiaries ⁽¹⁾ |
|--|-----------------------|---------------------|------------------------------|--|
| Cash flows from operating activities: | | | | |
| Net income | \$ 392,936 | \$ 37,630 | \$ 47 | \$ 355,259 |
| Changes in operating and intercompany assets and liabilities | | | | |
| and non-cash items included in net income | 727,591 | (57,518) | (47) | 785,156 |
| Net cash provided by (used in) operating activities | 1,120,527 | (19,888) | — | 1,140,415 |
| Cash flows from investing activities: | | | | |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | |
|--|--------------|-----------|------|--------------|
| Additions of property and equipment | (462,213) | (143) | — | (462,070) |
| Acquisitions and divestitures, net | (90,709) | — | — | (90,709) |
| Proceeds from discontinued operations | 6,865 | — | — | 6,865 |
| Investments and other items | (604,327) | (1,973) | — | (602,354) |
| Net cash used in investing activities | (1,150,384) | (2,116) | — | (1,148,268) |
| Cash flows from financing activities: | | | | |
| Long-term debt | 639,317 | — | — | 639,317 |
| Intercompany | — | (8,714) | — | 8,714 |
| Other items | (525,438) | — | — | (525,438) |
| Net cash used in by financing activities | 113,879 | (8,714) | — | 122,593 |
| Effect of exchange rate changes on cash | (1,844) | — | — | (1,844) |
| Net increase (decrease) in cash | 82,178 | (30,718) | — | 112,896 |
| Cash and cash equivalents at beginning of period | 965,241 | 112,448 | — | 852,793 |
| Cash and cash equivalents at end of period | \$ 1,047,419 | \$ 81,730 | \$ — | \$ 965,689 |

(1) After elimination of the unrestricted subsidiaries and the physician groups.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward-looking statements

This Management's Discussion and Analysis of Financial Condition and Results of Operations contains statements that are forward-looking statements within the meaning of the federal securities laws. All statements that do not concern historical facts are forward-looking statements and include, among other things, statements about our expectations, beliefs, intentions and/or strategies for the future. These forward-looking statements include statements regarding our future operations, financial condition and prospects, expectations for treatment growth rates, revenue per treatment, expense growth, levels of the provision for uncollectible accounts receivable, operating income, cash flow, operating cash flow, estimated tax rates, capital expenditures, the development of new dialysis centers and dialysis center acquisitions, government and commercial payment rates, revenue estimating risk and the impact of our level of indebtedness on our financial performance, and including earnings per share. These statements involve substantial known and unknown risks and uncertainties that could cause our actual results to differ materially from those described in the forward-looking statements, including but not limited to, risks resulting from the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, which may result in the loss of revenues or patients, a reduction in government payment rates under the Medicare end stage renal disease (ESRD) program or other government-based programs, the impact of the Center for Medicare and Medicaid Services (CMS) 2015 Medicare Advantage benchmark structure, risks arising from potential federal and/or state legislation that could have an adverse effect on our operations and profitability, changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing, legal compliance risks, including our continued compliance with complex government regulations, compliance with the provisions of our current corporate integrity agreement and current or potential investigations by various government entities and related government or private-party proceedings, restrictions on our business and operations required by our corporate integrity agreement and other settlement terms, and the financial impact thereof, continued increased competition from large- and medium-sized dialysis providers that compete directly with us, our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector that may erode our patient base and reimbursement rates such as accountable care organizations (ACOs), independent practice associations (IPAs) and integrated delivery systems, or to businesses outside of dialysis and HCP's business, our ability to complete acquisitions, mergers or dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire or have acquired, including HCP, or to expand our operations and services to markets outside the U.S., variability of our cash flows, the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all, risks arising from the use of accounting estimates, judgments and interpretations in our financial statements, loss of key HCP employees, potential disruption from the HCP transaction making it more difficult to maintain business and operational relationships with customers, partners, associated physicians and physician groups, hospitals and others, the risk that laws regulating the corporate practice of medicine could restrict the manner in which HCP conducts its business, the risk that the cost of providing services under HCP's agreements may exceed our compensation, the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact HCP's business, revenue and profitability, the risk that HCP may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability, the risk that a disruption in HCP's healthcare provider networks could have an adverse effect on HCP's business operations and profitability, the risk that reductions in the quality ratings of health maintenance organization plan customers of HCP could have an adverse effect on HCP's business, or the risk that health plans that acquire health maintenance organizations may not be willing to contract with HCP or may be willing to contract only on less favorable terms, and the other risk factors set forth in Part II, Item 1A. of this Quarterly Report on Form 10-Q. We base our forward-looking statements on information currently available to us, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new

information, future events or otherwise.

The following should be read in conjunction with our condensed consolidated financial statements.

Consolidated results of operations

We operate two major divisions, Kidney Care and HealthCare Partners (HCP). Our Kidney Care division is comprised of our U.S. dialysis and related lab services business, our ancillary services and strategic initiatives, including our international operations, and our corporate support costs. Our HCP division is comprised of our HCP integrated healthcare business.

Our largest major line of business is our U.S. dialysis and related lab services, which is a leading provider of kidney dialysis services in the U.S. for patients suffering from ESRD. Our other major line of business, HCP, is a patient- and physician-focused integrated health care delivery and management company.

The following is a summary of our consolidated operating results for the third quarter of 2015 compared with the prior sequential quarter and the same quarter of 2014, as well as the nine months ended September 30, 2015 compared to the same period in 2014.

| | Three months ended | | | September | | | Nine months ended | | | September | | |
|--|--------------------------|------------------|-------|--------------------------|-------|-------|-----------------------|-------|---------|--------------------------|--|--|
| | September 30, 2015 | June 30, 2015 | | September 30, 2014 | | | September 30, 2015 | | | September 30, 2014 | | |
| (dollar amounts rounded to nearest million) | | | | | | | | | | | | |
| Net revenues: | | | | | | | | | | | | |
| Patient service revenues | \$2,414 | \$2,364 | | \$2,243 | | | \$7,050 | | | \$6,544 | | |
| Less: Provision for uncollectible | | | | | | | | | | | | |
| accounts | (109) | (106) | | (99) | | | (315) | | | (270) | | |
| Net patient service revenues | 2,305 | 2,258 | | 2,144 | | | 6,735 | | | 6,274 | | |
| Capitated revenues | 927 | 866 | | 848 | | | 2,643 | | | 2,435 | | |
| Other revenues | 294 | 311 | | 260 | | | 870 | | | 758 | | |
| Total consolidated net | | | | | | | | | | | | |
| revenues | 3,526 | 100 % | 3,435 | 100 % | 3,252 | 100 % | 10,248 | 100 % | 9,467 | 100 % | | |
| Operating expenses and charges: | | | | | | | | | | | | |
| Patient care costs | 2,501 | 71 % | 2,446 | 71 % | 2,326 | 72 % | 7,310 | 71 % | 6,753 | 71 % | | |
| General and administrative | 354 | 10 % | 352 | 10 % | 323 | 10 % | 1,047 | 10 % | 905 | 10 % | | |
| Depreciation and amortization | 162 | 5 % | 159 | 5 % | 149 | 5 % | 475 | 5 % | 438 | 5 % | | |
| Provision for uncollectible | | | | | | | | | | | | |
| accounts | 3 | — | 2 | — | 4 | — | 6 | — | 10 | — | | |
| Equity investment income | (3) | — | (5) | — | (5) | — | (11) | — | (19) | — | | |
| Loss contingency reserve and settlement charge | — | — | — | — | 17 | — | 495 | 5 % | 17 | — | | |
| Total operating expenses and | | | | | | | | | | | | |
| charges | 3,017 | 86 % | 2,954 | 86 % | 2,814 | 87 % | 9,322 | 91 % | 8,104 | 86 % | | |
| Operating income | \$509 | 14 % | \$481 | 14 % | \$438 | 13 % | \$926 | 9 % | \$1,363 | 14 % | | |

The following table summarizes consolidated net revenues for our Kidney Care division and our HCP division:

| | Three months ended | | | Nine months ended | |
|--|--------------------|--------------------|--------------------|--------------------|--------------------|
| | September 30, 2015 | September 30, 2014 | September 30, 2015 | September 30, 2014 | September 30, 2014 |
| (dollar amounts rounded to nearest million) | | | | | |
| Net revenues: | | | | | |
| Kidney Care: | | | | | |
| U.S. dialysis and related lab services patient | | | | | |
| service revenues | \$2,301 | \$ 2,252 | \$ 2,165 | \$ 6,718 | \$ 6,307 |
| Less: Provision for uncollectible accounts | (103) | (101) | (92) | (302) | (258) |
| U.S. dialysis and related lab services net patient | | | | | |
| service revenues | \$2,198 | \$ 2,151 | \$ 2,073 | \$ 6,416 | \$ 6,049 |
| Other revenues | 3 | 3 | 3 | 10 | 10 |
| Total net U.S. dialysis and related lab | | | | | |
| services revenues | 2,201 | 2,154 | 2,076 | 6,426 | 6,059 |
| Other—Ancillary services and strategic | | | | | |
| initiatives revenues | 283 | 277 | 247 | 812 | 690 |
| Other—Capitated revenues | 20 | 18 | 21 | 56 | 53 |
| Other—Ancillary services and strategic initiatives | | | | | |
| net patient service revenues (less provision for | | | | | |
| uncollectible accounts) | 42 | 39 | 32 | 116 | 88 |
| Total net other-ancillary services and strategic | | | | | |
| initiatives revenues | 345 | 334 | 300 | 984 | 831 |
| Elimination of intersegment and division | | | | | |
| revenues | (21) | (19) | (16) | (57) | (43) |
| Total Kidney Care net revenues | 2,525 | 2,469 | 2,360 | 7,353 | 6,847 |
| HCP: | | | | | |
| HCP capitated revenues | 907 | 848 | 828 | 2,588 | 2,383 |
| HCP net patient service revenues (less | | | | | |
| provision for | | | | | |
| uncollectible accounts) | 79 | 82 | 50 | 241 | 164 |
| Other revenues | 15 | 36 | 14 | 66 | 73 |
| Total net HCP revenues | 1,001 | 966 | 892 | 2,895 | 2,620 |
| Total consolidated net revenues | \$3,526 | \$ 3,435 | \$ 3,252 | \$ 10,248 | \$ 9,467 |

The following table summarizes consolidated operating income and adjusted consolidated operating income:

| | Three months ended | | | Nine months ended | |
|---|--------------------|--------------------|--------------------|--------------------|--------------------|
| | September 30, 2015 | September 30, 2015 | September 30, 2014 | September 30, 2015 | September 30, 2014 |
| (dollar amounts rounded to nearest million) | | | | | |
| Operating income: | | | | | |
| Kidney Care: | | | | | |
| U.S. dialysis and related lab services | \$462 | \$ 438 | \$ 400 | \$795 | \$ 1,195 |
| Other—Ancillary services and strategic initiatives losses | (30) | (26) | (6) | (70) | (6) |
| Corporate support costs | (6) | (3) | (3) | (14) | (8) |
| Total kidney care operating income | 426 | 409 | 391 | 711 | 1,181 |
| HCP | 83 | 72 | 47 | 215 | 182 |
| Total consolidated operating income | 509 | 481 | 438 | 926 | 1,363 |
| Reconciliation of non-GAAP measures: | | | | | |
| Add: | | | | | |
| Loss contingency accrual and settlement charge | — | — | 17 | 495 | 17 |
| Adjusted consolidated operating income ⁽¹⁾ | \$509 | \$ 481 | \$ 455 | \$1,421 | \$ 1,380 |

⁽¹⁾For the nine months ended September 30, 2015 we have excluded \$495 million related to a settlement charge in connection with the Vainer private civil suit. In addition, for the three and nine months ended September 30, 2014, we have excluded \$17 million of a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations. These are non-GAAP measures and are not intended as a substitute for the GAAP equivalent measures. We have presented these adjusted

amounts because management believes that this presentation enhances a user's understanding of our normal consolidated operating income by excluding unusual items which we do not believe are indicative of our ordinary results of operations. As a result, adjusting for these amounts allows for comparison to our normal prior period results. We therefore consider these adjusted consolidated operating income amounts meaningful and comparable to our prior period results.

Consolidated net revenues

Consolidated net revenues for the third quarter of 2015 increased by approximately \$91 million, or 2.6%, as compared to the second quarter of 2015. The increase in consolidated net revenues was primarily due to an increase of approximately \$47 million associated with the U.S. dialysis and related lab services' net revenues, principally due to acquired and non-acquired treatment growth in existing centers, and one additional treatment day in the third quarter of 2015 as compared to the second quarter of 2015. Additionally, consolidated net revenues were positively impacted by an increase of approximately \$35 million associated with HCP. The increase in HCP net revenues was primarily related to an increase in senior capitated revenue due to non-acquired growth of senior capitated members, the timing of the recognition of additional Medicaid risk sharing revenue due to decreased costs related to a lower claims experience, as well as an improved commercial risk pool performance due to improved patient utilization. These increases were partially offset by the timing of revenue associated with HCP's annual premium reconciliation of senior capitated members and the recognition of additional revenue related to the maintenance of existing physician networks during the second quarter of 2015. The overall increase in consolidated net revenues was also due to an increase of approximately \$11 million associated with our ancillary services and strategic initiatives revenues, primarily from growth in our pharmacy revenues, partially offset by an increase in reserves for refunds of prior period pharmacy reimbursements.

Consolidated net revenues for the third quarter of 2015 increased by approximately \$274 million, or 8.4%, as compared to the third quarter of 2014. The increase in consolidated net revenues was primarily due to an increase of \$125 million in the U.S. dialysis and related lab services' net revenues, primarily as a result of volume growth from acquired and non-acquired treatment growth in existing and new centers and an increase in our average dialysis revenue per treatment of approximately \$7. The increase in our average dialysis revenue per treatment was primarily due to improvements in our commercial payor mix and an increase in some of our commercial payment rates. The increase in consolidated net revenues was also due to an increase in HCP net revenues of \$109 million, primarily due to an increase in the number of senior capitated members from acquisitions and non-acquired growth and the timing of the recognition of additional Medicaid risk sharing revenue described above for the third quarter of 2015 compared to the second quarter of 2015. This growth in consolidated net revenues was partially offset by a decline in the number of commercial members to whom HCP provides health care services as well as a decrease in senior Medicaid revenues due to the planned non-renewal of some unfavorable plans. In addition, the increase in consolidated net revenues was due to an increase of approximately \$45 million in our ancillary services and strategic initiatives, mainly from growth in our pharmacy services and international operations, partially offset by an increase in reserves for refunds of prior period pharmacy reimbursements.

Consolidated net revenues for the nine months ended September 30, 2015 increased by approximately \$781 million, or 8.2%, as compared to the same period in 2014. The increase in consolidated net revenues was primarily due to an increase of approximately \$367 million associated with the U.S. dialysis and related lab services' net revenues, principally due to volume growth from acquired and non-acquired treatment growth in existing and new centers, and an increase in our average dialysis revenue per treatment of approximately \$6. The increase in our average revenue per treatment was primarily due to an increase in our average commercial payment rates and improvements in our commercial payor mix. Consolidated net revenues also benefited from an increase in HCP's net revenues of approximately \$275 million. The increase in HCP net revenues was primarily attributable to an increase in fee-for-service revenues from acquisitions, as well as the same factors discussed above in the third quarter of 2015 as compared to the third quarter of 2014. The increase in consolidated net revenues was also due to an increase of

approximately \$153 million associated with our ancillary services and strategic initiatives revenues, primarily from growth in our pharmacy services and international operations, partially offset by an increase in reserves for refunds of prior period pharmacy reimbursements.

Consolidated operating income

Consolidated operating income for the third quarter of 2015 increased by approximately \$28 million, or 5.8%, as compared to the second quarter of 2015. The increase in the consolidated operating income was primarily due to an increase in U.S. dialysis and related lab services' net revenues impacted by an increase in the number of dialysis treatments from acquired and non-acquired growth and one additional treatment day. Consolidated operating income was also positively impacted by lower professional fees, travel expenses for management meetings and long-term incentive compensation costs. The increase in consolidated operating income was also due to an increase in HCP net revenues due to lower HCP medical claims expense as a result of improved utilization and an increase in Medicaid risk sharing revenue due to a lower claims experience, partially offset by the recognition of additional revenue related to the maintenance of existing physician networks during the second quarter of 2015. Consolidated operating income was also negatively impacted by an increase in labor costs and general professional insurance costs, as well as an increase in the amount of losses recognized in our other ancillary services and strategic initiatives businesses, primarily due to an increase in reserves for refunds of prior period pharmacy reimbursements.

Consolidated operating income for the third quarter of 2015 increased by approximately \$71 million as compared to the third quarter of 2014, including a loss contingency accrual of \$17 million recorded in the third quarter of 2014 related to the 2010 and 2011 U.S. Attorney physician relationship investigations. Excluding this item from the third quarter of 2014, adjusted consolidated operating income for the third quarter of 2015 would have increased by \$54 million, or 11.9%, as compared to the third quarter of 2014. Adjusted consolidated operating income increased primarily due to acquired and non-acquired treatment growth and an increase in average dialysis revenue per treatment of approximately \$7, as discussed above. Adjusted consolidated operating income was also positively impacted by an increase in HCP's operating income for the third quarter of 2015 of approximately \$36 million. The increase was primarily attributable to an increase in senior capitated members and patient service revenues due to acquisitions and non-acquired growth, and an increase in the Medicaid risk sharing revenue recognized in the third quarter of 2015. These increases were partially offset by a decrease in operating income in our other ancillary services and strategic initiatives businesses of approximately \$24 million, primarily due to an increase in reserves for refunds of prior period pharmacy reimbursements. Additionally, adjusted consolidated operating income was negatively impacted by higher labor and benefit costs, pharmaceutical costs and professional fees.

Consolidated operating income for the first nine months of 2015 decreased by approximately \$437 million as compared to the same period in 2014, including a settlement charge of \$495 million related to the Vainer suit and a loss contingency accrual of \$17 million related to the 2010 and 2011 U.S. Attorney physician relationship investigations recorded in the first quarter of 2015 and the third quarter of 2014, respectively. Excluding these items from their respective periods, adjusted consolidated operating income for the first nine months of 2015 would have increased by \$41 million, or 3.0%, as compared to the same period in 2014. This increase in adjusted consolidated operating income was primarily due to an increase in average dialysis revenue per treatment of \$6 as well as strong volume growth from additional treatments. The adjusted consolidated operating income was also positively impacted by the increase in operating results of HCP, of approximately \$33 million. This increase was primarily due to an increase in fee-for-service revenues due to acquisitions, senior capitated members due to acquisitions and non-acquired growth, an increase in Medicaid members due to Medicaid expansion, and an increase in Medicaid risk sharing revenue recognized in the third quarter of 2015, partially offset by a decrease in commercial members. These increases were negatively impacted by an increase in the amount of losses recognized in our other ancillary services and strategic initiatives businesses, primarily due to an increase in reserves for refunds of prior period pharmacy reimbursements and increased losses in our international businesses. Adjusted consolidated operating income was also negatively impacted by higher labor and benefit costs, and higher payroll taxes, as well as an increase in long-term incentive compensation costs, pharmaceutical costs, professional fees and in our dialysis provision for uncollectible accounts.

U.S. dialysis and related lab services business

Results of operations

| | Three months ended | | Nine months ended | |
|---|-------------------------------------|-----------|-------------------|-----------|
| | September | September | September | September |
| | 30, | 30, | 30, | 30, |
| | 2015 | 2015 | 2015 | 2014 |
| | (dollar amounts rounded to nearest | | | |
| | million, except per treatment data) | | | |
| Net revenues: | | | | |
| Dialysis and related lab services patient | \$2,301 | \$2,252 | \$2,165 | \$6,718 |
| | | | | \$6,307 |

Edgar Filing: DAVITA HEALTHCARE PARTNERS INC. - Form 10-Q

| | | | | | | | | | | |
|--|-----------|---|-----------|---|-----------|---|------------|---|------------|---|
| service revenues | | | | | | | | | | |
| Less: Provision for uncollectible accounts | (103 |) | (101 |) | (92 |) | (302 |) | (258 |) |
| Dialysis and related lab services net patient | | | | | | | | | | |
| service revenues | \$2,198 | | \$2,151 | | \$2,073 | | \$6,416 | | \$6,049 | |
| Other revenues | 3 | | 3 | | 3 | | 10 | | 10 | |
| Total net dialysis and related lab services revenues | \$2,201 | | \$2,154 | | \$2,076 | | \$6,426 | | \$6,059 | |
| Operating expenses and charges: | | | | | | | | | | |
| Patient care costs | 1,461 | | 1,436 | | 1,390 | | 4,294 | | 4,070 | |
| General and administrative | 170 | | 174 | | 170 | | 528 | | 490 | |
| Depreciation and amortization | 112 | | 110 | | 102 | | 326 | | 297 | |
| Loss contingency accrual and settlement charge | — | | — | | 17 | | 495 | | 17 | |
| Equity investment income | (4 |) | (4 |) | (3 |) | (12 |) | (10 |) |
| Total operating expenses and charges | 1,739 | | 1,716 | | 1,676 | | 5,631 | | 4,864 | |
| Operating income | \$462 | | \$438 | | \$400 | | \$795 | | \$1,195 | |
| Dialysis treatments | 6,611,799 | | 6,463,058 | | 6,343,706 | | 19,337,492 | | 18,515,727 | |
| Average dialysis treatments per treatment day | 83,694 | | 82,860 | | 80,300 | | 82,780 | | 79,330 | |
| Average dialysis and related lab services revenue | | | | | | | | | | |
| per treatment | \$348 | | \$348 | | \$341 | | \$347 | | \$341 | |

35

Net revenues

Dialysis and related lab services' net revenues for the third quarter of 2015 increased by approximately \$47 million, or approximately 2.2%, as compared to the second quarter of 2015. The increase was primarily due to volume growth from acquired and non-acquired treatment growth and one additional treatment day in the third quarter of 2015 as compared to the second quarter of 2015. The average dialysis revenue per treatment remained flat quarter over quarter.

Dialysis and related lab services' net revenues for the third quarter of 2015 increased by approximately \$125 million, or approximately 6.0%, as compared to the third quarter of 2014. The increase in net revenues was principally due to volume growth from additional treatments and an increase in our average dialysis revenue per treatment of approximately \$7. The increase in the number of treatments was primarily attributable to acquired and non-acquired treatment growth. The increase in our average dialysis revenue per treatment was primarily due to an increase in our average commercial payment rates and improvements in our commercial payor mix, partially offset by an increase in our provision for uncollectible accounts.

Dialysis and related lab services' net revenues for the nine months ended September 30, 2015 increased by approximately \$367 million, or approximately 6.1%, as compared to the same period in 2014. The increase in dialysis and related lab services' net revenues was due to strong growth from additional treatments and an increase in our average dialysis revenue per treatment of approximately \$6. The increase in our average dialysis revenue per treatment was primarily due to an increase in our average commercial payment rates and improvements in our commercial payor mix, partially offset by an increase in our dialysis provision for uncollectible accounts.

Provision for uncollectible accounts. The provision for uncollectible accounts receivable for dialysis and related lab services was 4.5% for the third quarter and second quarter of 2015, and 4.25% for the third quarter of 2014. We continue to experience higher amounts of non-covered Medicare write-offs due to non-covered Medicare copays. We assess our level of the provision for uncollectible accounts based upon our historical cash collection experience and trends, and have and will continue to adjust the provision as necessary as a result of changes in our cash collections.

Operating expenses and charges

Patient care costs. Dialysis and related lab services' patient care costs of approximately \$221 per treatment for the third quarter of 2015 decreased by approximately \$1 per treatment as compared to the second quarter of 2015. The decrease in patient care costs per treatment was primarily due to a decrease in professional fees related to legal settlements and compliance matters, and a decline in travel expenses related to management meetings, partially offset by an increase in labor and benefit costs and an increase in general and professional insurance costs.

Dialysis and related lab services' patient care costs per treatment for the third quarter of 2015 increased by approximately \$2 per treatment as compared to the third quarter of 2014. The increase was primarily attributable to an increase in labor and benefits costs, professional fees, occupancy costs and other direct operating expenses associated with our dialysis centers. These increases were partially offset by improved productivity and lower general and professional insurance costs.

Dialysis and related lab services' patient care costs per treatment for the nine months ended September 30, 2015 was approximately \$222, which represents an increase of approximately \$2 per treatment as compared to the same period in 2014. The increase was primarily attributable to an increase in labor and benefit costs, professional fees for legal and compliance matters, occupancy costs and other direct operating expenses associated with our dialysis centers,

partially offset by improved productivity and lower general and professional insurance costs.

General and administrative expenses. Dialysis and related lab services' general and administrative expenses of approximately \$170 million in the third quarter of 2015 decreased by approximately \$4 million as compared to the second quarter of 2015. The decrease in general and administrative expenses was primarily due to a decrease in payroll taxes and benefit costs, as well as lower long-term incentive compensation costs, partially offset by an increase in professional fees.

Dialysis and related lab services' general and administrative expenses for the third quarter of 2015 remained relatively flat as compared to the third quarter of 2014. Long-term incentive compensation costs decreased from the third quarter of 2014, offset by increases in labor costs and payroll taxes and a slight increase in professional fees and in other general administrative costs.

Dialysis and related lab services' general and administrative expenses of \$528 million for the nine months ended September 30, 2015 increased by approximately \$38 million as compared to the same period in 2014. The increase was primarily due to higher labor and benefit costs and long-term incentive compensation costs, as well as an increase in professional fees and other general administrative costs.

Depreciation and amortization. Depreciation and amortization for dialysis and related lab services was approximately \$112 million for the third quarter of 2015, \$110 million for the second quarter of 2015, and \$102 million for the third quarter of 2014. The increases in depreciation and amortization in the third quarter of 2015, as compared to the second quarter of 2015 and the third quarter of 2014, was primarily due to growth in newly developed centers and from acquired centers.

Settlement charge. In June 2015, we finalized the terms of the settlement agreement with plaintiffs regarding the Vainer private civil suit, which includes a settlement amount of \$450 million, and attorney fees and other costs of \$45 million. A majority of these costs were paid in June 2015.

Corporate Integrity Agreement. In connection with the resolution of the 2010 and 2011 U.S. Attorney physician relationship investigations, we entered into a five-year corporate integrity agreement (the Corporate Integrity Agreement) with the OIG. The Corporate Integrity Agreement requires that we maintain certain elements of our compliance programs and imposes certain expanded compliance-related requirements during the term of the Corporate Integrity Agreement, including the appointment of a compliance monitor and contains certain business restrictions related to a subset of our joint venture arrangement, including our agreeing to (1) unwind 11 joint venture transactions that were created through partial divestitures to, or partial acquisitions from, nephrologists and that cover 26 of our then either wholly- or majority-owned 2,119 clinics; (2) not enter into certain types of partial divestiture joint venture transactions with nephrologists during the term of the Corporate Integrity Agreement; (3) non-enforcement of certain patient-related non-solicitation restrictions; and (4) certain other restrictions. The OIG notified us that it considers us to be in breach of the CIA because of three implementation deficiencies. We remediated these deficiencies and have paid certain stipulated penalties.

Equity investment income. Equity investment income for dialysis and related lab services was approximately \$4 million for both the third and second quarter of 2015, as compared to \$3 million for the third quarter of 2014. The increase in equity investment income in the third quarter of 2015 as compared to the third quarter of 2014 was primarily due to an increase in the profitability of certain joint ventures.

Accounts receivable

Our dialysis and related lab services' accounts receivable balances, net of the provision for uncollectible accounts, at September 30, 2015 and June 30, 2015 were \$1,243 million and \$1,227 million, respectively, which represented approximately 51 days and 53 days, respectively. The decrease in day sales outstanding (DSO) in the third quarter of 2015 was primarily due to an increase in Medicare cash collections. Our DSO calculation is based on the current quarter's average revenues per day. There were no significant changes during the third quarter of 2015 from the second quarter of 2015 in the amount of unreserved accounts receivable over one year old or the amounts pending approval from third-party payors.

Segment operating income

Dialysis and related lab services' operating income for the third quarter of 2015 increased by approximately \$24 million as compared to the second quarter of 2015. The increase in operating income was primarily due to acquired and non-acquired treatment growth in existing centers as well as one additional treatment day in the third quarter of 2015. Operating income was positively impacted by lower professional fees, a decrease in travel expenses related to management meetings, and a decrease in general and administrative costs, partially offset by increases in labor costs, pharmaceutical costs, and general and professional insurance costs.

Dialysis and related lab services' operating income for the third quarter of 2015 increased by approximately \$62 million as compared to the third quarter of 2014, including a loss contingency accrual of \$17 million recorded in the

third quarter of 2014. Excluding this item from the third quarter of 2014, adjusted dialysis and related lab services' operating income would have increased by \$45 million. This increase in adjusted operating income was primarily attributable to volume growth in revenues from additional treatments as a result of acquired and non-acquired treatment growth, an increase in our average dialysis revenue per treatment of approximately \$7, as discussed above, improved productivity and lower general and professional insurance costs. These increases were partially offset by increases in labor and benefits costs, professional fees, occupancy costs and other direct operating expenses.

Dialysis and related lab services' operating income for the nine months ended September 30, 2015 decreased by approximately \$400 million as compared to the same period in 2014, including the settlement charge of \$495 million and the loss contingency accrual of \$17 million recorded in the first quarter of 2015 and the third quarter of 2014, respectively. Excluding these items from their respective periods, adjusted operating income would have increased by \$78 million. This increase in adjusted operating income was primarily due to an increase in our average dialysis revenue per treatment of \$6, as discussed above, strong volume growth from additional treatments, improved productivity and lower general and professional insurance costs. These were partially offset by increases in the provision for uncollectible accounts, labor and benefit costs, pharmaceutical costs, professional fees for legal and compliance matters, and occupancy costs.

HCP business

Results of operations

| | Three months ended | | | | | | Nine months ended | | | |
|--|--------------------|------|---------------|------|--------------------|------|--------------------|------|--------------------|------|
| | September 30, 2015 | | June 30, 2015 | | September 30, 2014 | | September 30, 2015 | | September 30, 2014 | |
| (dollar amounts rounded to nearest millions) | | | | | | | | | | |
| Net revenues: | | | | | | | | | | |
| HCP capitated revenue | \$907 | 91 % | \$848 | 88 % | \$828 | 93 % | \$2,588 | 89 % | \$2,383 | 91 % |
| Patient service revenue | 84 | | 86 | | 56 | | 252 | | 176 | |
| Less: Provision for | | | | | | | | | | |
| uncollectible accounts | (5) | | (4) | | (6) | | (11) | | (12) | |
| Net patient service revenue | 79 | 8 % | 82 | 9 % | 50 | 6 % | 241 | 9 % | 164 | 6 % |
| Other revenues | 15 | 1 % | 36 | 3 % | 14 | 1 % | 66 | 2 % | 73 | 3 % |
| Total net revenues | \$1,001 | 100% | \$966 | 100% | \$892 | 100% | \$2,895 | 100% | \$2,620 | 100% |
| Operating expenses: | | | | | | | | | | |
| Patient care costs | \$768 | 77 % | \$750 | 78 % | \$719 | 80 % | \$2,250 | 79 % | \$2,079 | 79 % |
| General and administrative | | | | | | | | | | |
| expense | 106 | 11 % | 102 | 11 % | 86 | 10 % | 300 | 10 % | 241 | 9 % |
| Depreciation and amortization | 43 | 4 % | 43 | 4 % | 42 | 5 % | 130 | 4 % | 127 | 5 % |
| Equity investment income | | | | | | | | | | |
| (loss) | 1 | — | (1) | — | (2) | — | — | — | (9) | — |
| Total expenses | 918 | 92 % | 894 | 93 % | 845 | 95 % | 2,680 | 93 % | 2,438 | 93 % |
| Operating income | \$83 | 8 % | \$72 | 7 % | \$47 | 5 % | \$215 | 7 % | \$182 | 7 % |

Capitated membership information

The following table provides (i) the total number of capitated members to whom HCP provided healthcare services as of September 30, 2015, June 30, 2015 and September 30, 2014 and (ii) the aggregate member months for the three and nine months ended September 30, 2015 and September 30, 2014, and three months ended June 30, 2015. Member months represent the aggregate number of months of healthcare services HCP has provided to capitated members during a period of time:

| | Members at | | Members months for | | | | | |
|---------------------|--------------------|--------------------|--------------------|--------------------|---------------|--------------------|--------------------|--------------------|
| | September 30, 2015 | June 30, 2015 | September 30, 2014 | Three months ended | | Nine months ended | | |
| | September 30, 2015 | September 30, 2015 | September 30, 2014 | September 30, 2015 | June 30, 2015 | September 30, 2014 | September 30, 2015 | September 30, 2014 |
| HCP total capitated | 808,300 | 826,500 | 828,300 | 2,445,300 | 2,472,400 | 2,481,100 | 7,400,100 | 7,263,400 |

membership

In addition to the members above, HCP provided healthcare services to members of Magan Medical Group and Tandigm Health, unconsolidated joint ventures that are accounted for as equity investments. The Magan Medical Group joint venture provided healthcare services for approximately 43,500 members as of September 30, 2015, and for approximately 130,500 member months for the quarter ended September 30, 2015. The Tandigm Health joint venture provided health care services for approximately 89,700 members as of September 30, 2015, and for approximately 270,800 member months for the quarter ended September 30, 2015.

Members and member months for the third quarter of 2015 decreased from the second quarter of 2015 primarily due to a planned reduction in Medicaid members and a decline in commercial members as employers shift to less expensive options for medical services for their employees, partially offset by an increase in senior members due to non-acquired growth.

Members and member months for the third quarter of 2015 decreased from the third quarter of 2014 primarily due to a decrease in commercial members for reasons described above, as well as a planned reduction in Medicaid members and planned non-renewal of certain plans. These decreases were partially offset by increased senior members resulting from new acquisitions and non-acquired growth.

Member months for the nine months ended September 30, 2015 increased as compared to the same period in 2014 primarily due to an increase in senior capitated memberships related to acquisitions and non-acquired growth, as well as an increase in Medicaid memberships year over year due to Medicaid expansion. These increases were partially offset by the planned non-renewal of certain plans in certain markets due to unfavorable economics and a decline in commercial members.

Revenues

The following table provides HCP's revenue by source:

| | Three months ended | | | | Nine months ended | | | | | |
|---------------------------------------|--------------------|----------|-----------|-------|-------------------|-------|-----------|-------|---------|-------|
| | September | | September | | September | | September | | | |
| | 30, | June 30, | 30, | 30, | 30, | 30, | 30, | 30, | | |
| | 2015 | 2015 | 2014 | 2014 | 2015 | 2015 | 2014 | 2014 | | |
| (dollars rounded to nearest millions) | | | | | | | | | | |
| HCP revenues: | | | | | | | | | | |
| Commercial revenues | \$181 | 18 % | \$177 | 18 % | \$188 | 21 % | \$543 | 19 % | \$552 | 21 % |
| Senior revenues | 641 | 64 % | 623 | 64 % | 605 | 68 % | 1,866 | 65 % | 1,745 | 67 % |
| Medicaid revenues | 85 | 9 % | 48 | 5 % | 35 | 4 % | 179 | 6 % | 86 | 3 % |
| Total capitated revenues | \$907 | 91 % | \$848 | 88 % | \$828 | 93 % | \$2,588 | 90 % | \$2,383 | 91 % |
| Patient service revenue, | | | | | | | | | | |
| net of provision for | | | | | | | | | | |
| uncollectible accounts | 79 | 8 % | 82 | 8 % | 50 | 6 % | 241 | 8 % | 164 | 6 % |
| Other revenues | 15 | 1 % | 36 | 4 % | 14 | 1 % | 66 | 2 % | 73 | 3 % |
| Total net revenues | \$1,001 | 100 % | \$966 | 100 % | \$892 | 100 % | \$2,895 | 100 % | \$2,620 | 100 % |

Net revenues

HCP's net revenue for the third quarter of 2015 increased by approximately \$35 million, or 3.6%, as compared to the second quarter of 2015. The increase in revenue was primarily attributable to an increase in senior capitated revenue due to non-acquired growth of senior capitated members, the timing of the recognition of additional Medicaid risk sharing revenue due to decreased costs related to lower claims, as well as an improved commercial risk pool performance due to improved patient utilization. These increases were partially offset by the timing of revenue associated with HCP's annual premium reconciliation of senior capitated members and the recognition of additional revenue related to the maintenance of existing physician networks during the second quarter of 2015.

HCP's net revenue for the third quarter of 2015 increased by approximately \$109 million, or 12.2%, as compared to the third quarter of 2014. The increase in revenue was primarily attributable to an increase in the number of senior capitated members from acquisitions and non-acquired growth, the timing of the recognition of additional Medicaid risk sharing revenue for the same reasons as described above for the third quarter of 2015 compared to the second quarter of 2015, and an increase in patient service revenue due to acquisitions. This growth in net revenues was partially offset by a decline in the number of commercial and Medicaid members to whom HCP provides health care services and a decrease in senior revenues due to the planned non-renewal of some plans due to unfavorable economics in certain markets.

HCP's net revenue for the first nine months of 2015 increased by approximately \$275 million, or 10.5%, as compared to the same period in 2014. The increase in revenue was primarily attributable to an increase in fee-for-service revenue from acquisitions, an increase in senior capitated members due to acquisitions and non-acquired growth, an increase in Medicaid memberships due to Medicaid expansion, and the timing of recognition of additional Medicaid risk sharing revenue described above. This improvement was negatively impacted by a decrease in the number of

commercial members to whom HCP provides health care services, as well as a decrease in senior revenues due to the planned non-renewal of some plans due to unfavorable economics in the market.

On April 6, 2015, CMS issued final guidance for 2016 Medicare Advantage rates, which incorporated a modification to the risk adjustment model calculation that CMS utilizes to determine the risk acuity scores of Medicare Advantage patients. We estimate that the final cumulative impact of the 2016 rate structure will represent a decrease of approximately 2.0% of HCP's average Medicare Advantage revenues it manages on behalf of its senior capitated population as compared to 2015, which compares to the industry average rate increase of approximately 1.25% as indicated by CMS.

The more significant decline in Medicare Advantage rates for HCP compared to the industry average is driven by a larger-than-average decline associated with CMS's modification to the risk adjustment model calculations. The full implementation of the 2014 CMS-HCC Risk Adjustment model negatively affects HCP and other providers like us who have differentially invested in wellness and prevention programs for patients with chronic conditions.

Operating expenses

Patient care costs. HCP's patient care costs of approximately \$768 million for the third quarter of 2015 increased by approximately \$18 million, or approximately 2.4%, as compared to the second quarter of 2015. The increase was primarily due to recognition of compensation expense related to higher Medicaid risk sharing revenues, as well as additional contractual payments made to physicians during the third quarter of 2015. These increases were partially offset by a decrease in hospital claims expense due to improved utilization during the third quarter of 2015.

HCP's patient care costs for the third quarter of 2015 increased by approximately \$49 million, or 6.8%, as compared to the third quarter of 2014. The increase was primarily attributable to an increase in senior capitated members from acquisitions and non-acquired growth, as well as market expansion and the timing of the recognition of additional benefit expense described above in the third quarter of 2015, compared to the second quarter of 2015. This increase in costs was partially offset by the decrease in commercial members to whom HCP provides health care services and a decrease in costs due to the planned non-renewal of some plans due to unfavorable economics in certain markets.

HCP's patient care costs of approximately \$2,250 million for the nine months ended September 30, 2015 increased by approximately \$171 million, or 8.2%, as compared to the same period in 2014. The increase was primarily attributable to the same factors as described above in the third quarter of 2015 as compared to the third quarter of 2014.

General and administrative expenses. HCP's general and administrative expenses of approximately \$106 million for the third quarter of 2015, increased by approximately \$4 million, or 3.9%, as compared to the second quarter of 2015. The increase in general and administrative expenses was primarily attributable to recognition of additional compensation expense, partially offset by lower business tax accruals in certain markets during the third quarter of 2015.

HCP's general and administrative expenses increased by approximately \$20 million, or 23.3%, as compared to the third quarter of 2014. The increase in general and administrative expenses was primarily attributable to an increase in corporate support expenses related to growth initiatives and recognition of additional compensation expense.

HCP's general and administrative expenses of approximately \$300 million for the nine months ended September 30, 2015 increased by approximately \$59 million, or 24.5%, as compared to the same period in 2014. The increase in general and administrative expenses was primarily attributable to an increase in corporate support expenses related to growth initiatives.

Depreciation and amortization. HCP's depreciation and amortization was approximately \$43 million for both the third and second quarter of 2015. Depreciation and amortization for the third quarter of 2015 increased by approximately \$1 million as compared to the third quarter of 2014. Finally, depreciation and amortization of approximately \$130 million for the nine months ended September 30, 2015 increased by approximately \$3 million as compared to the same period in 2014. These increases are primarily attributable to depreciation and amortization of acquired assets from acquisitions.

Segment operating income

HCP's operating income of \$83 million for the third quarter of 2015 increased by approximately \$11 million, or 15.3%, as compared to the second quarter of 2015. The increase was primarily attributable to higher senior capitated revenue due to non-acquired growth of senior capitated members, the timing of the recognition of Medicaid risk sharing revenue due to decreased costs as a result of lower claims, and an improved commercial risk pool performance. These increases in net revenues were partially offset by recognition of additional benefit expense related to the shared risk revenue during the third quarter of 2015, as well as the timing of revenue associated with HCP's annual premium reconciliation of senior capitated members, and the recognition of additional revenue related to the maintenance of existing physician networks which both occurred in the second quarter of 2015, as well as higher general and administrative costs.

HCP's operating income for the third quarter of 2015 increased by approximately \$36 million, or 76.6%, as compared to the third quarter of 2014. The increase was primarily attributable to an increase in senior capitated members, higher patient service revenues due to acquisitions and non-acquired growth, and the timing of the recognition of additional Medicaid risk sharing revenue. This increase was partially offset by the decline in commercial members to whom

HCP provides healthcare services and non-renewal of some plans due to unfavorable economics in certain markets and higher general and administrative costs.

HCP's operating income of \$215 million for the nine months ended September 30, 2015 increased by approximately \$33 million, or 18.1%, as compared to the same period in 2014. The increase was primarily attributable to an increase in fee-for-service revenue from acquisitions, an increase in senior capitated members due to acquisitions and non-acquired growth, an increase in Medicaid members due to Medicaid expansion and the timing of the recognition of additional Medicaid risk sharing revenue. These increases were partially offset by a decrease in commercial members to whom HCP provides healthcare services, a reduction of claims expense due to the planned non-renewal of some plans due to unfavorable economics in certain markets, as well as higher general and administrative costs.

Other—Ancillary services and strategic initiatives business

Our other operations include ancillary services and strategic initiatives which are primarily aligned with our core business of providing dialysis services to our network of patients. As of September 30, 2015, these consisted primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care and our international dialysis operations. The ancillary services and strategic initiatives generated approximately \$345 million of net revenues

in the third quarter of 2015, representing approximately 9.8% of our consolidated net revenues. We currently expect to continue to invest in our ancillary services and strategic initiatives, including our continued expansion into certain international markets as we work to develop successful new business operations in the U.S. as well as outside the U.S. However, any significant change in market conditions, business performance or the regulatory environment may impact the economic viability of any of these strategic initiatives. Any unfavorable changes in these strategic initiatives could result in a write-off or an impairment of some or all of our investments, including goodwill and could also result in significant termination costs if we were to exit a certain line of business or one or more of our international markets.

As of September 30, 2015, we provided dialysis and administrative services to a total of 104 outpatient dialysis centers located in ten countries outside of the U.S. The total net revenues generated from our international operations are provided below.

The following table reflects the results of operations for the ancillary services and strategic initiatives:

| | Three months ended | | | Nine months ended | |
|--|--------------------|-----------------|--------------------|--------------------|--------------------|
| | September 30, 2015 | August 30, 2015 | September 30, 2014 | September 30, 2015 | September 30, 2014 |
| (dollar amounts rounded to nearest millions) | | | | | |
| U.S. revenues | | | | | |
| Net patient service revenues | \$8 | \$ 6 | \$ 5 | \$ 19 | \$ 14 |
| Other revenues | 281 | 276 | 246 | 807 | 685 |
| Capitated revenues | 20 | 18 | 21 | 56 | 53 |
| Total | 309 | 300 | 272 | 882 | 752 |
| International revenues | | | | | |
| Net patient service revenues | 34 | 33 | 27 | 97 | 74 |
| Other revenues | 2 | 1 | 1 | 5 | 5 |
| Total | 36 | 34 | 28 | 102 | 79 |
| Total net revenues | \$345 | \$ 334 | \$ 300 | \$ 984 | \$ 831 |
| Total operating losses | \$(30) | \$(26) | \$(6) | \$(70) | \$(6) |

Net revenues

The ancillary services and strategic initiatives net revenues for the third quarter of 2015 increased by approximately \$11 million, or 3.3%, as compared to the second quarter of 2015. The increase was primarily related to an increase in pharmacy services volume and pharmaceutical rates and an increase in net revenues from our international business and other strategic initiatives. These increases were partially offset by an increase in reserves for refunds of prior period pharmacy reimbursements.

The ancillary services and strategic initiatives net revenues for the third quarter of 2015 increased by approximately \$45 million, or 15.0%, as compared to the third quarter of 2014. The increase was primarily due to an increase in our pharmacy services volume and pharmaceutical rates, and an increase in net revenues from our international expansion related to the opening of our Middle East locations. These increases were partially offset by an increase in reserves for refunds of prior period pharmacy reimbursements.

The ancillary services and strategic initiatives net revenues for the nine months ended September 30, 2015 increased by approximately \$153 million, or 18.4%, as compared to the same period in 2014. The increase was primarily from an increase in pharmacy services volume and pharmaceutical rates and an increase in net revenues from our international expansion related to the opening of our Middle East locations. These increases were partially offset by an increase in reserves for refunds of prior period pharmacy reimbursements.

Operating expenses

Ancillary services and strategic initiatives operating expenses for the third quarter of 2015 of \$375 million increased by approximately \$15 million, or 4.2%, as compared to the second quarter of 2015. The increase in operating expenses was primarily due to an increase in drug prescription dispensing volume and pharmaceutical costs, as well as higher labor costs in our ancillary services and strategic initiatives, partially offset by a charge for a write-down of certain assets which occurred in the second quarter of 2015.

Ancillary services and strategic initiatives operating expenses for the third quarter of 2015 increased by approximately \$69 million, or 22.5%, as compared to the third quarter of 2014. The increase in operating expenses was primarily due to an increase in drug prescription dispensing volume and pharmaceutical costs related to our pharmacy business, as well as higher labor costs in our ancillary services and strategic initiatives, additional expenses associated with our international dialysis expansion, and an increase in other general and administrative expenses.

Ancillary services and strategic initiatives operating expenses for the nine months ended September 30, 2015 of \$1,054 million increased by approximately \$217 million, or 25.9%, as compared to the same period in 2014. The increase in operating expenses was primarily due to an increase in costs in our pharmacy business, mainly related to higher labor costs, pharmaceutical costs and other direct expenses, and costs associated with the right to use newly-developed intellectual property, as well as an increase in expenses associated with our international dialysis expansion, an increase in other general and administrative costs, and a charge for a write-down of certain assets.

Segment operating losses

Ancillary services and strategic initiatives operating losses for the third quarter of 2015 increased by approximately \$4 million from the second quarter of 2015. The increase in operating losses was primarily due to an increase in drug prescription costs associated with our pharmacy business, an increase in our refunds of prior period pharmacy reimbursements, and higher labor costs. These increases were partially offset by an increase in net revenue in our pharmacy business, primarily from additional volume and increases in pharmaceutical rates and from a charge for a write-down of certain assets that occurred in the second quarter of 2015.

Ancillary services and strategic initiatives operating losses for the third quarter of 2015 increased by approximately \$24 million from the third quarter of 2014. The increase in operating losses was primarily due to an increase in drug prescription costs associated with our pharmacy business, an increase in our reserves for refunds of prior period pharmacy reimbursements, increases in expenses related to our international expansion and an increase in general and administrative costs mentioned above. These increases were partially offset by an increase in net revenue in our pharmacy business, primarily from increases in pharmacy services volumes and pharmaceutical rates.

Ancillary services and strategic initiatives operating losses for the nine months ended September 30, 2015 increased by approximately \$64 million from the same period in 2014. The increase in operating losses was primarily due to an increase in costs associated with our pharmacy business, an increase in our reserves for refunds of prior period pharmacy reimbursements, and increases in expenses related to our international expansion which includes a charge for a write-down of certain assets, costs associated with the right to use intellectual property and an increase in other general and administrative costs mentioned above. These increases were partially offset by an increase in net revenue in our pharmacy business, primarily from increases in pharmaceutical rates.

Corporate-level charges

Debt expense. Debt expense was \$103 million in the third quarter of 2015, representing a decrease of approximately \$1 million as compared to the second quarter of 2015 and an increase of \$3 million as compared to the third quarter of 2014. The decrease in debt expense in the third quarter of 2015 as compared to the second quarter of 2015 was primarily due to the issuance of our 5.0% Senior Notes due 2025 (the 5% Senior Notes) in April 2015 which contain lower weighted average interest rates, partially offset by higher weighted average outstanding principal balances. The increase in debt expense in the third quarter of 2015 as compared to the third quarter of 2014 was primarily related to an increase in the weighted average outstanding debt principal balances, partially offset by lower weighted average interest rates.

For the nine months ended September 30, 2015, debt expense of \$305 million decreased by approximately \$7 million as compared to the same period in 2014, primarily related to our entry into a new credit agreement and the issuance of our 5 % Senior Notes in June 2014, and the issuance of our 5.0% Senior Notes in April 2015 which contain lower weighted average interest rates, and lower amortization of deferred financing costs, partially offset by an increase in the weighted average outstanding principal balances.

Our overall weighted average effective interest rate for the third quarter of 2015 was 4.40% compared to 4.42% for the second quarter of 2015 and 4.52% for the third quarter of 2014.

Corporate support costs. Corporate support costs consist primarily of labor, benefits and long-term incentive compensation costs for departments which provide support to all of our various operating lines of business. Corporate support costs were approximately \$5 million in the third quarter of 2015, \$3 million in the second quarter of 2015 and \$4 million in third quarter of 2014. These expenses are included in our consolidated general and administrative expenses. The increase in corporate support costs in the third quarter of 2015 as compared to the second quarter of 2015 was primarily due to a decrease in internal management fees paid by our ancillary lines of businesses related to the licensing and rights to use newly-developed intellectual property and other corporate support services. The increase in corporate support costs in the third quarter of 2015 as compared to the third quarter of 2014 was primarily due to an increase in internal management fees as described above.

Corporate support costs were approximately \$15 million in the nine months ended September 30, 2015 as compared to \$8 million in the same period in 2014. The increase of approximately \$7 million in corporate support costs is primarily attributable to an increase in professional fees.

Other income. Other income for the third quarter and second quarter of 2015 was approximately \$2 million and a negative \$1 million for the third quarter of 2014. The increase in other income for the third quarter of 2015 as compared to the third quarter of 2014 was related to improved foreign exchange rates affecting certain accounts, as well as an increase in interest income as a result of an increase in short term investments.

Noncontrolling interests

Net income attributable to noncontrolling interests was \$45 million for the third quarter of 2015 as compared to \$37 million for the second quarter of 2015, and \$36 million for the third quarter of 2014. The increase in net income attributable to noncontrolling interests in the third quarter of 2015, as compared to the second quarter of 2015, was primarily due to an increase in revenue as a result of one additional treatment day in the third quarter of 2015. The increase in net income attributable to noncontrolling interest in the third quarter of 2015 compared to the third quarter of 2014 was primarily due to an increase in the overall number of joint ventures and an increase in profitability of certain joint ventures.

Accounts receivable

Our consolidated total accounts receivable balances at September 30, 2015 and June 30, 2015 were \$1,700 million and \$1,667 million, respectively, which is net of the provision for uncollectible accounts.

Outlook

We are updating our consolidated operating income for 2015 to now be in the range of \$1.870 billion to \$1.915 billion.

Our previous consolidated operating income guidance for 2015 was in the range of \$1.825 billion to \$1.925 billion.

We are also updating our operating income for Kidney Care for 2015 to now be in the range of \$1.630 billion to \$1.655 billion.

Our previous operating income guidance for Kidney Care for 2015 was in the range of \$1.600 billion to \$1.650 billion.

We are updating our operating income for HCP for 2015 to now be in the range of \$240 million to \$260 million.

Our previous operating income guidance for HCP for 2015 was in the range of \$225 million to \$275 million.

We are updating our consolidated operating cash flow for 2015 to now be in the range of \$1.675 billion to \$1.775 billion.

Our previous consolidated operating cash flow for 2015 was in the range of \$1.600 billion to \$1.750 billion.

The above projected ranges exclude the Vainer suit settlement charge and the corresponding settlement payments made in 2015.

These projections and the underlying assumptions involve significant risks and uncertainties, and actual results may vary significantly from these current projections. See page 31 for further details regarding our forward looking statements.

Liquidity and capital resources

Liquidity and capital resources. Cash flow from operations during the third quarter of 2015 was \$679 million, compared to \$848 million during the third quarter of 2014. The decrease in cash flows from operations in the third quarter of 2015 was primarily due to a decrease in cash collections and the timing of certain other working capital items. Non-operating cash outflows for the third quarter of 2015 included capital asset expenditures of \$171 million, including \$95 million for new center developments and relocations and \$76 million for maintenance and information technology. In addition, we spent \$46 million for acquisitions, we paid distributions to noncontrolling interests of \$47 million and we repurchased a total of 4,555,868 shares of our common stock for \$341 million, of which \$300 million was settled during the third quarter of 2015. Non-operating cash outflows for the third quarter of 2014 included capital asset expenditures of \$165 million, including \$97 million for new center developments and relocations and \$68 million for maintenance and information technology. In addition, we spent \$120 million for acquisitions and we paid distributions to noncontrolling interests of \$39 million in that period.

Cash flow from operations during the nine months ended September 30, 2015 was \$1,121 million, compared to \$1,529 million during the same period in 2014. Cash flow from operations for the nine months ended September 30, 2015 decreased primarily due to payments of approximately \$494 million, or \$304 million after-tax, made in connection with the settlement of the Vainer private civil suit, the timing of certain other working capital items, including the timing of income tax payments. Non-operating cash outflows for the nine months ended September 30, 2015, included capital asset expenditures of \$462 million, including \$267 million for new center developments and relocations and \$195 million for maintenance and information technology. In addition, we spent \$91 million for acquisitions, we paid distributions to noncontrolling interests of \$126 million and we repurchased a total of 5,623,007 shares of our

common stock for \$425 million, of which \$384 million was settled during the first nine months of 2015. Non-operating cash outflows for the nine months ended September 30, 2014, included capital asset expenditures of \$444 million, including \$218 million for new center developments and relocations and \$182 million for maintenance and information technology. In addition, we spent \$218 million for acquisitions and we paid distributions to noncontrolling interests of \$105 million in that period.

On August 17, 2015, the Company entered into a definitive agreement to acquire Colorado-based Renal Ventures Limited, LLC (Renal Ventures), including a 100 percent interest in all dialysis centers owned by Renal Ventures, for approximately \$415 million in cash, subject to, among other things, adjustments for certain items such as working capital. Renal Ventures currently operates 36 dialysis clinics in six states serving approximately 2,400 patients and also operates other ancillary businesses. The transaction is subject to approval by the Federal Trade Commission (FTC) including Hart-Scott-Rodino antitrust clearance. The Company anticipates that it will be required by the FTC to divest a certain number of outpatient dialysis centers as a condition of the transaction. The Company currently expects the transaction to close in early 2016.

During the third quarter of 2015, our U.S. dialysis and related lab services business acquired five dialysis centers, opened 15 dialysis centers, and closed five centers. In addition, our international dialysis operations acquired six dialysis centers and opened two dialysis centers. During the third quarter of 2014, our U.S. dialysis and related lab services business acquired a total of 15 dialysis centers, opened 29 dialysis centers, sold one dialysis center, and closed ten dialysis centers. In addition, our international dialysis operations acquired one dialysis center and opened two dialysis centers during the third quarter of 2014.

During the nine months ended September 30, 2015, our U.S. dialysis and related lab services business acquired six dialysis centers, opened 46 dialysis centers, closed seven centers, and provided management and administrative services to one additional center. In addition, our international dialysis operations acquired seven dialysis centers and opened six dialysis centers. During the nine months ended September 30, 2014, our U.S. dialysis and related lab services business acquired a total of 16 dialysis centers, opened 75 dialysis centers, sold one dialysis center, and closed 12 dialysis centers. In addition, our international dialysis operations acquired four dialysis centers, opened nine dialysis centers, closed two dialysis centers and provided management and administrative services to three additional centers.

During the third quarter of 2015, our HCP business acquired one family practice and one primary care physician practice. During the nine months ended September 30, 2015, our HCP business acquired five private medical practices, two family practices, one non-profit medical practice, one primary care physician practice, and one medical consulting organization. During the third quarter of 2014, our HCP business acquired one private medical practice. During the nine months ended September 30, 2014, our HCP business acquired one management services organization, seven private medical practices, one family practice and two primary care physician practices.

During the first nine months of 2015, we made mandatory principal payments under our Senior Secured Credit Facilities totaling \$37.5 million on the Term Loan A and \$26.3 million on the Term Loan B.

Debt transactions

In April 2015, we issued \$1.500 billion 5.0% Senior Notes due 2025 (the 5.0% Senior Notes). The 5.0% Senior Notes pay interest on May 1 and November 1 of each year beginning November 1, 2015. The 5.0% Senior Notes are unsecured senior obligations and rank equally in right of payment with our existing and future unsecured senior indebtedness. The 5.0% Senior Notes are guaranteed by certain of our domestic subsidiaries. We may redeem up to

35% of the 5.0% Senior Notes at any time prior to May 1, 2018 at a certain specified price from the proceeds of one or more equity offerings. In addition, we may redeem some or all of the 5.0% Senior Notes at any time prior to May 1, 2020 at make whole redemption rates and on or after such date at certain specified redemption prices.

The proceeds from the 5.0% Senior Notes were used to repurchase all of the outstanding principal balances of the \$775 million 6 % Senior Notes due 2020 (the 6 % Senior Notes) through a combination of a tender offer and a redemption process, and to pay fees and expenses. The remaining proceeds may be used for general corporate purposes, future acquisitions and share repurchases. As a result of these transactions, we incurred \$48 million of pre-tax debt redemption charges consisting of tender and redemption fees and the write-off of deferred financing fees associated with the repurchase of the 6 % Senior Notes.

Share repurchases

During the three months ended September 30, 2015, we repurchased a total of 4,555,868 shares of our common stock for \$341 million, or an average price of \$74.76 per share. During the nine months ended September 30, 2015, we repurchased a total of 5,623,007 shares of our common stock for \$425 million, or an average price of \$75.53 per share. We also repurchased a total of 2,200 shares of our common stock subsequent to September 30, 2015 for \$0.2 million, or an average price of \$71.01 per share.

On April 14, 2015, our Board of Directors approved additional share repurchases in the amount of \$726 million. These recently approved share repurchases are in addition to the \$274 million remaining under our Board of Directors' prior share repurchase approval announced on November 4, 2010. As a result of these transactions, we now have a total of \$659 million in outstanding authorizations available for share repurchases as of October 30, 2015. These share repurchase authorizations have no expiration dates.

Swap and cap agreements

As of September 30, 2015, we maintain several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts totaling \$783.8 million. These agreements have the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the Term Loan A margin of 2.00%. The overall weighted average effective interest rate also includes the effects of \$153.8 million of unhedged Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 2.00%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the nine months ended September 30, 2015, we recognized debt expense of \$2.1 million from these swaps. As of September 30, 2015, the total fair value of these swap agreements was a net liability of approximately \$0.9 million. During the nine months ended September 30, 2015, we recorded a loss of \$4.8 million in other comprehensive income due to a decrease in the unrealized fair value of these swap agreements. We estimate that approximately \$0.9 million of existing unrealized pre-tax losses in other comprehensive income at September 30, 2015 will be reclassified into income over the next twelve months.

As of September 30, 2015, we maintain several forward interest rate cap agreements that were entered into in November 2014 with notional amounts totaling \$3.500 billion. These forward cap agreements will be effective September 30, 2016 and will have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 3.50% on an equivalent amount of our debt. The cap agreements expire on June 30, 2018. As of September 30, 2015, the total fair value of these cap agreements was an asset of approximately \$2.2 million. During the nine months ended September 30, 2015, we recorded a loss of \$10.2 million in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

As of September 30, 2015, we maintain several active interest rate cap agreements that were entered into in March 2013 with notional amounts totaling \$2.735 billion on our Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 2.50% on an equivalent amount of our Term Loan B. During the nine months ended September 30, 2015, we recognized debt expense of \$1.8 million from these caps. The cap agreements expire on September 30, 2016. As of September 30, 2015, the total fair value of these cap agreements was an asset of \$43 thousand. During the nine months ended September 30, 2015, we recorded a loss of \$1.6 million in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

In October 2015, we entered into several forward interest rate cap agreements with notional amounts totaling \$3.500 billion. These forward cap agreements will be effective June 29, 2018 and will have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 3.50% on an equivalent amount of our debt. These cap agreements expire on June 30, 2020.

Other items

As a result of an embedded LIBOR floor on the Term Loan B debt agreement and the swap and cap agreements, our overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.50%, based on the current margins in effect of 2.00% for the Term Loan A and 2.75% for the Term Loan B, as of September 30, 2015.

As of September 30, 2015, the interest rate on our Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date. The Term Loan B is also subject to interest rate caps if LIBOR should rise above 2.50%. Interest rates on our senior notes are fixed by their terms. The LIBOR variable component of our interest rate on the majority of our Term Loan A is economically fixed as a result of interest rate swaps.

Our overall weighted average effective interest rate during the quarter ended September 30, 2015 was 4.40% and as of September 30, 2015 was 4.40%.

As of September 30, 2015, we had undrawn revolving credit facilities totaling \$1.000 billion of which approximately \$40 million was committed for outstanding letters of credit. In addition, we have outstanding letters of credit of approximately \$56 million, of which \$1 million is secured by a certificate of deposit. The remaining amount is unencumbered.

We believe that we will have sufficient liquidity and will generate significant operating cash flows to fund our scheduled debt service and other obligations for the foreseeable future, including the next 12 months, under the terms of our debt agreements. Our primary sources of liquidity are cash from operations and cash from borrowings.

Goodwill

HCP's current and expected future operating results have eroded, primarily as a result of recent reductions in its Medicare Advantage reimbursement rates, including the Medicare Advantage final benchmark rates for 2016 announced on April 6, 2015.

As a result, we have determined that three of HCP's reporting units, HCP California, HCP Nevada and HCP New Mexico, remain at risk of goodwill impairment. As of September 30, 2015, HCP California, HCP Nevada and HCP New Mexico have goodwill of \$2.519 billion, \$521 million and \$72 million, respectively.

We prepared valuation updates, informed by third-party assistance, for these three businesses as of September 30, 2015, which indicate estimated fair values of HCP California, HCP Nevada and HCP New Mexico that exceed their total carrying values by approximately 15.2%, 8.8% and 16.2%, respectively.

Further reductions in HCP's reimbursement rates or other significant adverse changes in its expected future cash flows or valuation assumptions could result in a goodwill impairment charge in the future. For example, a sustained, long-term reduction of 3% in operating income for HCP California, HCP Nevada and HCP New Mexico could reduce their estimated fair values by up to 1.8%, 1.9% and 2.1%, respectively. Separately, an increase in their respective discount rates of 100 basis points could reduce the estimated fair values of HCP California, HCP Nevada and HCP New Mexico by up to 4.6%, 3.4% and 3.9%, respectively.

During the first nine months of 2015, we recorded an immaterial goodwill impairment charge related to our international operations. Except as described above, no significant goodwill associated with our various other reporting units was considered at risk of impairment as of September 30, 2015. Since the dates of our last annual goodwill impairment tests, there have been certain developments, events, changes in operating performance and other changes in key circumstances that have affected our businesses. However, these have not caused management to believe it is more likely than not that the fair value of any of its reporting units would be less than its carrying amount.

Long-term incentive compensation

Long-term incentive program (LTIP) compensation includes both stock-based awards (principally stock-settled stock appreciation rights, restricted stock units and performance stock units) as well as long-term performance-based cash awards. Long-term incentive compensation expense, which was primarily general and administrative in nature, was attributed to our dialysis and related lab services business, our HCP business, corporate support costs, and the ancillary services and strategic initiatives.

Our stock-based compensation awards are measured at their estimated fair values on the date of grant if settled in shares or at their estimated fair values at the end of each reporting period if settled in cash. The value of stock-based awards so measured is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures.

During the nine months ended September 30, 2015, we granted 920 thousand stock-settled stock appreciation rights with an aggregate grant-date fair value of \$16.8 million and a weighted-average expected life of approximately 4.1 years and also granted 272 thousand stock units with an aggregate grant-date fair value of \$21.9 million and a weighted-average expected life of approximately 3.1 years.

Long-term incentive compensation costs of \$30.5 million in the third quarter of 2015 decreased by approximately \$5.8 million as compared to the second quarter of 2015 and decreased by approximately \$4.9 million as compared to the third quarter of 2014. The decrease in long-term incentive compensation costs in both periods was primarily due to a

cumulative revaluation of liability-based awards in the second quarter for changes in estimated ultimate payouts, partially offset by a full quarter's expense on the 2015 broad grant granted late in the second quarter.

Long-term incentive compensation costs for the nine months ended September 30, 2015 increased by approximately \$11.8 million as compared to the same period in 2014. The increase in costs was primarily due to an increase in the value of LTIP awards that contributed expense to this period.

As of September 30, 2015, there was \$145.9 million of total estimated unrecognized compensation cost for outstanding LTIP awards, including \$75.6 million related to stock-based compensation arrangements under our equity compensation and stock purchase plans. We expect to recognize the performance-based cash component of these LTIP costs over a weighted average remaining period of 1.1 years and the stock-based component of these LTIP costs over a weighted average remaining period of 1.3 years.

Off-balance sheet arrangements and aggregate contractual obligations

In addition to the debt obligations reflected on our balance sheet, we have commitments associated with operating leases and letters of credit, as well as potential obligations associated with our equity investments in nonconsolidated businesses and to dialysis centers that are wholly-owned by third parties. Substantially all of our U.S. dialysis facilities are leased. We have potential obligations to purchase the noncontrolling interests held by third parties in several of our majority-owned joint ventures, non-owned and minority-owned entities. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, we would be required to purchase the third-party owners' noncontrolling interests at either the appraised fair market value or a predetermined multiple of earnings or cash flow attributable to the noncontrolling interests put to us, which is intended to approximate fair value. The methodology we use to estimate the fair values of noncontrolling interests subject to put provisions assumes the higher of either a liquidation value of net assets or an average multiple of earnings, based on historical earnings, patient mix and other performance indicators that can affect future results, as well as other factors. The estimated fair values of the noncontrolling interests subject to put provisions is a critical accounting estimate that involves significant judgments and assumptions and may not be indicative of the actual values at which the noncontrolling interests may ultimately be settled, which could vary significantly from our current estimates. The estimated fair values of noncontrolling interests subject to put provisions can fluctuate and the implicit multiple of earnings at which these noncontrolling interests obligations may be settled could vary significantly depending upon market conditions including potential purchasers' access to the capital markets, which can impact the level of competition for dialysis and non-dialysis related businesses, the economic performance of these businesses and the restricted marketability of the third-party owners' noncontrolling interests. The amount of noncontrolling interests subject to put provisions that employ a contractually predetermined multiple of earnings rather than fair value are immaterial. For additional information see Note 10 to the condensed consolidated financial statements.

We also have certain other potential commitments to provide operating capital to several dialysis centers that are wholly-owned by third parties or centers in which we own a minority equity investment as well as to physician-owned vascular access clinics or medical practices that we operate under management and administrative services agreements of approximately \$1 million.

The following is a summary of these contractual obligations and commitments as of September 30, 2015 (in millions):

| | Remainder of 2015 | 1-3 years | 4-5 years | After 5 years | Total |
|--|----------------------|--------------|--------------|------------------|----------|
| Scheduled payments under contractual obligations: | | | | | |
| Long-term debt | \$ 26 | \$390 | \$761 | \$7,778 | \$8,955 |
| Interest payments on the senior notes | — | 629 | 473 | 840 | 1,942 |
| Interest payments on the Term Loan B(1) | 31 | 362 | 235 | 58 | 686 |
| Interest payments on the Term Loan A(2) | 5 | 55 | 8 | — | 68 |
| Capital lease obligations | 4 | 39 | 33 | 180 | 256 |
| Operating leases | 113 | 1,191 | 580 | 960 | 2,844 |
| | \$ 179 | \$2,666 | \$2,090 | \$9,816 | \$14,751 |
| Potential cash requirements under existing commitments: | | | | | |
| Letters of credit | \$ 96 | \$— | \$— | \$— | \$96 |

| Noncontrolling interests subject to | | | | | |
|---|--------|-------|-------|-------|---------|
| put provisions | 512 | 144 | 120 | 121 | 897 |
| Non-owned and minority owned put provisions | 47 | — | — | — | 47 |
| Pay-fixed swaps potential obligations | 1 | — | — | — | 1 |
| Operating capital advances | 1 | — | — | — | 1 |
| | \$ 657 | \$144 | \$120 | \$121 | \$1,042 |

(1) Assuming no changes to LIBOR-based interest rates as the Term Loan B currently bears interest at LIBOR (floor of 0.75%) plus an interest rate margin of 2.75%.

(2) Based upon current LIBOR-based interest rates in effect at September 30, 2015 plus an interest rate margin of 2.00% for the Term Loan A.

47

The pay-fixed swap obligations represent the estimated fair market values of our interest rate swap agreements that are based upon valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs and other current market conditions that existed as of September 30, 2015. This amount represents the estimated potential obligation that we would be required to pay based upon the estimated future settlement of each specific tranche over the term of the swap agreements, assuming no future changes in the forward yield curve. The actual amount of our obligation associated with these swaps in the future will depend upon changes in the LIBOR-based interest rates that can fluctuate significantly depending upon market conditions, and other relevant factors that can affect the fair market value of these swap agreements.

In addition to the above commitments, we have committed to purchase a certain amount of our hemodialysis products and supplies at fixed prices from Baxter in connection with a purchase agreement with Baxter. Our total expenditures for the nine months ended September 30, 2015 on such products were approximately 1% of our total U.S. dialysis operating costs. In addition, we have an agreement with Fresenius which commits us to purchase a certain amount of dialysis equipment, parts and supplies from them through 2015. Our total expenditures for the nine months ended September 30, 2015 on such dialysis products were approximately 2% of our total U.S. dialysis operating costs. The actual amount of purchases in future years from Baxter and Fresenius will depend upon a number of factors, including the operating requirements of our centers, the number of centers we acquire and growth of our existing centers.

In November 2011, we entered into a seven year sourcing and supply agreement with Amgen USA Inc. that expires on December 31, 2018. Under the terms of this agreement, we will purchase EPO in amounts necessary to meet no less than 90% of our requirements for erythropoiesis stimulating agents (ESAs). The actual amount of EPO that we will purchase from Amgen will depend upon the amount of EPO administered during dialysis as prescribed by physicians and the overall number of patients that we serve.

Settlements of approximately \$48 million of existing income tax liabilities for unrecognized tax benefits, including interest, penalties and other long-term tax liabilities, are excluded from the above table as reasonably reliable estimates of their timing cannot be made.

Supplemental information concerning certain Physician Groups and unrestricted subsidiaries

The following information is presented as supplemental data as required by the indentures governing our senior notes.

We provide services to certain physician groups that, while consolidated in our financial statements for financial reporting purposes, are not subsidiaries of or owned by us, do not constitute "Subsidiaries", as defined in the indentures governing our outstanding senior notes, and which do not guarantee those senior notes. In addition, we have entered into management agreements with these physician groups pursuant to which we receive management fees from them.

As of September 30, 2015, if these physician groups were not consolidated in our financial statements, our consolidated indebtedness would have been approximately \$9.211 billion excluding the debt discount associated with our Term Loan B, our consolidated other liabilities (excluding indebtedness) would have been approximately \$3.293 billion, and our consolidated assets would have been approximately \$18.367 billion. If these physician groups were not consolidated in our financial statements for the nine months ended September 30, 2015, our consolidated total net revenues (including approximately \$490 million of management fees payable to us), consolidated operating income and consolidated net income would be reduced by approximately \$849 million, \$52 million, and \$38 million, respectively.

In addition, we own a 67% equity interest in California Medical Group Insurance (CMGI). CMGI is an Unrestricted Subsidiary, as defined in the indentures governing our outstanding senior notes, and does not guarantee those senior

notes. Our equity interest in CMGI is accounted for under the equity method of accounting, meaning that, although CMGI is not consolidated in our financial statements for financial reporting purposes, our consolidated income statements reflect our pro rata share of CMGI's net loss as equity investment loss.

For the nine months ended September 30, 2015, our equity investment income attributable to CMGI was approximately \$78 thousand, and for the nine months ended September 30, 2015, excluding our equity investment income attributable to CMGI, our consolidated operating income and consolidated net income would be decreased by approximately \$78 thousand and \$47 thousand, respectively. See Note 21, Supplemental data, to the condensed consolidated financial statements for further details.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest rate sensitivity

The tables below provide information about our financial instruments that are sensitive to changes in interest rates. The table below presents principal repayments and current weighted average interest rates on our debt obligations as of September 30, 2015. The variable rates presented reflect the weighted average LIBOR rates in effect for all debt tranches plus interest rate margins in effect as of September 30, 2015. The Term Loan A margin in effect is 2.00% at September 30, 2015, and along with the revolving line of credit are subject to adjustment depending upon changes in certain of our financial ratios, including a leverage ratio. The Term Loan B currently bears interest at LIBOR (floor of 0.75%) plus an interest rate margin of 2.75%.

| | Expected maturity date | | | | | | | Total | Average interest rate | Fair value |
|------------------------|------------------------|-------|-------|--------|--------|-------|------------|----------|-----------------------|------------|
| | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Thereafter | | | |
| | (dollars in millions) | | | | | | | | | |
| Long term debt: | | | | | | | | | | |
| Fixed rate | \$ 17 | \$ 56 | \$ 59 | \$ 58 | \$ 58 | \$ 57 | \$ 7,957 | \$ 8,262 | 4.63 % | \$ 8,213 |
| Variable rate | \$ 13 | \$ 64 | \$ 90 | \$ 102 | \$ 677 | \$ 2 | \$ 1 | \$ 949 | 2.20 % | \$ 947 |

| | Notional amount | Contract maturity date | | | | | Pay fixed | Receive variable | Fair value |
|----------------|-----------------------|------------------------|----------|------|----------|------|----------------|----------------------|------------|
| | | 2015 | 2016 | 2017 | 2018 | 2019 | | | |
| | (dollars in millions) | | | | | | | | |
| Swaps: | | | | | | | | | |
| Pay-fixed rate | \$ 784 | \$ 24 | \$ 760 | \$ — | \$ — | \$ — | 0.49% to 0.52% | LIBOR | \$ — |
| Cap agreements | | | | | | | | LIBOR above 2.5% and | |
| | \$ 6,235 | \$ — | \$ 2,735 | \$ — | \$ 3,500 | \$ — | | 3.5% | \$ 2 |

Our Senior Secured Credit Facilities, which include the Term Loan A and the Term Loan B, consist of various individual tranches of debt that can range in maturity from one month to twelve months (currently, all tranches are one month in duration). For the Term Loan A, each tranche bears interest at a LIBOR rate that is determined by the duration of such tranche plus an interest rate margin. The LIBOR variable component of the interest rate for each tranche is reset as such tranche matures and a new tranche is established. LIBOR can fluctuate significantly depending upon conditions in the credit and capital markets. However, the LIBOR variable component of the interest rate for the majority of the Term Loan A is economically fixed as a result of our swap agreements, as described below.

The Term Loan B is subject to a LIBOR floor of 0.75%. Because actual LIBOR, as of September 30, 2015, was lower than this embedded LIBOR floors, the interest rate on the Term Loan B is treated as “effectively fixed” for purposes of the table above. We have included the Term Loan B in the fixed rate totals in the table above until such time as the actual LIBOR-based variable component of our interest rate exceeds 0.75% on the Term Loan B. At such time, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate for the Term Loan B, but limited to a maximum LIBOR rate of 2.50% on \$2.735 billion of outstanding principal debt on the Term Loan B as a result of the interest rate cap agreements, as described below. The remaining \$721 million outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of

0.75%.

As of September 30, 2015, we maintain several interest rate swap agreements that were entered into in March 2013 with amortizing notional amounts of these swap agreements totaling \$784 million. These agreements have the economic effect of modifying the LIBOR variable component of our interest rate on an equivalent amount of our Term Loan A to fixed rates ranging from 0.49% to 0.52%, resulting in an overall weighted average effective interest rate of 2.26%, including the Term Loan A margin of 2.00%. The overall weighted average effective interest rate also includes the effects of \$154 million of unhedged Term Loan A debt that bears interest at LIBOR plus an interest rate margin of 2.00%. The swap agreements expire on September 30, 2016 and require monthly interest payments. During the nine months ended September 30, 2015, we recognized debt expense of \$2.1 million from these swaps. As of September 30, 2015, the total fair value of these swap agreements was a net liability of approximately \$0.9 million. During the nine months ended September 30, 2015, we recorded a loss of \$4.8 million in other comprehensive income due to a decrease in the unrealized fair value of these swap agreements. We estimate that approximately \$0.9 million of existing unrealized pre-tax losses in other comprehensive income at September 30, 2015 will be reclassified into income over the next twelve months.

As of September 30, 2015, we maintain several forward interest rate cap agreements that were entered into in November 2014 with notional amounts totaling \$3.500 billion. These forward cap agreements will be effective September 30, 2016 and will have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 3.50% on an equivalent amount of our debt. The cap agreements expire on June 30, 2018. As of September 30, 2015, the total fair value of these cap agreements was an asset of approximately \$2.2 million. During the nine months ended September 30, 2015, we recorded a loss of \$10.2 million in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

As of September 30, 2015, we maintain several active interest rate cap agreements that were entered into in March 2013 with notional amounts totaling \$2.735 billion on our Term Loan B debt. These agreements have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 2.50% on an equivalent amount of our Term Loan B. During the nine months ended September 30, 2015, we recognized debt expense of \$1.8 million from these caps. The cap agreements expire on September 30, 2016. As of September 30, 2015, the total fair value of these cap agreements was an asset of \$43 thousand. During the nine months ended September 30, 2015, we recorded a loss of \$1.6 million in other comprehensive income due to a decrease in the unrealized fair value of these cap agreements.

In October 2015, we entered into several forward interest rate cap agreements with notional amounts totaling \$3.500 billion. These forward cap agreements will be effective June 29, 2018 and will have the economic effect of capping the LIBOR variable component of our interest rate at a maximum of 3.50% on an equivalent amount of our debt. The cap agreements expire on June 30, 2020.

As a result of an embedded LIBOR floor on the Term Loan B debt agreement and the swap and cap agreements, our overall weighted average effective interest rate on the Senior Secured Credit Facilities was 3.50%, based upon the current margins in effect of 2.00% for the Term Loan A and 2.75% for the Term Loan B, as of September 30, 2015.

As of September 30, 2015, the interest rate on our Term Loan B debt is effectively fixed because of an embedded LIBOR floor which is higher than actual LIBOR as of such date and the Term Loan B is also subject to an interest rate cap if LIBOR should rise above 2.50%. Interest rates on our senior notes are fixed by their terms. The LIBOR variable component of our interest rate on the majority of our Term Loan A is economically fixed as a result of interest rate swaps.

Our overall weighted average effective interest rate during the quarter ended September 30, 2015 was 4.40% and as of September 30, 2015 was 4.40%.

Item 4. Controls and Procedures

Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow for timely decisions regarding required disclosures.

At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures in accordance with the Exchange Act requirements. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are effective for timely identification and review of material information required to be included in the Company's Exchange Act reports, including this report on Form 10-Q. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.

There has not been any change in the Company's internal control over financial reporting that was identified during the evaluation that occurred during the fiscal quarter covered by this report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

We provide services in a highly regulated industry and are a party to various legal actions and regulatory and other governmental and internal audits and investigations in the ordinary course of business (including investigations resulting from our obligation to self-report suspected violations of law). We cannot predict the ultimate outcome of pending litigation and regulatory and other governmental and internal audits and investigations. The following is a description of pending legal proceedings, governmental reviews, audits and investigation to which we are subject.

Inquiries by the Federal Government and Certain Related Civil Proceedings

Swoben Private Civil Suit: In April 2013, the Company's HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the qui tam provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a qui tam action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP's motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court's disposition of the appeal is pending.

2015 U.S. Attorney Transportation Investigation: In February 2015, the Company announced that it received six subpoenas from the OIG for medical records from six different dialysis centers in southern California operated by the Company. Specifically, each subpoena seeks the medical records of a single patient of the respective dialysis center. The Company has been advised by an attorney with the Civil Division of the United States Attorney's Office for the Central District of California that the subpoenas relate to an investigation concerning the medical necessity of patient transportation. The Company does not provide transportation or bill for the transport of its dialysis patients. The Company does not know the scope of the investigation by the government, nor what conduct or activities might be the subject of the investigation.

2015 U.S. OIG Medicare Advantage Civil Investigation: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of HCP, received a subpoena from the OIG. The Company has been advised by an attorney with the Civil Division of the United States Department of Justice in Washington, D.C., that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers' risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA's communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted. The Company is producing the requested information and is cooperating with the government's investigation.

In addition to the subpoena described above, in June 2015, DaVita HealthCare Partners Inc. (the "Company") received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to the Company's and its subsidiaries' (including HealthCare Partners and its subsidiary JSA HealthCare Corporation) provision of services to Medicare Advantage plans and Medicare Advantage organizations and related patient diagnosis coding and risk adjustment submissions and payments. We believe that the request is part of a broader industry investigation into Medicare Advantage patient diagnosis coding and risk adjustment practices and potential overpayments by the government. Some of the information requested relates to what we

disclosed in the risk factors of our quarterly report on Form 10-Q for the first quarter of 2015 as a potentially improper historical HealthCare Partners (“HCP”) coding practice related to a particular condition. The practice in question was discontinued following our November 1, 2012 acquisition of HCP and, as we previously disclosed, we notified CMS of the legacy coding practice and potential overpayments. In connection with the HCP merger, we have certain indemnification rights against the sellers and an escrow was established as security for the indemnification. In the event that the Company were to incur liability related to this matter, the Company would pursue an indemnification claim against the sellers secured by the escrow. We can make no assurances that the indemnification and escrow would cover the full amount of our potential losses related to this matter. The Company is cooperating with the government and will gather and produce the requested information.

Except for the private civil complaint filed by the relator as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.

Other

The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.

A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and that settlement has been finalized. The amount of the settlement is not material to the Company’s consolidated financial statements. In June 2015, we have reached an agreement in principle to resolve the remainder of the claims in this litigation. The settlement must be approved by the court, and the parties are in the process of seeking that approval. The amount of the settlement is not material to the Company’s consolidated financial statements.

In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.

Item 1A. Risk Factors

An updated description of the risk factors associated with our business is set forth below. This description includes any material changes to and supersedes the description of the risk factors associated with our business previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014. The risks discussed below are not the only ones facing our business. Please read the cautionary notice regarding forward-looking statements under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

Risk factors related to our U.S. dialysis and related lab services, ancillary services and strategic initiatives:

If the average rates that commercial payors pay us decline significantly, it would have a material adverse effect on our revenues, earnings and cash flows.

Approximately 34% of our dialysis and related lab services' revenues for the nine months ended September 30, 2015, were generated from patients who have commercial payors as their primary payor. The majority of these patients have insurance policies that pay us on terms and at rates that are generally significantly higher than Medicare rates. The payments we receive from commercial payors generate nearly all of our profit and all of our nonacute dialysis profits come from commercial payors. We continue to experience downward pressure on some of our commercial payment rates as a result of general conditions in the market, recent and future consolidations among commercial payors, increased focus on dialysis services and other factors. Specifically, in the second quarter of 2015, two planned mergers of large commercial payors were announced. If completed, these announced mergers could put increased pressure on the dialysis rates we receive from commercial payors. There is no guarantee that commercial payment rates will not be materially lower in the future.

We are continuously in the process of negotiating our existing or potentially new agreements with commercial payors who tend to be aggressive in their negotiations with us. Sometimes many significant agreements are up for renewal or being renegotiated at the same time. In the event that our continual negotiations result in overall commercial rate reductions in excess of overall commercial rate increases, the cumulative effect could have a material adverse effect on our financial results. Consolidations have significantly increased the negotiating leverage of commercial payors. Our negotiations with payors are also influenced by competitive pressures, and we may experience decreased contracted rates with commercial payors or experience decreases in patient volume as our negotiations with commercial payors continue. In addition to downward pressure on contracted commercial payor rates, payors have been attempting to impose restrictions and limitations on non-contracted or out-of-network providers, and in some circumstances designate our centers as out-of-network providers. Rates for out-of-network providers are on average higher than rates for in-network providers. We believe commercial payors have or will begin to restructure their benefits to create disincentives for patients to select or remain with out-of-network providers and to decrease payment rates for out-of-network providers. Decreases in out-of-network rates and restrictions on out-of-network access, our turning away new patients in instances where we are unable to come to agreement on rates, or decreases in contracted rates could result in a significant decrease in our overall revenues derived from commercial payors. If the average rates that commercial payors pay us decline significantly, or if we see a decline in commercial patients, it would have a material adverse effect on our revenues, earnings and cash flows. For additional details regarding specific risks we face regarding regulatory changes that could result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates, see the discussion of individual and small group health plans in the risk factor below under the heading "Healthcare reform could substantially reduce our revenues, earnings and cash flows."

If the number of patients with higher-paying commercial insurance declines, then our revenues, earnings and cash flows would be substantially reduced.

Our revenue levels are sensitive to the percentage of our patients with higher-paying commercial insurance coverage. A patient's insurance coverage may change for a number of reasons, including changes in the patient's or a family member's employment status. Currently, for a patient covered by an employer group health plan, Medicare generally becomes the primary payor after 33 months, or earlier, if the patient's employer group health plan coverage terminates. When Medicare becomes the primary payor, the payment rate we receive for that patient decreases from the employer group health plan rate to the lower Medicare payment rate. We have seen an increase in the number of patients who have government-based programs as their primary payors which we believe is largely a result of improved mortality and recent economic conditions which have a negative impact on the percentage of patients covered under commercial

insurance plans. To the extent there are sustained or increased job losses in the U.S., independent of whether general economic conditions might be improving, we could experience a continued decrease in the number of patients covered under commercial plans. We could also experience a further decrease if changes to the healthcare regulatory system result in fewer patients covered under commercial plans or an increase of patients covered under more restrictive commercial plans with lower reimbursement rates. In addition, our continuous process of negotiations with commercial payors under existing or potentially new agreements could result in a decrease in the number of patients under commercial plans to the extent that we cannot reach agreement with commercial payors on rates and other terms, resulting in termination or non-renewals of existing agreements or our inability to enter into new ones. If there is a significant reduction in the number of patients under higher-paying commercial plans relative to government-based programs that pay at lower rates, it would have a material adverse effect on our revenues, earnings and cash flows.

Changes in the structure of and payment rates under the Medicare ESRD program could substantially reduce our revenues, earnings and cash flows.

Approximately 44% of our dialysis and related lab services' revenues for the nine months ended September 30, 2015 was generated from patients who have Medicare as their primary payor. For patients with Medicare coverage, all ESRD payments for dialysis treatments are made under a single bundled payment rate which provides a fixed payment rate to encompass all goods and services provided during the dialysis treatment, including pharmaceuticals that were historically separately reimbursed to the dialysis

providers, such as EPO, vitamin D analogs and iron supplements, irrespective of the level of pharmaceuticals administered or additional services performed. Most lab services that used to be paid directly to laboratories are also included in the bundled payment. The bundled payment rate is also adjusted for certain patient characteristics, a geographic usage index and certain other factors.

The current bundled payment system presents certain operating, clinical and financial risks, which include:

- Risk that our rates are reduced by CMS. Uncertainty about future payment rates remains a material risk to our business. CMS issued the 2014 final rule for the ESRD prospective payment system (PPS), which phases in the payment reductions mandated by the American Taxpayer Relief Act of 2012 (ATRA) as modified by the “Protecting Access to Medicare Act” (PAMA), that will reduce our market basket inflation adjustment by 1.25% in 2016 and 2017, and 1% in 2018. CMS also recently issued the 2016 final rule for the ESRD PPS, which cuts dialysis facilities’ bundled payment rate and includes adjustments for certain co-morbidities and other patient health factors, low volume facilities, and rural facilities. CMS believes its 2016 final rule for the ESRD PPS will (i) increase overall payments to both hospital-based and freestanding dialysis facilities modestly by approximately 0.20%, and (ii) decrease overall payments to rural dialysis facilities by approximately 0.10%.
- Risk that increases in our operating costs will outpace the Medicare rate increases we receive. We expect to continue experiencing increases in operating costs that are subject to inflation, such as labor and supply costs, regardless of whether there is a compensating inflation-based increase in Medicare payment rates or in payments under the bundled payment rate system.
- Risk of federal budget sequestration cuts. As a result of the Budget Control Act of 2011 (BCA) and subsequent activity in Congress, a \$1.2 trillion sequester (across-the-board spending cuts) in discretionary programs took effect on March 1, 2013. In particular, a 2% reduction to Medicare payments took effect on April 1, 2013, which was subsequently extended through 2014 and 2015. The across-the-board spending cuts pursuant to the sequester have affected and will continue to adversely affect our revenues, earnings and cash flows.
- Risk that, if our clinical systems fail to accurately capture the data we report to CMS in connection with claims for which at least part of the government’s payments to us is based on clinical performance or patient outcomes or co-morbidities, we might be over-reimbursed by the government which could subject us to certain liability. For example, we are required to return overpayments including, federal funds, within sixty days of identification or claims associated with those overpayments are subject to FCA penalties.

For additional details regarding the risks we face for failing to adhere to our Medicare and Medicaid regulatory compliance obligations, see the risk factor below under the heading “If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings, cash flows and stock price.”

Healthcare reform could substantially reduce our revenues, earnings and cash flows.

We cannot predict how employers, private payors or persons buying insurance might react to the changes brought on by broad U.S. healthcare reform legislation or what form many of these regulations will take before implementation.

The healthcare reform legislation introduced healthcare insurance exchanges which provide a marketplace for eligible individuals and small employers to purchase healthcare insurance. Although we cannot predict the short- or long-term effects of these measures, we believe the healthcare insurance exchanges could result in a reduction in ESRD patients covered by traditional commercial insurance policies and an increase in the number of patients covered through the exchanges under more restrictive commercial plans with lower reimbursement rates or higher deductibles and co-payments that patients may not be able to pay. To the extent that the implementation of such exchanges results in a reduction in patients covered by commercial insurance or a reduction in reimbursement rates for our services from commercial and/or government payors, our revenues, earnings and cash flows could be adversely affected.

In addition, the healthcare reform legislation broadened the potential for penalties under the FCA for the knowing and improper retention of overpayments collected from government payors and reduced the timeline to file Medicare claims. As a result, we made significant initial investments in new resources to accelerate the time it takes us to identify and process overpayments and we deployed significant resources to reduce our timeline and improve our claims processing methods to ensure that our Medicare claims are filed in a timely fashion. We may be required to make additional investments in the future. Failure to timely identify and return overpayments may result in significant penalties, which may have a negative impact on our revenues, earnings and cash flows. Failure to file a claim within the one year window could result in payment denials, adversely affecting our revenues, earnings and cash flows.

The healthcare reform legislation also added several new tax provisions that, among other things, impose various fees and excise taxes, and limit compensation deductions for health insurance providers and their affiliates. These rules could negatively impact our cash flow and tax liabilities.

CMS Center for Medicare & Medicaid Innovation (Innovation Center) is currently working with various healthcare providers to develop, refine and implement ACOs and other innovative models of care for Medicare and Medicaid beneficiaries. We are currently uncertain of the extent to which the long-term operation and evolution of these care models, including ACOs, Bundled Payments for Care Improvement Initiative, Comprehensive ESRD Care Model (which includes the development of ESRD Seamless Care Organizations (ESCOs)), the Comprehensive Primary Care Initiative, the Duals Demonstration, and other models, will impact the healthcare market over time. Our U.S. dialysis business may choose to participate in one or several of these models either as a partner with other providers or independently. We are currently seeking to participate in the Comprehensive ESRD Care Model with the Innovation Center. Even if we do not participate in this or other programs, some of our patients may be assigned to a program, in which case the quality and cost of care that we furnish will be included in an ACO's or other programs' calculations. As new models of care emerge and evolve, we may be at risk of losing our Medicare patient base, which would have a materially adverse effect on our revenues, earnings and cash flow. Other initiatives in the government or private sector may arise, including the development of models similar to ACOs, IPAs and integrated delivery systems or evolutions of those concepts which could adversely impact our business.

CMS instituted new screening procedures which we expect will delay the Medicare contractor approval process, potentially causing a delay in reimbursement. We anticipate the new screening and enrollment requirements will require additional personnel and financial resources and will potentially delay the enrollment and revalidation of our centers which in turn will delay payment. These delays may negatively impact our revenues, earnings and cash flows.

Other reform measures allow CMS to place a moratorium on new enrollment of providers and to suspend payment to providers upon a credible allegation of fraud from any source. These types of reform measures, as well as other measures, could adversely impact our revenues, earnings and cash flows depending upon the scope and breadth of the implementing regulations.

There is also a considerable amount of uncertainty as to the prospective implementation of the federal healthcare reform legislation and what similar measures might be enacted at the state level. There have been multiple attempts through legislative action and legal challenges to repeal or amend the Patient Protection and Affordable Care Act of 2010, as modified by the Health Care and Education Reconciliation Act of 2010 (Health Reform Laws), including the case that was recently heard by the U.S. Supreme Court, *King v. Burwell*. Although the Supreme Court upheld the provision by the federal government of subsidies to individuals in federally facilitated health care exchanges in *Burwell*, which ultimately did not disrupt significantly the implementation of the healthcare reform legislation, we cannot predict whether other current or future efforts to repeal or amend these laws will be successful, nor can we predict the impact that such a repeal or amendment would have on our business and operations, or on our revenues and earnings. The enacted reforms as well as future legislative changes could have a material adverse effect on our results of operations, including lowering our reimbursement rates and increasing our expenses.

Changes in state Medicaid or other non-Medicare government-based programs or payment rates could reduce our revenues, earnings and cash flows.

Approximately 21% of our dialysis and related lab services' revenues for the nine months ended September 30, 2015 was generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs (VA), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, we may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs. For example, certain state Medicaid programs and the VA have recently considered, proposed or implemented payment rate reductions.

The VA adopted Medicare's bundled PPS pricing methodology for any veterans receiving treatment from non-VA providers under a national contracting initiative. Since we are a non-VA provider, these reimbursements are tied to a percentage of Medicare reimbursement, and we have exposure to any dialysis reimbursement changes made by CMS. Approximately 2% of our dialysis and related lab services' revenues for the nine months ended September 30, 2015 was generated by the VA.

In 2013, we entered into a five-year Nationwide Dialysis Services contract with the VA which is subject to one-year renewal periods, consistent with all provider agreements with the VA under this contract. During the length of the contract, the VA has elected not to make adjustments to reimbursement percentages that are tied to a percentage of Medicare reimbursement rates. These agreements provide the VA with the right to terminate the agreements without cause on short notice. Should the VA not renew or cancel these agreements for any reason, we may cease accepting patients under this program and may be forced to close centers, which could adversely affect our revenues, earnings and cash flows.

State Medicaid programs are increasingly adopting Medicare-like bundled payment systems, but sometimes these payment systems are poorly defined and are implemented without any claims processing infrastructure, or patient or facility adjusters. If these payment systems are implemented without any adjusters and claims processing changes, Medicaid payments will be substantially reduced and the costs to submit such claims may increase, which will have a negative impact on our revenues, earnings and cash flows. In addition, some state Medicaid program eligibility requirements mandate that citizen enrollees in such programs provide documented proof of citizenship. If our patients cannot meet these proof of citizenship documentation requirements, they may be

denied coverage under these programs, resulting in decreased patient volumes and revenue. These Medicaid payment and enrollment changes, along with similar changes to other non-Medicare government programs could reduce the rates paid by these programs for dialysis and related services, delay the receipt of payment for services provided, and further limit eligibility for coverage which could adversely affect our revenues, earnings and cash flows.

Changes in clinical practices, payment rates or regulations impacting EPO and other pharmaceuticals could adversely affect our operating results, reduce our revenues, earnings and cash flows and negatively impact our ability to care for patients.

Medicare bundles EPO into the PPS such that dosing variations do not change the amount paid to a dialysis facility. Although some Medicaid programs and other payors suggest movement towards a bundled payment system inclusive of EPO, some non-Medicare payors continue to pay for EPO separately from the treatment rate. The administration of EPO and other pharmaceuticals that are separately billable accounted for approximately 2% of our dialysis and related lab services' revenues for the nine months ended September 30, 2015, with EPO alone accounting for approximately 1% of our dialysis and related lab services' revenues during that period.

Evaluations on the utilization and reimbursement for ESAs, which have occurred in the past and may occur in the future, and related actions by the U.S. Congress and federal agencies, could result in further restrictions on the utilization and reimbursement for ESAs. Additionally, commercial payors have increasingly examined their administration policies for EPO and, in some cases, have modified those policies. Changes in labeling of EPO and other pharmaceuticals in a manner that alters physician practice patterns or accepted clinical practices, changes in private and governmental payment criteria, including the introduction of EPO administration policies or the conversion to alternate types of administration of EPO or other pharmaceuticals that result in further decreases in utilization of EPO for patients covered by commercial payors could have a material adverse effect on our revenues, earnings and cash flows. Further increased utilization of EPO for patients for whom the cost of EPO is included in a bundled reimbursement rate, or further decreases in reimbursement for EPO and other pharmaceuticals that are not included in a bundled reimbursement rate, could also have a material adverse effect on our revenues, earnings and cash flows.

Additionally, as a result of the current high level of scrutiny and controversy, we may be subject to increased inquiries or audits from a variety of governmental bodies or claims by third parties. Although we believe our anemia management practices and other pharmaceutical administration practices have been compliant with existing laws and regulations, increased inquiries or audits from governmental bodies or claims by third parties would require management's attention, and could result in significant legal expense. Any negative findings could result in substantial financial penalties or repayment obligations, the imposition of certain obligations on and changes to our practices and procedures as well as the attendant financial burden on us to comply with the obligations, or exclusion from future participation in the Medicare and Medicaid programs, and could have a material adverse effect on our revenues, earnings and cash flows.

Changes in EPO pricing could materially reduce our earnings and cash flows and affect our ability to care for our patients.

Future increases in the cost of EPO without corresponding increases in payment rates for EPO from commercial payors and without corresponding increases in the Medicare bundled rate could have a material adverse effect on our earnings and cash flows and ultimately reduce our income. In November 2011, we entered into a seven year Sourcing and Supply Agreement with Amgen USA Inc. (Amgen), pursuant to which we committed to purchase EPO in amounts necessary to meet no less than 90% of our requirements for ESAs. As long as we meet certain conditions, the agreement limits Amgen's ability to unilaterally increase the price for EPO during the term of the agreement. Our agreement with Amgen provides for discounted pricing and rebates for EPO. However, some of the rebates are subject

to various conditions including, but not limited to, future pricing levels of EPO by Amgen and data submission by us. In addition, the rebates are subject to certain limitations. We cannot predict whether, over the seven year term of the agreement, we will continue to receive the rebates for EPO that we have received in the past, or whether we will continue to achieve the same levels of rebates within that structure as we have historically achieved. Factors that could impact our ability to qualify for rebates provided for in our agreement with Amgen in the future include, but are not limited to, our ability to track certain data elements. We cannot predict whether we will be able to meet the applicable qualification requirements for receiving rebates. Failure to meet certain targets and earn the specified rebates could have a material adverse effect on our earnings and cash flows.

If we fail to comply with our Corporate Integrity Agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs that may adversely impact our revenues, earnings and cash flows.

In October 2014, we entered into a Settlement Agreement with the United States and relator David Barbetta to resolve the then pending 2010 and 2011 U.S. Attorney physician relationship investigations and paid \$406 million in settlement amounts, civil forfeiture, and interest to the United States and certain states. In connection with the resolution of these matters, and in exchange for the OIG's agreement not to exclude us from participating in the federal healthcare programs, we have entered into a five-year Corporate Integrity Agreement (CIA) with the OIG. The CIA (i) requires that we maintain certain elements of our compliance programs, (ii) imposes certain expanded compliance-related requirements during the term of the CIA, (iii) requires ongoing monitoring and reporting by an independent monitor, reporting, certification, records retention and training obligations, the formal

allocation of certain oversight responsibility to the Board's Compliance Committee, the creation of a Management Compliance Committee and the retention of an independent compliance advisor to the Board, and (iv) contains certain business restrictions related to a subset of our joint venture arrangements, including our agreeing to: (1) unwind 11 joint venture transactions that were created through partial divestitures to, or partial acquisitions from, nephrologists and that cover 26 of our 2,119 clinics that existed at the time we entered into the Settlement Agreement; (2) not enter into certain types of partial divestiture joint venture transactions with nephrologists during the term of the CIA; (3) non-enforcement of certain patient-related non-solicitation restrictions; and (4) certain other restrictions. The costs associated with compliance with the CIA could be substantial and may be greater than we currently anticipate. In addition, in the event of a breach of the CIA, we could become liable for payment of certain stipulated penalties, and could be excluded from participation in federal healthcare programs. The OIG notified us that it considers us to be in breach of the CIA because of three implementation deficiencies. We have remediated the deficiencies and have paid certain stipulated penalties. In general, the costs associated with compliance with the CIA, or any liability or consequences associated with a breach, could have a material adverse effect on our revenues, earnings and cash flows.

If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings, cash flows and stock price.

Our operations are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations, federal and state anti-kickback laws, the physician self-referral law (Stark Law) and analogous state self-referral prohibition statutes, Federal Acquisition Regulations, the FCA and federal and state laws regarding the collection, use and disclosure of patient health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related to claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements upon dialysis providers as well. A violation or departure from any of these legal requirements may result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments.

We endeavor to comply with all legal requirements, however, there is no guarantee that we will be able to adhere to all of the complex government regulations that apply to our business. We further endeavor to structure all of our relationships with physicians to comply with state and federal anti-kickback and physician self-referral laws. We utilize considerable resources to monitor the laws and implement necessary changes. However, the laws and regulations in these areas are complex and often subject to varying interpretations. For example, if an enforcement agency were to challenge the level of compensation that we pay our medical directors or the number of medical directors whom we engage, we could be required to change our practices, face criminal or civil penalties, pay substantial fines or otherwise experience a material adverse effect as a result of a challenge to these arrangements. In addition, the FCA amended the Social Security Act to make the knowing failure to report and return overpayments within 60 days of when the overpayment was identified an "obligation" for purposes of the FCA, 31 U.S.C. § 3729(b)(3). These amendments could subject our procedures for identifying and processing overpayments to greater scrutiny. We have made significant investments in new resources to decrease the time it takes to identify and process overpayments and we may be required to make additional investments in the future. An acceleration in our ability to identify and process overpayments could result in us refunding overpayments to government and other payors more rapidly than we have in the past which could have a material adverse effect on our operating cash flows. Additionally, amendments to the federal anti-kickback statute in the health reform law make anti-kickback violations potentially subject to liability under the FCA, including qui tam or whistleblower suits.

If any of our operations are found to violate these or other government regulations, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings, cash flows and stock price, including:

- Suspension or termination of our participation in government payment programs;
- Refunds of amounts received in violation of law or applicable payment program requirements;
- Loss of required government certifications or exclusion from government payment programs;
- Loss of licenses required to operate healthcare facilities or administer pharmaceuticals in some of the states in which we operate;
- Reductions in payment rates or coverage for dialysis and ancillary services and related pharmaceuticals;
- Fines, damages or monetary penalties for anti-kickback law violations, Stark Law violations, FCA violations, civil or criminal liability based on violations of law, or other failures to meet regulatory requirements;
- Enforcement actions by governmental agencies and/or state claims for monetary damages by patients who believe their protected health information has been used, disclosed or not properly safeguarded in violation of federal or state patient privacy laws, including but not limited to the Health Insurance Portability and Accountability Act (HIPAA) of 1996 or the Privacy Act of 1974;
- Mandated changes to our practices or procedures that significantly increase operating expenses;

- Imposition of and compliance with corporate integrity agreements that could subject us to ongoing audits and reporting requirements as well as increased scrutiny of our billing and business practices which could lead to potential fines;
- Termination of relationships with medical directors; and
- Harm to our reputation which could impact our business relationships, affect our ability to obtain financing and decrease access to new business opportunities.

Delays in state Medicare and Medicaid certification of our dialysis centers could adversely affect our revenues, earnings and cash flows.

Before we can begin billing for patients treated in our outpatient dialysis centers who are enrolled in government-based programs, we are required to obtain state and federal certification for participation in the Medicare and Medicaid programs. As state agencies responsible for surveying dialysis centers on behalf of the state and Medicare program face increasing budgetary pressure, certain states are having difficulty keeping up with certifying dialysis centers in the normal course resulting in significant delays in certification. If state governments continue to have difficulty keeping up with certifying new centers in the normal course and we continue to experience significant delays in our ability to treat and bill for services provided to patients covered under government programs, it could cause us to incur write-offs of investments or accelerate the recognition of lease obligations in the event we have to close centers or our centers' operating performance deteriorates, and it could have an adverse effect on our revenues, earnings and cash flows.

If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings and cash flows.

As of September 30, 2015, we owned a controlling interest in numerous dialysis-related joint ventures, which represented approximately 23% of our U.S. dialysis and related lab services' revenues for the nine months ended September 30, 2015. In addition, we also owned minority equity investments in several other dialysis related joint ventures. We may continue to increase the number of our joint ventures. Many of our joint ventures with physicians or physician groups also have certain physician owners providing medical director services to centers we own and operate. Because our relationships with physicians are governed by the federal and state anti-kickback statutes, we have sought to structure our joint venture arrangements to satisfy as many federal safe harbor requirements as we believe are commercially reasonable. However, although our joint venture arrangements do not satisfy all of the elements of any safe harbor under the federal anti-kickback statute, they are not automatically prohibited under the federal anti-kickback statute but are susceptible to government scrutiny. In October 2014, we entered into a Settlement Agreement with the United States and relator David Barbetta to resolve the then pending 2010 and 2011 U.S. Attorney physician relationship investigations regarding certain of our joint ventures and paid \$406 million in settlement amounts, civil forfeiture, and interest to the United States and certain states. For further details, please see "If we fail to comply with our Corporate Integrity Agreement, we could be subject to substantial penalties and exclusion from participation in federal healthcare programs that may adversely impact our revenues, earnings and cash flows".

There are significant estimating risks associated with the amount of dialysis revenues and related refund liabilities that we recognize and if we are unable to accurately estimate our revenues and related refund liabilities, it could impact the timing and the amount of our revenues recognition or have a significant impact on our operating results.

There are significant estimating risks associated with the amount of dialysis and related lab services' revenues and related refund liabilities that we recognize in a reporting period. The billing and collection process is complex due to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage, and other payor issues. Determining applicable primary and secondary coverage for approximately 177,000 U.S. patients at any point in time, together with the changes in patient coverage that occur each month, requires complex,

resource-intensive processes. Errors in determining the correct coordination of benefits may result in refunds to payors. Revenues associated with Medicare and Medicaid programs are also subject to estimating risk related to the amounts not paid by the primary government payor that will ultimately be collectible from other government programs paying secondary coverage, the patient's commercial health plan secondary coverage or the patient. Collections, refunds and payor retractions typically continue to occur for up to three years and longer after services are provided. We generally expect our range of U.S. dialysis and related lab services' revenues estimating risk to be within 1% of net revenues for the segment, which represents approximately 5% of dialysis and related lab services' adjusted operating income. If our estimates of dialysis and related lab services revenues and related refund liabilities are materially inaccurate, it could impact the timing and the amount of our revenues recognition and have a significant impact on our operating results.

Our ancillary services and strategic initiatives, including our international dialysis operations, that we invest in now or in the future may generate losses and may ultimately be unsuccessful. In the event that one or more of these activities is unsuccessful, we may have to write off our investment and incur other exit costs.

Our ancillary services and strategic initiatives currently include pharmacy services, disease management services, vascular access services, ESRD clinical research programs, physician services, physician practice management services, direct primary care and our international dialysis operations. We expect to add additional service offerings and pursue additional strategic initiatives in the future as circumstances warrant, which could include healthcare services not related to dialysis. Many of these initiatives require or would require investments of both management and financial resources and can generate significant losses for a substantial period of time and may not become profitable. There can be no assurance that any such strategic initiative will ultimately be successful. Any significant change in market conditions, or business performance, or in the political, legislative or regulatory environment, may impact the economic viability of any of these strategic initiatives. If any of our ancillary services or strategic initiatives, including our international dialysis operations, do not perform as planned, we may incur a material write-off or an impairment of our investment, including goodwill, in one or more of these activities or we could incur significant termination costs if we were to exit a certain line of business.

If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to regulatory or other reasons, it would have a material adverse effect on our revenues, earnings and cash flows.

We believe that physicians prefer to have their patients treated at dialysis centers where they or other members of their practice supervise the overall care provided as medical director of the center. As a result, the primary referral source for most of our centers is often the physician or physician group providing medical director services to the center.

Our medical director contracts are for fixed periods, generally ten years, and at any given time a large number of them could be up for renewal at the same time. Medical directors have no obligation to extend their agreements with us and if we are unable to enforce noncompetition provisions contained in terminated medical director agreements, our former medical directors may choose to provide medical director services for competing providers or establish their own dialysis centers in competition with ours. Neither our current nor former medical directors have an obligation to refer their patients to our centers.

Opportunities presented by our competitors or different affiliation models in the changing healthcare environment, such as an increase in the number of physicians becoming employed by hospitals or a perceived decrease in the quality of service levels at our centers may negatively impact a medical director's decision to enter into or extend his or her agreement with us, refer patients to our centers or otherwise negatively impact treatment volumes.

In addition, we may take actions to restructure existing relationships or take positions in negotiating extensions of relationships to assure compliance with the anti-kickback statute, Stark Law and other similar laws. If the terms of any existing agreement are found to violate applicable laws, we may not be successful in restructuring the relationship which could lead to the early termination of the agreement, or cause the physician to stop referring patients to our dialysis centers. These actions in an effort to comply with applicable laws and regulations could negatively impact the decision of physicians to extend their medical director agreements with us or to refer their patients to us. If a significant number of physicians were to cease referring patients to our dialysis centers, our revenues, earnings and cash flows would be substantially reduced.

Deterioration in economic conditions as well as further disruptions in the financial markets could have a material adverse effect on our revenues, earnings and cash flows and otherwise adversely affect our financial condition.

Deterioration in economic conditions could adversely affect our business and our profitability. Among other things, the potential decline in federal and state revenues that may result from such conditions may create additional pressures to contain or reduce reimbursements for our services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment rate in the U.S. as a result of adverse economic conditions has and may continue to result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers may also select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a further slowdown in collections and a reduction in the amounts we expect to collect. In addition, uncertainty in the financial markets could adversely affect the variable interest rates payable under our credit facilities or could make it more difficult to obtain or renew such facilities or to obtain other forms of financing in the future, if at all. Any or all of these factors, as well as other consequences of a deterioration in economic conditions which cannot currently be anticipated, could have a material adverse effect on our revenues, earnings and cash flows and otherwise adversely affect our financial condition.

If there are shortages of skilled clinical personnel or if we experience a higher than normal turnover rate, we may experience disruptions in our business operations and increases in operating expenses.

We are experiencing increased labor costs and difficulties in hiring nurses due to a nationwide shortage of skilled clinical personnel. We compete for nurses with hospitals and other healthcare providers. This nursing shortage may limit our ability to expand our operations. In addition, changes in certification requirements or increases in the required staffing levels for skilled clinical personnel can impact our ability to maintain sufficient staff levels to the extent our teammates are not able to meet new requirements or we experience a higher than normal turnover rate due to increased competition for qualified clinical personnel. If we are unable to hire skilled clinical personnel when needed, or if we experience a higher than normal turnover rate for our skilled clinical personnel, our operations and treatment growth will be negatively impacted, which would result in reduced revenues, earnings and cash flows.

Our business is labor intensive and could be adversely affected if we are unable to maintain satisfactory relations with our employees or if union organizing activities result in significant increases in our operating costs or decreases in productivity.

Our business is labor intensive, and our results are subject to variations in labor-related costs, productivity and the number of pending or potential claims against us related to labor and employment practices. If political efforts at the national and local level result in actions or proposals that increase the likelihood of union organizing activities at our facilities or if union organizing activities increase for other reasons, or if labor and employment claims, including the filing of class action suits, trend upwards, our operating costs could increase and our employee relations, productivity, earnings and cash flows could be adversely affected.

Complications associated with our new billing and collections system could have a material adverse effect on our revenues, cash flows and operating results.

We recently launched a new billing system that is critical to our billing operations. If there are defects in the new billing system, we may experience difficulties in our ability to successfully bill and collect for services rendered, including a delay in collections, a reduction in the amounts collected, increased risk of retractions from and refunds to commercial and government payors, an increase in our provision for uncollectible accounts receivable and noncompliance with reimbursement regulations. To mitigate this risk, we are launching the new system in phases; however, any defects in the new billing and collection system could have a material adverse effect on our revenues, cash flows and operating results.

Our ability to effectively provide the services we offer could be negatively impacted if certain of our suppliers are unable to meet our needs or if we are unable to effectively access new technology, which could substantially reduce our revenues, earnings and cash flows.

We have significant suppliers that are either the sole or primary source of products critical to the services we provide, including Amgen, Baxter Healthcare Corporation, NxStage Medical, Inc. and others or to which we have committed obligations to make purchases including Gambro Healthcare and Fresenius Medical Care (FMC). If any of these suppliers are unable to meet our needs for the products they supply, including in the event of a product recall or shortage, and we are not able to find adequate alternative sources, or if some of the drugs that we purchase are not reimbursed or not adequately reimbursed by commercial payors or through the bundled payment rate by Medicare, our revenues, earnings and cash flows could be substantially reduced. In addition, the technology related to the products critical to the services we provide is subject to new developments and may result in superior products. If we are not able to access superior products on a cost-effective basis or if suppliers are not able to fulfill our requirements for such products, we could face patient attrition which could substantially reduce our revenues, earnings and cash flows.

Risk factors related to HCP:

HCP is subject to many of the same risks to which our dialysis business is subject.

As a participant in the healthcare industry, HCP is subject to many of the same risks to which our dialysis business is subject to as described in the risk factors set forth above in this Part II, Item 1A, any of which could materially and adversely affect HCP's revenues, earnings or cash flows. Among these risks are the following:

- The healthcare business is heavily regulated and changes in laws, regulations, or government programs could have a material impact on HCP;
- Failure to comply with complex governmental regulations could have severe consequences to HCP, including, without limitation, exclusion from governmental payor programs like Medicare and Medicaid;
- HCP could become the subject of governmental investigations, claims, and litigation;

60

- HCP may be unable to continue to explore potential acquisition candidates, make acquisitions or successfully integrate such acquisitions into its business, and such acquisitions may include liabilities of which HCP was not aware; and
- As a result of the broad scope of HCP's medical practice, HCP is exposed to medical malpractice claims, as well as claims for damages and other expenses, that may not be covered by insurance or for which adequate limits of insurance coverage may not be available.

Under most of HCP's agreements with health plans, HCP assumes some or all of the risk that the cost of providing services will exceed its compensation.

Over 91% of HCP's revenue for the nine months ended September 30, 2015 is derived from fixed Per Member Per Month (PMPM) fees paid by health plans under capitation agreements with HCP or its associated physician groups. While there are variations specific to each arrangement, HCP, through DaVita HealthCare Partners Plan, Inc., a subsidiary of HealthCare Partners Holdings, LLC and a restricted Knox-Keene licensed entity (DaVita HealthCare Partners Plan), and, in certain instances, HCP's associated physician groups generally contract with health plans to receive a PMPM fee for professional services and assume the financial responsibility for professional services only. In some cases, the health plans separately enter into capitation contracts with third parties (typically hospitals) who receive directly a PMPM fee and assume contractual financial responsibility for hospital services. In other cases, the health plan does not pay any portion of the PMPM fee to the hospital, but rather administers claims for hospital expenses itself. In both scenarios, HCP enters into managed care-related administrative services agreements or similar arrangements with those third parties (typically hospitals) under which HCP agrees to be responsible for utilization review, quality assurance, and other managed care-related administrative functions and claim payments. As compensation for such administrative services, HCP is entitled to receive a percentage of the amount by which the institutional capitation revenue received from health plans exceeds institutional expenses; any such risk-share amount to which HCP is entitled is recorded as medical revenues and HCP is also responsible for a percentage of any short-fall in the event that institutional expenses exceed institutional revenues. To the extent that members require more care than is anticipated, aggregate fixed PMPM amounts, or capitation payments, may be insufficient to cover the costs associated with treatment. If medical expenses exceed estimates, except in very limited circumstances, HCP will not be able to increase the PMPM fee received under these risk agreements during their then-current terms and could, directly or indirectly through its contracts with its associated physician groups, suffer losses with respect to such agreements.

Changes in HCP's or its associated physician groups' anticipated ratio of medical expense to revenue can significantly impact HCP's financial results. Accordingly, the failure to adequately predict and control medical expenses and to make reasonable estimates and maintain adequate accruals for incurred but not reported claims, may have a material adverse effect on HCP's financial condition, results of operations or cash flows.

Historically, HCP's and its associated physician groups' medical expenses as a percentage of revenue have fluctuated. Factors that may cause medical expenses to exceed estimates include:

- the health status of members;
- higher than expected utilization of new or existing healthcare services or technologies;
- an increase in the cost of healthcare services and supplies, including pharmaceuticals, whether as a result of inflation or otherwise;
- changes to mandated benefits or other changes in healthcare laws, regulations, and practices;
- periodic renegotiation of provider contracts with specialist physicians, hospitals, and ancillary providers;
- periodic renegotiation of contracts with HCP's affiliated primary care physicians and specialists;
- changes in the demographics of the participating members and medical trends;
- contractual or claims disputes with providers, hospitals, or other service providers within a health plan's network;
- the occurrence of catastrophes, major epidemics, or acts of terrorism; and

- the reduction of health plan premiums.

Risk-sharing arrangements that HCP and its associated physician groups have with health plans and hospitals could result in their costs exceeding the corresponding revenues, which could reduce or eliminate any shared risk profitability.

Most of the agreements between health plans and HCP and its associated physician groups contain risk-sharing arrangements under which the physician groups can earn additional compensation from the health plans by coordinating the provision of quality, cost-effective healthcare to members. However, such arrangements may require the physician group to assume a portion of any loss sustained from these arrangements, thereby reducing HCP's net income. Under these risk-sharing arrangements, HCP and its associated physician groups are responsible for a portion of the cost of hospital services or other services that are not capitated. The

terms of the particular risk-sharing arrangement allocate responsibility to the respective parties when the cost of services exceeds the related revenue, which results in a deficit, or permit the parties to share in any surplus amounts when actual costs are less than the related revenue. The amount of non-capitated medical and hospital costs in any period could be affected by factors beyond the control of HCP, such as changes in treatment protocols, new technologies, longer lengths of stay by the patient, and inflation. Certain of HCP's agreements with health plans stipulate that risk-sharing pool deficit amounts are carried forward to offset any future years' surplus amounts HCP would otherwise be entitled to receive. HCP accrues for any such risk-sharing deficits. To the extent that such non-capitated medical and hospital costs are higher than anticipated, revenue may not be sufficient to cover the risk-sharing deficits the health plans and HCP are responsible for, which could reduce HCP's revenues and profitability.

Renegotiation, renewal, or termination of capitation agreements with health plans could have a significant impact on HCP's future profitability.

Under most of HCP's and its associated physician groups' capitation agreements with health plans, the health plan is generally permitted to modify the benefit and risk obligations and compensation rights from time to time during the terms of the agreements. If a health plan exercises its right to amend its benefit and risk obligations and compensation rights, HCP and its associated physician groups are generally allowed a period of time to object to such amendment. If HCP or its associated physician group so objects, under some of the risk agreements, the relevant health plan may terminate the applicable agreement upon 90 to 180 days written notice. If HCP or its associated physician groups enter into capitation contracts or other risk sharing arrangements with unfavorable economic terms, or a capitation contract is amended to include unfavorable terms, HCP could, directly or indirectly through its contracts with its associated physician groups, suffer losses with respect to such contract. Since HCP does not negotiate with CMS or any health plan regarding the benefits to be provided under their Medicare Advantage plans, HCP often has just a few months to familiarize itself with each new annual package of benefits it is expected to offer. Depending on the health plan at issue and the amount of revenue associated with the health plan's risk agreement, the renegotiated terms or termination may have a material adverse effect on our HCP division and the Company's future revenues and profitability.

Laws regulating the corporate practice of medicine could restrict the manner in which HCP is permitted to conduct its business and the failure to comply with such laws could subject HCP to penalties or require a restructuring of HCP.

Some states have laws that prohibit business entities, such as HCP, from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (also known collectively as the corporate practice of medicine) or engaging in certain arrangements, such as fee-splitting, with physicians. In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. Of the states in which HCP currently operates, California and Nevada prohibit the corporate practice of medicine, and other states may as well.

In California and Nevada, HCP operates by maintaining long-term contracts with its associated physician groups which are each owned and operated by physicians and which employ or contract with additional physicians to provide physician services. Under these arrangements, HCP provides management services and, receives a management fee for providing non-medical management services; however, HCP does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by the physicians or the associated physician groups.

In addition to the above management arrangements, HCP has certain contractual rights relating to the orderly transfer of equity interests in certain of its associated California and Nevada physician groups through succession agreements and other arrangements with their physician equity holders. However, such equity interests cannot be transferred to or held by HCP or by any non-professional organization. Accordingly, neither HCP nor HCP's subsidiaries directly own

any equity interests in any physician groups in California and Nevada. In the event that any of these associated physician groups fails to comply with the management arrangement or any management arrangement is terminated and/or HCP is unable to enforce its contractual rights over the orderly transfer of equity interests in its associated physician groups, such events could have a material adverse effect on HCP's business, financial condition or results of operations.

It is possible that a state regulatory agency or a court could determine that HCP's agreements with physician equity holders of certain managed California and Nevada associated physician groups as described above, either independently or coupled with the management services agreements with such associated physician groups, are in violation of the corporate practice of medicine doctrine. As a result, these arrangements could be deemed invalid, potentially resulting in a loss of revenues and an adverse effect on results of operations derived from such associated physician groups. Such a determination could force a restructuring of HCP's management arrangements with associated physician groups in California and/or Nevada, which might include revisions of the management services agreements, including a modification of the management fee and/or establishing an alternative structure, which would permit HCP to contract with a physician network without violating the corporate practice of medicine prohibition. There can be no assurance that such a restructuring would be feasible, or that it could be accomplished within a reasonable time frame without a material adverse effect on HCP's operations and financial results. In December 2013, DaVita HealthCare Partners Plan obtained a restricted Knox-Keene license in California pursuant to the California Knox-Keene Health Care Service Plan Act of 1975 (the Knox-Keene Act), which permits DaVita HealthCare Partners Plan to contract with health plans in California to accept global risk without

violating the corporate practice of medicine prohibition. However, HCP's Nevada associated physician groups and HCP, as well as those physician equity holders of associated physician groups who are subject to succession agreements with HCP, could be subject to criminal or civil penalties or an injunction for practicing medicine without a license or aiding and abetting the unlicensed practice of medicine.

If HCP's agreements or arrangements with any physician equity holder(s) of associated physicians, physician groups, or IPAs are deemed invalid under state law, including laws against the corporate practice of medicine, or federal law, or are terminated as a result of changes in state law, or if there is a change in accounting standards by the Financial Accounting Standards Board (FASB) or the interpretation thereof affecting consolidation of entities, it could impact HCP's consolidation of total revenues derived from such associated physician groups.

HCP's financial statements are consolidated in accordance with applicable accounting standards and include the accounts of its majority-owned subsidiaries and certain non-owned HCP-associated and managed physician groups. Such consolidation for accounting and/or tax purposes does not, is not intended to, and should not be deemed to, imply or provide to HCP any control over the medical or clinical affairs of such physician groups. In the event of a change in accounting standards promulgated by FASB or in interpretation of its standards, or if there were an adverse determination by a regulatory agency or a court, or a change in state or federal law relating to the ability to maintain present agreements or arrangements with such physician groups, HCP may not be permitted to continue to consolidate the total revenues of such organizations. A change in accounting for consolidation with respect to HCP's present agreement or arrangements would diminish HCP's reported revenues but would not be expected to materially adversely affect its reported results of operations, while regulatory or legal rulings or changes in law interfering with HCP's ability to maintain its present agreements or arrangements could materially diminish both revenues and results of operations.

If DaVita HealthCare Partners Plan is not able to satisfy financial solvency or other regulatory requirements, DaVita HealthCare Partners could become subject to sanctions and its license to do business in California could be limited, suspended or terminated.

The Knox-Keene Act requires healthcare service plans operating in California to comply with financial solvency and other requirements overseen by the California Department of Managed Health Care (DMHC). Under the Knox-Keene Act, DaVita HealthCare Partners Plan is required to, among other things:

- Maintain, at all times, a minimum tangible net equity;
- Submit periodic financial solvency reports to the DMHC containing various data regarding performance and financial solvency;
- Comply with extensive regulatory requirements; and
- Submit to periodic regulatory audits and reviews concerning DaVita HealthCare Partner Plan operations and compliance with the Knox-Keene Act.

In the event that DaVita HealthCare Partners Plan is not in compliance with the provisions of the Knox-Keene Act, it could be subject to sanctions, or limitations on, or suspension of its license to do business in California.

If HCP's associated physician group is not able to satisfy the California DMHC's financial solvency requirements, HCP's associated physician group could become subject to sanctions and HCP's ability to do business in California could be limited or terminated.

The California DMHC has instituted financial solvency regulations to monitor the financial solvency of capitated physician groups. Under these regulations, HCP's associated physician group is required to, among other things:

.

Maintain, at all times, a minimum cash-to-claims ratio (where cash-to-claims ratio means the organization's cash, marketable securities, and certain qualified receivables, divided by the organization's total unpaid claims liability). The regulation currently requires a cash-to-claims ratio of 0.75.

· Submit periodic reports to the California DMHC containing various data and attestations regarding performance and financial solvency, including incurred but not reported calculations and documentation, and attestations as to whether or not the organization was in compliance with the Knox-Keene Act requirements related to claims payment timeliness had maintained positive tangible net equity (i.e., at least \$1.00), and had maintained positive working capital (i.e., at least \$1.00).

In the event that HCP's associated physician group is not in compliance with any of the above criteria, HCP's associated physician group could be subject to sanctions, or limitations on, or removal of, its ability to do business in California.

Reductions in Medicare Advantage health plan reimbursement rates stemming from recent healthcare reforms and any future related regulations may negatively impact HCP's business, revenue and profitability.

A significant portion of HCP's revenue is directly or indirectly derived from the monthly premium payments paid by CMS to health plans for medical services provided to Medicare Advantage enrollees. As a result, HCP's results of operations are, in part, dependent on government funding levels for Medicare Advantage programs. Any changes that limit or reduce Medicare Advantage reimbursement levels, including those recently approved and effective in 2015, such as reductions in or limitations of reimbursement amounts or rates under programs, reductions in funding of programs, expansion of benefits without adequate funding, elimination of coverage for certain benefits, or elimination of coverage for certain individuals or treatments under programs, could have a material adverse effect on HCP's revenues, earnings and cash flows. On April 7, 2014 CMS issued final guidance for 2015 Medicare Advantage rates, which incorporated a re-blending of the risk adjustment models that CMS utilizes to determine risk acuity scores of Medicare Advantage patients. In 2014, CMS blended the risk scores calculated using the 2013 CMS-HCC model and the 2014 CMS-HCC model by weighting the scores from the 2013 model by 25% and the scores from the 2014 model by 75%. In 2015, CMS will blend the scores by 67% and 33%, respectively. Although we estimate that the final cumulative impact of the 2015 rate structure represents an increase of up to approximately 0.5% of HCP's average Medicare Advantage revenues as compared to 2014, there is no guarantee that CMS's risk acuity adjustment models and the resulting Medicare Advantage rates will, in the future, increase HCP's Medicare Advantage revenues.

On April 6, 2015, CMS issued its final rule establishing the 2016 Medicare Advantage benchmark payment rates as well as announcing the model it will use to blend risk acuity scores. In 2016, CMS will blend the risk scores calculated using the 2013 CMS-HCC model and the 2014 CMS-HCC model by weighting the scores from the 2013 model by 0% and the scores from the 2014 model by 100%. Based upon our preliminary analysis of the final rule, we estimate that the reduction in 2016 rates, including adjustments for the new Affordable Care Act (ACA) blended benchmark county rates and qualifying bonuses, will lead to a reduction in Medicare Advantage rates to HCP of approximately 2%, or a net impact of approximately \$50 million to our 2016 operating income. This compares to an industry average rate increase of approximately 1.25% as indicated by CMS in its final rule regarding the 2016 rates. The final impact of 2016 Medicare Advantage rates can vary from this estimate and will be impacted by the relative growth of HCP's Medicare Advantage patient volumes across markets as well as by the benefit plan designs submitted. It is possible that we underestimated the impact of the 2016 Medicare Advantage rates on our business, and it has a material adverse effect on our financial position, results of operation or cash flows.

This more significant decline in Medicare Advantage rates for us compared to the industry average is driven by a larger-than-average decline associated with CMS's modification to the risk adjustment model calculation. The move to the 2014 CMS-HCC model negatively affects us and other providers like us who have differentially invested in wellness and prevention programs for patients with chronic conditions because the 2014 model tends to over-predict costs for very low-cost beneficiaries and under-predict costs for very high-cost beneficiaries.

In addition, we may need to take a goodwill impairment charge against earnings in a future period relating to the impact of this decrease in rates on the carrying value of net assets of our HCP reporting units. An impairment occurs when the carrying value of a reporting unit's goodwill is in excess of its implied fair value and the amount of such non-cash charge, if any, could be significant. In estimating the fair value of our HCP reporting units, we will update our forecasts for each HCP reporting unit to reflect the expected future cash flows that we believe market participants would use in determining the fair values of our HCP reporting units if they were to acquire these reporting units. We will also use certain estimates and key assumptions in determining our estimate of these fair values, including discount and long-term growth rates, market data and future reimbursement rates. Our estimates of the fair value of our HCP reporting units could differ from the actual fair values a market participant would pay for these reporting units.

HCP's Medicare Advantage revenues may continue to be volatile in the future, which could have a material impact on HCP's ongoing financial performance.

The Health Reform Acts contain a number of provisions that negatively impact Medicare Advantage plans, which may each have an adverse effect on HCP's revenues, earnings, and cash flows. These provisions include the following:

- Medicare Advantage benchmarks for 2011 were frozen at 2010 levels. Beginning in 2012, Medicare Advantage benchmark rates are being phased down from prior levels to levels that are between 95% and 115% of the Medicare fee-for-service (FFS) costs, depending on a plan's geographic area. If our costs escalate faster than can be absorbed by the level of revenues implied by these benchmark rates, then it could have a significant negative impact on HCP's earnings and cash flows.
- Rebates received by Medicare Advantage plans that underbid based on payment benchmarks will be reduced, with larger reductions for plans failing to receive certain quality ratings.

64

- The Secretary of HHS has been granted the explicit authority to deny Medicare Advantage plan bids that propose significant increases in cost sharing or decreases in benefits. If the bids submitted by plans contracted with HCP are denied, this would have a significant negative impact on HCP's revenues, earnings and cash flows.
 - Medicare Advantage plans with medical loss ratios below 85% are required to pay a rebate to the Secretary of HHS. The rebate amount is the total revenue under the contract year multiplied by the difference between 85% and the plan's actual medical loss ratio. The Secretary of HHS will halt enrollment in any plan failing to meet this ratio for three consecutive years, and terminate any plan failing to meet the ratio for five consecutive years. If an HCP-contracting Medicare Advantage plan experiences a limitation on enrollment or is otherwise terminated from the Medicare Advantage program, HCP may suffer materially adverse consequences to its business or financial condition.
- Prescription drug plans are now required to cover all drugs on a list developed by the Secretary of HHS, which could increase the cost of providing care to Medicare Advantage enrollees, and thereby reduce HCP's revenues and earnings. The Medicare Part D premium subsidy for high-income beneficiaries has been reduced by 25%, which could lower the number of Medicare Advantage enrollees, which would have a negative impact on HCP's revenues, earnings and cash flows.
- CMS increased coding intensity adjustments for Medicare Advantage plans beginning in 2014 and continuing through 2018, which reduces CMS payments to Medicare Advantage plans, which in turn will likely reduce the amounts payable to HCP and its associated physicians, physician groups, and IPAs under its capitation agreements. The President's proposed 2016 budget proposed nearly \$500 billion in cuts to Medicare, Medicaid and other programs run by HHS over the next decade. Although the majority of the cuts are not targeted at Medicare Advantage plans, the broad cuts could signal further downward pressure on reimbursement to Medicare providers and Medicare Advantage plans, which would have a negative impact on HCP's revenues, earnings and cash flows. The final 2015 budget did not contain significant changes to Medicare funding, but cuts in future budgets could impact HCP's revenues.

There is uncertainty regarding both Medicare Advantage payment rates and beneficiary enrollment, which, if reduced as a result of the implementation of the Health Reform Acts, would reduce HCP's overall revenues and net income. For example, although the Congressional Budget Office (CBO) predicted in 2012 that Medicare Advantage participation would drop precipitously by 2020, in 2013 the CBO reversed its prediction and instead predicted that enrollment in Medicare Advantage could increase by up to 50% in the next decade. Although Medicare Advantage enrollment increased by approximately 5.6 million, or by 50 percent, between the enactment of the ACA in 2010 and 2015, there can be no assurance that this trend will continue. Further, fluctuation in Medicare Advantage payment rates were evidenced by CMS's announcement in its final 2015 "Call Letter" that Medicare Advantage rates would rise an average of 0.4% in 2015, instead of falling 1.9% as it had predicted in February 2014. On April 6, 2015, CMS announced its Medicare Advantage rates for 2016. See above for further details. Uncertainty over Medicare Advantage enrollment and payment rates present a continuing risk to HCP's business.

Medicare Advantage enrollment continues to be highly concentrated among a few Medicare Advantage plans, both nationally and in local markets. In approximately 15 states, more than half of all enrollees are in plans offered by one company – an indicator that those markets may lack competition. Consolidation among Medicare Advantage plans, or the Medicare programs failure to attract additional plans to participate in the Medicare Advantage program, could have a negative impact of HCP's revenues, earnings, and/or cash flows.

HCP's operations are dependent on competing health plans and, at times, a health plan's and HCP's economic interests may diverge.

For the nine months ended September 30, 2015, 61% of HCP's consolidated capitated medical revenues were earned through contracts with three health plans.

HCP expects that, going forward, substantially all of its revenue will continue to be derived from its contracts with health plans. Each health plan may immediately terminate any of HCP's contracts and/or any individual credentialed physician upon the occurrence of certain events. They may also amend the material terms of the contracts under certain circumstances. Failure to maintain the contracts on favorable terms, for any reason, would materially and adversely affect HCP's results of operations and financial condition. A material decline in the number of members could also have a material adverse effect on HCP's results of operations.

Notwithstanding each health plan's and HCP's current shared interest in providing service to HCP's members who are enrolled in the subject health plans, the health plans may have different and, at times, opposing economic interests from those of HCP. The health plans provide a wide range of health insurance services across a wide range of geographic regions, utilizing a vast network of providers. As a result, they and HCP may have different views regarding the proper pricing of services and/or the proper pricing of the various service providers in their provider networks, the cost of which HCP bears to the extent that the services of such service providers are utilized. These health plans may also have different views than HCP regarding the efforts and expenditures that they,

HCP, and/or other service providers should make to achieve and/or maintain various quality ratings. In addition, several health plans have acquired or announced their intent to acquire provider organizations. If health plans with which HCP contracts acquire a significant number of provider organizations, they may not continue to contract with HCP or contract on less favorable terms or seek to prevent HCP from acquiring or entering into arrangements with certain providers. Similarly, as a result of changes in laws, regulations, consumer preferences, or other factors, the health plans may find it in their best interest to provide health insurance services pursuant to another payment or reimbursement structure. In the event HCP's interests diverge from the interests of the health plans, HCP may have limited recourse or alternative options in light of its dependence on these health plans. There can be no assurances that HCP will continue to find it mutually beneficial to work with these health plans. As a result of various restrictive provisions that appear in some of the managed care agreements with health plans, HCP may at times have limitations on its ability to cancel an agreement with a particular health plan and immediately thereafter contract with a competing health plan with respect to the same service area.

HCP and its associated physicians, physician groups and IPAs and other physicians may be required to continue providing services following termination or renegotiation of certain agreements with health plans.

There are circumstances under federal and state law pursuant to which HCP and its associated physician groups, IPAs, and other physicians could be obligated to continue to provide medical services to HCP members in their care following a termination of their applicable risk agreement with health plans and termination of the receipt of payments thereunder. In certain cases, this obligation could require the physician group or IPA to provide care to such member following the bankruptcy or insolvency of a health plan. Accordingly, the obligations to provide medical services to HCP members (and the associated costs) may not terminate at the time the applicable agreement with the health plan terminates, and HCP may not be able to recover its cost of providing those services from the health plan, which could have a material adverse effect on HCP's financial condition, results of operations, and/or cash flows.

HCP operates primarily in Arizona, California, Florida, Nevada, New Mexico and Colorado and may not be able to successfully establish a presence in new geographic regions.

HCP derives substantially all of its revenue from operations in Arizona, California, Florida, Nevada, New Mexico and Colorado (hereinafter referred to as the Existing Geographic Regions). As a result, HCP's exposure to many of the risks described herein is not mitigated by a greater diversification of geographic focus. Furthermore, due to the concentration of HCP's operations in the Existing Geographic Regions, it may be adversely affected by economic conditions, natural disasters (such as earthquakes or hurricanes), or acts of war or terrorism that disproportionately affect the Existing Geographic Regions as compared to other states and geographic markets.

To expand the operations of its network outside of the Existing Geographic Regions, HCP must devote resources to identifying and exploring such perceived opportunities. Thereafter, HCP must, among other things, recruit and retain qualified personnel, develop new offices, establish potentially new relationships with one or more health plans, and establish new relationships with physicians and other healthcare providers. The ability to establish such new relationships may be significantly inhibited by competition for such relationships and personnel in the healthcare marketplace in the targeted new geographic regions. Additionally, HCP may face the risk that a substantial portion of the patients served in a new geographic area may be enrolled in a Medicare FFS program and will not desire to transition to a Medicare Advantage program, such as those offered through the health plans that HCP serves, or they may enroll with other health plans with whom HCP does not contract to receive services, which could reduce substantially HCP's perceived opportunity in such geographic area. In addition, if HCP were to seek to expand outside of the Existing Geographic Regions, HCP would be required to comply with laws and regulations of states that may differ from the ones in which it currently operates, and could face competitors with greater knowledge of such local markets. HCP anticipates that any geographic expansion may require it to make a substantial investment of management time, capital, and/or other resources. There can be no assurance that HCP will be able to establish

profitable operations or relationships in any new geographic markets.

66

Reductions in the quality ratings of the health plans HCP serves could have an adverse effect on its results of operations, financial condition, and/or cash flow.

As a result of the Health Reform Acts, HCP anticipates that the level of reimbursement each health plan receives from CMS will be dependent, in part, upon the quality rating of the Medicare plan that such health plan serves. Such ratings are expected to impact the percentage of any cost savings rebate and any bonuses earned by such health plan. Since a significant portion of HCP's revenue is expected to be calculated as a percentage of CMS reimbursements received by these health plans with respect to HCP members, reductions in the quality ratings of a health plan that HCP serves could have an adverse effect on its results of operations, financial condition, and/or cash flows. In addition, CMS has announced its intention to terminate any plan that has a rating of less than three stars for three consecutive years. Medicare Advantage plans with five stars are permitted to conduct enrollment throughout the year and enrollees in plans with 4.5 or fewer stars are permitted to change plans during the year. Given each health plan's control of its plans and the many other providers that serve such plans, HCP believes that it will have limited ability to influence the overall quality rating of any such plan. Accordingly, since low quality ratings can potentially lead to the termination of a plan that HCP serves, HCP may not be able to prevent the potential termination of a contracting plan or a shift of patients to other plans based upon quality issues which could, in turn, have an adverse effect on HCP's results of operations, financial condition, and/or cash flows.

HCP's records and submissions to a health plan may contain inaccurate or unsupported information regarding risk adjustment scores of members, which could cause HCP to overstate or understate its revenue and subject it to various penalties.

HCP, on behalf of itself and its associated physicians, physician groups and IPAs, submits to health plans claims and encounter data that support the risk adjustment factor, or RAF, scores attributable to members. These RAF scores determine, in part, the revenue to which the health plans and, in turn, HCP is entitled for the provision of medical care to such members. The data submitted to CMS by each health plan is based, in part, on medical charts and diagnosis codes prepared and submitted by HCP. Each health plan generally relies on HCP and its employed or affiliated physicians to appropriately document and support such RAF data in HCP's medical records. Each health plan also relies on HCP and its employed or affiliated physicians to appropriately code claims for medical services provided to members. HCP may periodically review medical records and may find inaccurate or unsupported coding or otherwise inaccurate records. Erroneous claims and erroneous encounter records and submissions could result in inaccurate PMPM fee revenue and risk adjustment payments, which may be subject to correction or retroactive adjustment in later periods. This corrected or adjusted information may be reflected in financial statements for periods subsequent to the period in which the revenue was recorded. HCP might also need to refund a portion of the revenue that it received, which refund, depending on its magnitude, could damage its relationship with the applicable health plan and could have a material adverse effect on HCP's results of operations, financial condition or cash flows. We have identified a potentially improper historical HCP coding practice related to a particular condition, which was discontinued following our acquisition of HCP. We have notified CMS and we intend to cooperate with government authorities to address this issue. We are continuing to review other HCP coding practices.

Additionally, CMS audits Medicare Advantage plans for documentation to support RAF-related payments for members chosen at random. The Medicare Advantage plans ask providers to submit the underlying documentation for members that they serve. It is possible that claims associated with members with higher RAF scores could be subject to more scrutiny in a CMS audit. HCP has experienced increases in RAF scores attributable to its members, and thus there is a possibility that a Medicare Advantage plan may seek repayment from HCP as a result of CMS payment adjustments to the Medicare Advantage plan. The plans also may hold HCP liable for any penalties owed to CMS for inaccurate or unsupported RAF scores provided by HCP. In addition, HCP could be liable for penalties to the government.

CMS has indicated that payment adjustments will not be limited to RAF scores for the specific Medicare Advantage enrollees for which errors are found but may also be extrapolated to the entire Medicare Advantage plan subject to a particular CMS contract. CMS has described its audit process as plan-year specific and stated that it will not extrapolate audit results for plan years prior to 2011. Because CMS has not stated otherwise, there is a risk that payment adjustments made as a result of one plan year's audit would be extrapolated to prior plan years after 2011.

There can be no assurance that a health plan will not be randomly selected or targeted for review by CMS or that the outcome of such a review will not result in a material adjustment in HCP's revenue and profitability, even if the information HCP submitted to the plan is accurate and supportable. Since the CMS rules, regulations, and statements regarding this audit program are still not well defined and, in some cases, have not been published in final form, there is also a risk that CMS may adopt new rules and regulations that are inconsistent with their existing rules, regulations, and statements.

Separately, as described in further detail below, on March 13, 2015, JSA HealthCare Corporation (JSA), a subsidiary of HCP, received a subpoena from the OIG that relates, in part, to risk adjustment practices and data. On June 18, 2015, we received a subpoena from the OIG requesting information relating to our and our subsidiaries', including HCP and its subsidiary JSA's, provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments.

A failure to accurately estimate incurred but not reported medical expense could adversely affect HCP's profitability.

Patient care costs include estimates of future medical claims that have been incurred by the patient but for which the provider has not yet billed HCP. These claim estimates are made utilizing actuarial methods and are continually evaluated and adjusted by management, based upon HCP's historical claims experience and other factors, including an independent assessment by a nationally recognized actuarial firm. Adjustments, if necessary, are made to medical claims expense and capitated revenues when the assumptions used to determine HCP's claims liability changes and when actual claim costs are ultimately determined.

Due to the inherent uncertainties associated with the factors used in these estimates and changes in the patterns and rates of medical utilization, materially different amounts could be reported in HCP's financial statements for a particular period under different conditions or using different, but still reasonable, assumptions. It is possible that HCP's estimates of this type of claim may be inadequate in the future. In such event, HCP's results of operations could be adversely impacted. Further, the inability to estimate these claims accurately may also affect HCP's ability to take timely corrective actions, further exacerbating the extent of any adverse effect on HCP's results.

HCP faces certain competitive threats which could reduce HCP's profitability and increase competition for patients.

HCP faces certain competitive threats based on certain features of the Medicare programs, including the following:

- As a result of the direct and indirect impacts of the Health Reform Acts, many Medicare beneficiaries may decide that an original Medicare FFS program is more attractive than a Medicare Advantage plan. As a result, enrollment in the health plans HCP serves may decrease.
- Managed care companies offer alternative products such as regional preferred provider organizations (PPOs) and private FFS plans. Medicare PPOs and private FFS plans allow their patients more flexibility in selecting physicians than Medicare Advantage health plans, which typically require patients to coordinate care with a primary care physician. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 has encouraged the creation of regional PPOs through various incentives, including certain risk corridors, or cost reimbursement provisions, a stabilization fund for incentive payments, and special payments to hospitals not otherwise contracted with a Medicare Advantage plan that treat regional plan enrollees. The formation of regional Medicare PPOs and private FFS plans may affect HCP's relative attractiveness to existing and potential Medicare patients in their service areas.
- The payments for the local and regional Medicare Advantage plans are based on a competitive bidding process that may indirectly cause a decrease in the amount of the PMPM fee or result in an increase in benefits offered.
- The annual enrollment process and subsequent lock-in provisions of the Health Reform Acts may adversely affect HCP's level of revenue growth as it will limit the ability of a health plan to market to and enroll new Medicare beneficiaries in its established service areas outside of the annual enrollment period.
- CMS allows Medicare beneficiaries who are enrolled in a Medicare Advantage plan with a quality rating of 4.5 stars or less to enroll in a 5-star rated Medicare Advantage plan at any time during the benefit year. Therefore, HCP may face a competitive disadvantage in recruiting and retaining Medicare beneficiaries.

In addition to the competitive threats intrinsic to the Medicare programs, competition among health plans and among healthcare providers may also have a negative impact on HCP's profitability. For example, due to the large population of Medicare beneficiaries, HCP's Existing Geographic Regions have become increasingly attractive to health plans that may compete with HCP. HCP may not be able to continue to compete profitably in the healthcare industry if additional competitors enter the same market. If HCP cannot compete profitably, the ability of HCP to compete with other service providers that contract with competing health plans may be substantially impaired.

HCP competes directly with various regional and local companies that provide similar services in HCP's Existing Geographic Regions. HCP's competitors vary in size and scope and in terms of products and services offered. HCP

believes that some of its competitors and potential competitors may be significantly larger than HCP and have greater financial, sales, marketing, and other resources. Furthermore, it is HCP's belief that some of its competitors may make strategic acquisitions or establish cooperative relationships among themselves.

68

A disruption in HCP's healthcare provider networks could have an adverse effect on HCP's operations and profitability.

In any particular service area, healthcare providers or provider networks could refuse to contract with HCP, demand higher payments, or take other actions that could result in higher healthcare costs, disruption of benefits to HCP's members, or difficulty in meeting applicable regulatory or accreditation requirements. In some service areas, healthcare providers or provider networks may have significant market positions. If healthcare providers or provider networks refuse to contract with HCP, use their market position to negotiate favorable contracts, or place HCP at a competitive disadvantage, then HCP's ability to market or to be profitable in those service areas could be adversely affected. HCP's provider networks could also be disrupted by the financial insolvency of a large provider group. Any disruption in HCP's provider networks could result in a loss of members or higher healthcare costs.

HCP's revenues and profits could be diminished if HCP fails to retain and attract the services of key primary care physicians.

Key primary care physicians with large patient enrollment could retire, become disabled, terminate their provider contracts, get lured away by a competing independent physician association or medical group, or otherwise become unable or unwilling to continue practicing medicine or contracting with HCP or its associated physicians, physician groups, or IPAs. In addition, HCP's associated physicians, physician groups and IPAs could view the business model as unfavorable or unattractive to such providers, which could cause such associated physicians, physician groups or IPAs to terminate their relationships with HCP. Moreover, given limitations relating to the enforcement of post-termination noncompetition covenants in California, it would be difficult to restrict a primary care physician from competing with HCP's associated physicians, physician groups, or IPAs. As a result, members who have been served by such physicians could choose to enroll with competitors' physician organizations or could seek medical care elsewhere, which could reduce HCP's revenues and profits. Moreover, HCP may not be able to attract new physicians to replace the services of terminating physicians or to service its growing membership.

Participation in Accountable Care Organization programs is new and subject to federal regulation, supervision, and evolving regulatory developments and may result in financial liability.

The Health Reform Acts established Medicare Shared Savings Programs (MSSP) for ACOs, which took effect in January 2012. Under the MSSP, eligible organizations are accountable for the quality, cost and overall care of Medicare beneficiaries assigned to an ACO and may be eligible to share in any savings below a specified benchmark amount. The Secretary of HHS is also authorized, but not required, to use capitation payment models with ACOs. HCP has formed an MSSP ACO through a subsidiary and is evaluating whether to participate in more ACOs in the future. The continued development and expansion of ACOs will have an uncertain impact on HCP's revenue and profitability.

The ACO programs are new and therefore operational and regulatory guidance is limited. It is possible that the operations of HCP's subsidiary ACO may not fully comply with current or future regulations and guidelines applicable to ACOs, may not achieve quality targets or cost savings, or may not attract or retain sufficient physicians or patients to allow HCP to meet its objectives. Additionally, poor performance could put the HCP ACO at financial risk with a potential obligation to CMS. Traditionally, other than FFS billing by the medical clinics and healthcare facilities operated by HCP, HCP has not directly contracted with CMS and has not operated any health plans or provider sponsored networks. Therefore, HCP may not have the necessary experience, systems, or compliance to successfully achieve a positive return on its investment in the ACO or to avoid financial or regulatory liability. HCP believes that its historical experience with fully delegated managed care will be applicable to operation of its subsidiary ACO, but there can be no such assurance.

California hospitals may terminate their agreements with HCPAMG or reduce the fees they pay to HCP.

In California, HCPAMG maintains significant hospital arrangements designed to facilitate the provision of coordinated hospital care with those services provided to members by HCPAMG and its associated physicians, physician groups, and IPAs. Through contractual arrangements with certain key hospitals, HCPAMG provides utilization review, quality assurance, and other management services related to the provision of patient care services to members by the contracted hospitals and downstream hospital contractors. In the event that any one of these key hospital agreements is amended in a financially unfavorable manner or is otherwise terminated, such events could have a material adverse effect on HCP's financial condition, and results of operations.

HCP's professional liability and other insurance coverage may not be adequate to cover HCP's potential liabilities.

HCP maintains primary professional liability insurance and other insurance coverage through California Medical Group Insurance Company, Risk Retention Group, an Arizona corporation in which HCP is the majority owner, and through excess coverage contracted through third-party insurers. HCP believes such insurance is adequate based on its review of what it believes to be all applicable factors, including industry standards. Nonetheless, potential liabilities may not be covered by insurance, insurers may dispute coverage or may be unable to meet their obligations, the amount of insurance coverage and/or related reserves may be inadequate, or the amount of any HCP self-insured retention may be substantial. There can be no assurances that HCP will be able to obtain insurance coverage in the future, or that insurance will continue to be available on a cost-effective basis, if at all. Moreover,

even if claims brought against HCP are unsuccessful or without merit, HCP would have to defend itself against such claims. The defense of any such actions may be time-consuming and costly and may distract HCP management's attention. As a result, HCP may incur significant expenses and may be unable to effectively operate its business.

Changes in the rates or methods of third-party reimbursements may adversely affect HCP operations.

Any negative changes in governmental capitation or FFS rates or methods of reimbursement for the services HCP provides could have a significant adverse impact on HCP's revenue and financial results. Since governmental healthcare programs generally reimburse on a fee schedule basis rather than on a charge-related basis, HCP generally cannot increase its revenues from these programs by increasing the amount it charges for its services. Moreover, if HCP's costs increase, HCP may not be able to recover its increased costs from these programs. Government and private payors have taken and may continue to take steps to control the cost, eligibility for, use, and delivery of healthcare services due to budgetary constraints, and cost containment pressures as well as other financial issues. HCP believes that these trends in cost containment will continue. These cost containment measures, and other market changes in non-governmental insurance plans have generally restricted HCP's ability to recover, or shift to non-governmental payors, any increased costs that HCP experiences. HCP's business and financial operations may be materially affected by these cost containment measures, and other market changes.

HCP's business model depends on numerous complex management information systems and any failure to successfully maintain these systems or implement new systems could materially harm HCP's operations and result in potential violations of healthcare laws and regulations.

HCP depends on a complex, specialized, and integrated management information system and standardized procedures for operational and financial information, as well as for HCP's billing operations. HCP may experience unanticipated delays, complications, or expenses in implementing, integrating, and operating these integrated systems. Moreover, HCP may be unable to enhance its existing management information system or implement new management information systems where necessary. HCP's management information system may require modifications, improvements, or replacements that may require both substantial expenditures as well as interruptions in operations. HCP's ability to implement and operate its integrated systems is subject to the availability of information technology and skilled personnel to assist HCP in creating and maintaining these systems.

HCP's failure to successfully implement and maintain all of its systems could have a material adverse effect on its business, financial condition, and results of operations. For example, HCP's failure to successfully operate its billing systems could lead to potential violations of healthcare laws and regulations. If HCP is unable to handle its claims volume, or if HCP is unable to pay claims timely, HCP may become subject to a health plan's corrective action plan or de-delegation until the problem is corrected, and/or termination of the health plan's agreement with HCP. This could have a material adverse effect on HCP's operations and profitability. In addition, if HCP's claims processing system is unable to process claims accurately, the data HCP uses for its incurred but not reported (IBNR) estimates could be incomplete and HCP's ability to accurately estimate claims liabilities and establish adequate reserves could be adversely affected. Finally, if HCP's management information systems are unable to function in compliance with applicable state or federal rules and regulations, including, without limitation, medical information confidentiality laws such as HIPAA, possible penalties and fines due to this lack of compliance could have a material adverse effect on HCP's financial condition, and results of operations.

HCP may be impacted by eligibility changes to government and private insurance programs.

Due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. The Health Reform Acts have increased the participation of individuals in the Medicaid program in states that elected to participate in the expanded Medicaid

coverage. A shift in payor mix from managed care and other private payors to government payors as well as an increase in the number of uninsured patients may result in a reduction in the rates of reimbursement to HCP or an increase in uncollectible receivables or uncompensated care, with a corresponding decrease in net revenue. Changes in the eligibility requirements for governmental programs such as the Medicaid program under the Health Reform Acts and state decisions on whether to participate in the expansion of such programs also could increase the number of patients who participate in such programs and the number of uninsured patients. Even for those patients who remain in private insurance plans, changes to those plans could increase patient financial responsibility, resulting in a greater risk of uncollectible receivables. These factors and events could have a material adverse effect on HCP's business, financial condition, and results of operations.

Negative publicity regarding the managed healthcare industry generally or HCP in particular could adversely affect HCP's results of operations or business.

Negative publicity regarding the managed healthcare industry generally, the Medicare Advantage program or HCP in particular, may result in increased regulation and legislative review of industry practices that further increase HCP's costs of doing business and adversely affect HCP's results of operations or business by:

- requiring HCP to change its products and services;
- increasing the regulatory, including compliance, burdens under which HCP operates, which, in turn, may negatively impact the manner in which HCP provides services and increase HCP's costs of providing services;
- adversely affecting HCP's ability to market its products or services through the imposition of further regulatory restrictions regarding the manner in which plans and providers market to Medicare Advantage enrollees; or
- adversely affecting HCP's ability to attract and retain members.

Risk factors related to our overall business and ownership of our common stock:

We are the subject of a number of investigations by the federal government and a private civil suit, any of which could result in substantial penalties or awards against us, the imposition of certain obligations on our practices and procedures, exclusion from future participation in the Medicare, Medicaid and other federal healthcare programs and possible criminal penalties.

We are the subject of a number of investigations by the federal government. We have received subpoenas or other requests for documents from the federal government in connection with the Swoben private civil suit, the 2011 U.S. Attorney Medicaid investigation, the 2015 U.S. Attorney Transportation Investigation and the investigations underlying the two subpoenas regarding patient diagnosis coding received by HCP and its JSA subsidiary described below.

In the Swoben private civil suit, a relator filed a complaint against us in federal court under the FCA qui tam provisions, as well as the provision of the California False Claims Act. In July 2013, the court granted HCP's motion and dismissed with prejudice all of the claims in the Third Amended Complaint, and in October 2013 the plaintiff filed an appeal of the dismissal, which is currently pending.

Additionally, in March 2015, JSA, a subsidiary of HCP, received a subpoena from the OIG. We have been advised by an attorney with the Civil Division of the United States Department of Justice in Washington, D.C. that the subpoena relates to an ongoing civil investigation concerning Medicare Advantage service providers' risk adjustment practices and data, including identification and verification of patient diagnoses and factors used in making the diagnoses. The subpoena requests documents and information for the period from January 1, 2008 through December 31, 2013, for certain Medicare Advantage plans for which JSA provided services. It also requests information regarding JSA's communications about patient diagnoses as they relate to certain Medicare Advantage plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted.

In June 2015, we received a subpoena from the OIG. This civil subpoena covers the period from January 1, 2008 through the present and seeks production of a wide range of documents relating to our and our subsidiaries' (including HealthCare Partners and its subsidiary JSA HealthCare Corporation) provision of services to Medicare Advantage plans and related patient diagnosis coding and risk adjustment submissions and payments. Some of the information requested relates to a potentially improper historical HCP coding practice related to a particular condition. The practice in question was discontinued following our November 1, 2012 acquisition of HCP and, as we previously disclosed, we notified CMS of the coding practice and potential overpayments. We are cooperating with the government and will gather and produce the requested information.

Responding to subpoenas, investigations and civil suits as well as defending ourselves in such matters will continue to require management's attention and we will continue to incur significant legal expense. Any negative findings or certain terms and conditions that we might agree to accept as part of a negotiated resolution could result in substantial financial penalties or awards against or substantial payments made by us, the imposition of certain obligations on our practices and procedures, exclusion from future participation in the Medicare and Medicaid programs and, in certain cases, criminal penalties. It is possible that criminal proceedings may be initiated against us in connection with investigations by the federal government. To our knowledge, no proceedings have been initiated by the federal government against us at this time. At this time, we cannot predict the ultimate outcome of these inquiries, or the potential outcome of the claims in the relators' civil suit (except as described above), or the potential range of damages, if any. See Note 9 to the condensed consolidated financial statements of this report for additional details regarding these and other matters.

Disruptions in federal government operations and funding create uncertainty in our industry and could have a material adverse effect on our revenues, earnings and cash flows and otherwise adversely affect our financial condition.

A substantial portion of our revenues is dependent on federal healthcare program reimbursement, and any disruptions in federal government operations could have a material adverse effect on our revenues, earnings and cash flows. If the U.S. government defaults on its debt, there could be broad macroeconomic effects that could raise our cost of borrowing funds, and delay or prevent our future growth and expansion. Any future federal government shutdown, U.S. government default on its debt and/or failure of the U.S. government to enact annual appropriations could have a material adverse effect on our revenues, earnings and cash flows. Additionally, disruptions in federal government operations may negatively impact regulatory approvals and guidance that are important to our operations, and create uncertainty about the pace of upcoming healthcare regulatory developments.

Changes in CMS diagnosis and inpatient procedure coding require us to make modifications to processes and information systems, which could result in significant development costs and which if unsuccessful could adversely affect our revenues, earnings and cash flows.

CMS has mandated the use of new patient codes for reporting medical diagnosis and inpatient procedures, referred to as ICD-10, which requires all providers, payors, clearinghouses, and billing services to utilize ICD-10 when submitting claims for payment. ICD-10 will affect diagnosis and inpatient procedure coding for everyone covered by HIPAA, not just those who submit Medicare or Medicaid claims. Claims for services provided on or after the date that CMS sets must use ICD-10 for medical diagnosis and inpatient procedures or they will not be paid. We anticipate that if our services, processes or information systems or those of our payors do not comply with ICD-10 requirements at any future date, it could potentially delay or even reduce reimbursement payments to us. These delays or reductions could negatively impact our revenues, earnings and cash flows.

While Congress voted to delay the ICD-10 implementation deadline until no earlier than October 1, 2015, CMS has the authority to delay implementation even further, which leads to uncertainty about when ICD-10 will be mandated. Such uncertainty could lead to additional costs of running both ICD-9 and ICD-10 systems, which could negatively impact our revenues, earnings and cash flows.

Federal and state privacy and information security laws are complex, and if we fail to comply with applicable laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information on our behalf, or if we fail to properly maintain the integrity of our data, protect our proprietary rights to our systems, or defend against cybersecurity attacks, we may be subject to government or private actions due to privacy and security breaches, and our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.

We must comply with numerous federal and state laws and regulations governing the collection, dissemination, access, use, security and privacy of protected health information (PHI), including HIPAA and its implementing privacy and security regulations, as amended by the federal HITECH Act and collectively referred to as HIPAA. If we fail to comply with applicable privacy and security laws, regulations and standards, including with respect to third-party service providers that utilize sensitive personal information, including PHI, on our behalf, properly maintain the integrity of our data, protect our proprietary rights to our systems, or defend against cybersecurity attacks, our business, reputation, results of operations, financial position and cash flows could be materially and adversely affected.

Information security risks have significantly increased in recent years in part because of the proliferation of new technologies, the use of the internet and telecommunications technologies to conduct our operations, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state

agents. Our operations rely on the secure processing, transmission and storage of confidential, proprietary and other information in our computer systems and networks.

We are continuously implementing multiple layers of security measures through technology, processes, and our people; utilize current security technologies; and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, our facilities and systems and those of our third-party service providers may be vulnerable to privacy and security incidents; security attacks and breaches; acts of vandalism or theft; computer viruses; coordinated attacks by activist entities; emerging cybersecurity risks; misplaced or lost data; programming and/or human errors; or other similar events. Emerging and advanced security threats, including coordinated attacks, require additional layers of security which may disrupt or impact efficiency of operations.

Any security breach involving the misappropriation, loss or other unauthorized disclosure or use of confidential information, including protected health information, financial data, competitively sensitive information, or other proprietary data, whether by us or a third party, could have a material adverse effect on our business, reputation, financial condition, cash flows, or results of operations. The occurrence of any of these events could result in interruptions, delays, the loss or corruption of data, cessations in the availability of systems or liability under privacy and security laws, all of which could have a material adverse effect on our financial position and results of operations and harm our business reputation. If we are unable to protect the physical and electronic security and privacy of

our databases and transactions, we could be subject to potential liability and regulatory action, our reputation and relationships with our patients and vendors would be harmed, and our business, operations, and financial results may be materially adversely affected. Failure to adequately protect and maintain the integrity of our information systems (including our networks) and data, or to defend against cybersecurity attacks, could subject us to monetary fines, civil suits, civil penalties or criminal sanctions and requirements to disclose the breach publicly, and may further result in a material adverse effect on our results of operations, financial position, and cash flows.

We may engage in acquisitions, mergers or dispositions, which may affect our results of operations, debt-to-capital ratio, capital expenditures or other aspects of our business, and if businesses we acquire have liabilities we are not aware of, we could suffer severe consequences that would materially and adversely affect our business.

Our business strategy includes growth through acquisitions of dialysis centers and other businesses. We may engage in acquisitions, mergers, dispositions or new business models, which may affect our results of operations, debt-to-capital ratio, capital expenditures, or other aspects of our business. There can be no assurance that we will be able to identify suitable acquisition targets or merger partners or that, if identified, we will be able to acquire these targets on acceptable terms or agree to terms with merger partners. There can also be no assurance that we will be successful in completing any acquisitions, mergers or dispositions that we announce, executing new business models or integrating any acquired business into our overall operations. There is no guarantee that we will be able to operate acquired businesses successfully as stand-alone businesses, or that any such acquired business will operate profitably or will not otherwise adversely impact our results of operations. Further, we cannot be certain that key talented individuals at the business being acquired will continue to work for us after the acquisition or that they will be able to continue to successfully manage or have adequate resources to successfully operate any acquired business.

Businesses we acquire may have unknown or contingent liabilities or liabilities that are in excess of the amounts that we originally estimated, and may have other issues, including those related to internal controls over financial reporting or issues that could affect our ability to comply with healthcare laws and regulations and other laws applicable to our expanded business. As a result, we cannot make any assurances that the acquisitions we consummate will be successful. Although we generally seek indemnification from the sellers of businesses we acquire for matters that are not properly disclosed to us, we are not always successful. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits, the amounts held in escrow for our benefit (if any), or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that would substantially reduce our earnings and cash flows or otherwise materially and adversely affect our business.

If we are not able to continue to make acquisitions, or maintain an acceptable level of non-acquired growth, or if we face significant patient attrition to our competitors or a reduction in the number of our medical directors or associated physicians, it could adversely affect our business.

Acquisitions, patient retention and medical director and physician retention are an important part of our growth strategy. We face intense competition from other companies for acquisition targets. In our U.S. dialysis business, we continue to face increased competition from large and medium-sized providers which compete directly with us for acquisition targets as well as for individual patients and medical directors. In addition, as we continue our international dialysis expansion into various international markets, we will face competition from large and medium-sized providers for these acquisition targets as well. Because of the ease of entry into the dialysis business and the ability of physicians to be medical directors for their own centers, competition for growth in existing and expanding markets is not limited to large competitors with substantial financial resources. Occasionally, we have experienced competition from former medical directors or referring physicians who have opened their own dialysis centers. In addition, FMC, our largest competitor, manufactures a full line of dialysis supplies and equipment in

addition to owning and operating dialysis centers. This may give it cost advantages over us because of its ability to manufacture its own products. If we are not able to continue to make acquisitions, continue to maintain acceptable levels of non-acquired growth, or if we face significant patient attrition to our competitors or a reduction in the number of our medical directors or associated physicians, it could adversely affect our business.

73

HCP operates in a different line of business from our historical business. We may face challenges managing HCP as a new business and may not realize anticipated benefits.

As a result of the HCP transaction, we are now significantly engaged in a new line of business. We may not have the expertise, experience, and resources to pursue all of our businesses at once, and we may be unable to successfully operate all businesses in the combined company. The administration of HCP will require implementation of appropriate operations, management, and financial reporting systems and controls. We may experience difficulties in effectively implementing these and other systems. The management of HCP will require the focused attention of our management team, including a significant commitment of its time and resources. The need for management to focus on these matters could have a material and adverse impact on our revenues and operating results. If the HCP operations are less profitable than we currently anticipate or we do not have the experience, the appropriate expertise, or the resources to pursue all businesses in the combined company, the results of operations and financial condition may be materially and adversely affected.

If we fail to successfully maintain an effective internal control over financial reporting, the integrity of our financial reporting could be compromised which could result in a material adverse effect on our reported financial results.

The integration of HCP into our internal control over financial reporting has required and will continue to require significant time and resources from our management and other personnel and will increase our compliance costs. Failure to maintain an effective internal control environment could have a material adverse effect on our ability to accurately report our financial results and the market's perception of our business and our stock price.

The market price of our common stock may be affected by factors different from those affecting the shares of our common stock prior to consummation of the HCP transaction.

Our historical business differs substantially from that of HCP. Accordingly, the results of operations of the combined company and the market price of our common stock may be affected by factors different from those that previously affected the independent results of operations of each of the Company and HCP.

Expansion of our operations to and offering our services in markets outside of the U.S. subjects us to political, economical, legal, operational and other risks that could adversely affect our business, results of operations and cash flows.

We are continuing an expansion of our operations by offering our services outside of the U.S., which increases our exposure to the inherent risks of doing business in international markets. Depending on the market, these risks include, without limitation, those relating to:

- changes in the local economic environment;
- political instability, armed conflicts or terrorism;
- social changes;
- intellectual property legal protections and remedies;
- trade regulations;
- procedures and actions affecting approval, production, pricing, reimbursement and marketing of products and services;
- foreign currency;
- repatriating or moving to other countries cash generated or held abroad, including considerations relating to tax-efficiencies and changes in tax laws;
- export controls;
- lack of reliable legal systems which may affect our ability to enforce contractual rights;

- changes in local laws or regulations;
- potentially longer ramp-up times for starting up new operations and for payment and collection cycles;
- financial and operational, and information technology systems integration; and
- failure to comply with U.S. or local laws that prohibit us or our intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business.

74

Additionally, some factors that will be critical to the success of our international business and operations will be different than those affecting our domestic business and operations. For example, conducting international operations requires us to devote significant management resources to implement our controls and systems in new markets, to comply with local laws and regulations and to overcome the numerous new challenges inherent in managing international operations, including those based on differing languages, cultures and regulatory environments, and those related to the timely hiring, integration and retention of a sufficient number of skilled personnel to carry out operations in an environment with which we are not familiar.

We anticipate expanding our international operations through acquisitions of varying sizes or through organic growth, which could increase these risks. Additionally, though we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, there is no assurance that we will be able to operate them profitably anytime soon, if at all. As a result, we would expect these costs to be dilutive to our earnings over the next several years as we start-up or acquire new operations.

These risks could have a material adverse effect on our financial condition, results of operations and cash flows.

The level of our current and future debt could have an adverse impact on our business and our ability to generate cash to service our indebtedness depends on many factors beyond our control.

We have substantial debt outstanding, we incurred a substantial amount of additional debt in connection with the HCP transaction and we may incur additional indebtedness in the future. Our substantial indebtedness could have important consequences to you, for example, it could:

- make it difficult for us to make payments on our debt securities;
- increase our vulnerability to general adverse economic and industry conditions;
- require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, acquisitions and investments and other general corporate purposes;
- limit our flexibility in planning for, or reacting to, changes in our business and the markets in which we operate;
- expose us to interest rate volatility that could adversely affect our earnings and cash flow and our ability to service our indebtedness;
- place us at a competitive disadvantage compared to our competitors that have less debt; and
- limit our ability to borrow additional funds.

In addition, we may incur substantial additional indebtedness in the future. The terms of the indentures governing our senior notes and the agreement governing our Senior Secured Credit Facilities will allow us to incur substantial additional debt. If new debt is added to current debt levels, the related risks described above could intensify.

Our ability to make payments on our indebtedness and to fund planned capital expenditures and expansion efforts, including any strategic acquisitions we may make in the future, will depend on our ability to generate cash. This, to a certain extent, is subject to general economic, financial, competitive, regulatory and other factors that are beyond our control.

We cannot provide assurance that our business will generate sufficient cash flow from operations in the future or that future borrowings will be available to us in an amount sufficient to enable us to service our indebtedness or to fund other liquidity needs. If we are unable to generate sufficient funds to service our outstanding indebtedness, we may be required to refinance, restructure, or otherwise amend some or all of such obligations, sell assets, or raise additional cash through the sale of our equity. We cannot make any assurances that we would be able to obtain such refinancing on terms as favorable as our existing financing terms or that such restructuring activities, sales of assets, or issuances of equity can be accomplished or, if accomplished, would raise sufficient funds to meet these obligations.

The borrowings under our Senior Secured Credit Facilities are guaranteed by a substantial portion of our direct and indirect wholly-owned domestic subsidiaries and are secured by a substantial portion of DaVita HealthCare Partners Inc.'s and its subsidiaries' assets.

75

We may be subject to liability claims for damages and other expenses not covered by insurance that could reduce our earnings and cash flows.

Our operations and how we manage the Company may subject the Company, as well as its officers and directors to whom the Company owes certain defense and indemnity obligations, to litigation and liability for damages. Our business, profitability and growth prospects could suffer if we face negative publicity or we pay damages or defense costs in connection with a claim that is outside the scope or limits of coverage of any applicable insurance coverage, including claims related to adverse patient events, contractual disputes, professional and general liability, and directors' and officers' duties. In addition, we have received several notices of claims from commercial payors and other third parties related to our historical billing practices and the historical billing practices of the centers acquired from Gambro Healthcare and other matters related to their settlement agreement with the Department of Justice. Although the ultimate outcome of these claims cannot be predicted, an adverse result with respect to one or more of these claims could have a material adverse effect on our financial condition, results of operations, and cash flows. We currently maintain insurance coverage for those risks we deem are appropriate to insure against and make determinations about whether to self-insure as to other risks or layers of coverage. However, a successful claim, including a professional liability, malpractice or negligence claim which is in excess of any applicable insurance coverage, or that is subject to our self-insurance retentions, could have a material adverse effect on our earnings and cash flows.

In addition, if our costs of insurance and claims increase, then our earnings could decline. Market rates for insurance premiums and deductibles have been steadily increasing. Our earnings and cash flows could be materially and adversely affected by any of the following:

- the collapse or insolvency of our insurance carriers;
- further increases in premiums and deductibles;
- increases in the number of liability claims against us or the cost of settling or trying cases related to those claims; or
- an inability to obtain one or more types of insurance on acceptable terms, if at all.

Provisions in our charter documents, compensation programs and Delaware law may deter a change of control that our stockholders would otherwise determine to be in their best interests.

Our charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in our management, or limit the ability of our stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting our stockholders from acting by written consent; requiring 90 days advance notice of stockholder proposals or nominations to our Board of Directors; and granting our Board of Directors the authority to issue preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval.

Most of our outstanding employee stock-based compensation awards include a provision accelerating the vesting of the awards in the event of a change of control. We also maintain a change of control protection program for our employees who do not have a significant number of stock awards, which has been in place since 2001, and which provides for cash bonuses to the employees in the event of a change of control. Based on the market price of our common stock and shares outstanding on September 30, 2015, these cash bonuses would total approximately \$603 million if a change of control transaction occurred at that price and our Board of Directors did not modify this program. These change of control provisions may affect the price an acquirer would be willing to pay for our Company.

We are also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit us from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder.

These provisions may discourage, delay or prevent an acquisition of our Company at a price that our stockholders may find attractive. These provisions could also make it more difficult for our stockholders to elect directors and take other corporate actions and could limit the price that investors might be willing to pay for shares of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c) Share repurchases

The following table summarizes the Company's repurchases of its common stock during the third quarter of 2015:

| Period | Total number of shares purchased | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs | Approximate |
|----------------------|--|--|---|--|
| | | | | dollar value of shares that may yet be purchased under the plans or programs (in millions) |
| July 1-31, 2015 | — | — | — | 1,000.0 |
| August 1-31, 2015 | 833,111 | 75.71 | 833,111 | 936.9 |
| September 1-30, 2015 | 3,722,757 | 74.55 | 3,722,757 | 659.4 |
| Total | 4,555,868 | \$ 74.76 | 4,555,868 | |

In November 2010, our Board of Directors authorized repurchases of our common stock in an aggregate amount of up to \$800 million. This share repurchase program has no expiration date. We are authorized to make purchases from time to time in the open market or in privately negotiated transactions, depending upon market conditions and other considerations. On April 14, 2015, our Board of Directors approved additional share repurchases in the amount of \$726 million. These share repurchases are in addition to the approximately \$274 million remaining under our Board of Directors' prior share repurchase approval announced on November 4, 2010. As of October 30, 2015, there were \$659 million outstanding authorizations available for share repurchases. These share repurchase authorizations have no expiration dates. However, we are subject to share repurchase limitations under the terms of the Senior Secured Credit Facilities and the indentures governing our senior notes.

Items 3, 4 and 5 are not applicable

Item 6. Exhibits

(a) Exhibits

Exhibit
Number

- 12.1 Ratio of earnings to fixed charges. P
- 31.1 Certification of the Chief Executive Officer, dated November 4, 2015, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. P
- 31.2 Certification of the Chief Financial Officer, dated November 4, 2015, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. P
- 32.1 Certification of the Chief Executive Officer, dated November 4, 2015, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. P
- 32.2 Certification of the Chief Financial Officer, dated November 4, 2015, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. P
- 101.INS XBRL Instance Document. P
- 101.SCH XBRL Taxonomy Extension Schema Document. P
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. P
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. P
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document. P
- 101.PRE XBRL Taxonomy Extension Presentation, Linkbase Document. P

PFiled herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DAVITA HEALTHCARE PARTNERS
INC.

BY: /s/ JAMES K. HILGER
James K. Hilger
Interim Chief Financial Officer and

Chief Accounting Officer*

Date: November 4, 2015

*Mr. Hilger has signed both on behalf of the Registrant as a duly authorized officer and as the Registrant's principal accounting officer.

INDEX TO EXHIBITS

Exhibit
Number

- 12.1 Ratio of earnings to fixed charges. P
- 31.1 Certification of the Chief Executive Officer, dated November 4 2015, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. P
- 31.2 Certification of the Chief Financial Officer, dated November 4, 2015, pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. P
- 32.1 Certification of the Chief Executive Officer, dated November 4, 2015, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. P
- 32.2 Certification of the Chief Financial Officer, dated November 4, 2015, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. P
- 101.INS XBRL Instance Document. P
- 101.SCH XBRL Taxonomy Extension Schema Document. P
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. P
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document. P
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document. P
- 101.PRE XBRL Taxonomy Extension Presentation, Linkbase Document. P

PFiled herewith.